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The Orchidaceae makes up the largest and most diverse family of flowering plants.  Orchids are 
popular, often expensive ornamentals, with a broad range of ethnobotanical applications. There 
is very limited documented information on South African medicinal orchid species; no formal 
pharmacopoeia outlining ethnobotanical uses; and ethnobotanical and distribution records are 
either scarce or inconsistent and plant populations are becoming gradually smaller.  There have 
been significant developments in medicinal orchid research worldwide with medicinal use and 
corresponding pharmacological and phytochemical properties being extensively investigated.  It 
is evident from the literature that there is no pharmacological research on South African 
medicinal orchids; hence the need to explore biological activity and chemical composition of 
South African medicinal orchid species.  The ethnobotanical approach used to select the orchid 
species for pharmacological and phytochemical research elsewhere, yielded valuable biological 
compounds. Thus, a similar approach was applied to South African medicinal orchids.   
 
There are approximately 20 000 species and 796 genera of orchids distributed across the world.  
In southern Africa, orchids are widely represented with 55 genera and 494 species.  
Approximately 75% are endemic to this region.  As part of the current investigation a review of 
available ethnobotanical literature on South African medicinal orchids was prepared.  The review 
revealed that an estimated 49 indigenous orchid species from 20 orchid genera are currently 
being informally traded and used in South African traditional medicine. They are used primarily 
for medicinal and cultural purposes, especially by the Zulu community in South Africa.  
Medicinal uses of orchid species include:  treatment of inflammatory, intestinal, neurological and 
reproductive disorders and emetics are used to cause emesis.  Non-medicinal uses of orchid 
species include:  love, fertility, protective and lethal charms.  Based on their ethnobotanical uses 
and endemism, South African orchids were considered to be one of the untapped sources of 
bioactive compounds that needed to be researched.   
 
The current investigation addressed the broader aims of medicinal plant research by determining 
the efficacy, safety and chemical profile of seven indigenous orchid species used in South 
African traditional medicine and practices.  The biological and toxic effects of orchid plant 
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extracts were assessed using established pharmacological bioassays.  The phytochemical 
evaluation of the seven orchid plant extracts provided insight into the classes of chemical 
compounds present and their possible role in the observed biological activities.  The potential of 
plant extracts from seven orchid species used in South African traditional medicine, as sources of 
natural bioactive products, are discussed.  The current investigation determined the biological 
activity and chemical profile of seven orchid species commonly traded in KwaZulu-Natal herbal 
markets:  Ansellia africana Lindl., Bulbophyllum scaberulum (Rolfe) Bolus, Cyrtorchis arcuata 
(Lindl.) Schltr., Eulophia hereroensis Schltr., Eulophia petersii (Rchb.f.) Rchb.f., Polystachya 
pubescens (Lindl.) Rchb.f. and Tridactyle tridentata (Harv.) Schltr.   
 
Well established in vitro micro-dilution bioassays were used to determine the antibacterial, 
antifungal, anthelmintic activities of crude orchid extracts.  A minimum inhibitory and/or lethal 
effect of organic and aqueous crude orchid extracts was observed against Bacillus subtilis, 
Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Candida albicans and 
Caenorhabditis elegans.  Tridactyle tridentata aqueous root extract produced the most effective 
antibacterial activity against S. aureus (0.049 mg/ml).  All T. tridentata organic root extracts 
produced significant inhibitory activities against B. subtilis and S. aureus.  Eulophia petersii 
DCM pseudobulb extracts significantly inhibited all bacterial strains tested (0.39 mg/ml against 
S. aureus and 0.78 mg/ml against B. subtilis, E. coli, and K. pneumoniae).  Eulophia hereroensis 
80% EtOH root extract was the only other extract to exhibit significant inhibitory effects against 
K. pneumoniae (0.65 mg/ml).  After 48 h C. albicans was most susceptible to P. pubescens 
aqueous pseudobulb extract (0.0816 mg/ml).  Eulophia petersii DCM pseudobulb extract 
however, exhibited significant activity against C. albicans (0.65 mg/ml) over 72 h.  Cyrtorchis 
arcuata leaf and root extracts were the most effective anthelmintic extracts with MLCs of 0.041 
mg/ml for 80% EtOH leaf and root extracts; 0.049 mg/ml for aqueous leaf extracts and 0.78 
mg/ml for aqueous and DCM root extracts.  Caenorhabditis elegans was most susceptible to all 
A. africana and T. tridentata organic root extracts.  A similar significant effect was observed for 
all E. petersii organic pseudobulb extracts, DCM extracts and organic root extracts of B. 
scaberulum.  Only the DCM tuber and root extracts of E. hereroensis exhibited lethal effects on 
C. elegans.  All of the P. pubescens extracts showed poor anthelmintic activity. 
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Similarly, in vitro enzyme based cyclooxygenase (COX) 1 and 2 and acetylcholinesterase 
(AChE) inhibitory bioassays, revealed significant inhibition of COX-1, COX-2 and AChE 
enzymes by crude organic and certain aqueous orchid extracts.  Out of a total of 53 evaluated 
extracts, 21 and 13 extracts exhibited significant anti-inflammatory activity in the COX-1 and 
COX-2 assays respectively.  The DCM tuber extract of E. hereroensis was the only extract to 
significantly inhibit both COX enzymes, 100.02±0.11% and 87.97±8.38% respectively. All B. 
scaberulum root extracts (DCM, EtOH and water) exhibited COX-2 selective inhibitory activity 
(100.06±0.01, 93.31±2.33 and 58.09±3.25%).  Overall, the DCM root extract of A. africana was 
found to be the most potent extract (EC50 0.25±0.10 mg/ml).  The 80% EtOH root extract of B. 
scaberulum was the most potent in the COX-2 assay (EC50 0.44±0.32 mg/ml).  Generally the 
root extracts exhibited greater AChE inhibitory activity; where the most active extract was B. 
scaberulum DCM root extract (EC50 0.02±0.00 mg/ml).  All aqueous extracts, except that of A. 
africana roots and B. scaberulum pseudobulbs, showed poor or no COX-1 and COX-2 
inhibition.   
 
The antioxidant capacity of crude orchid extracts was determined using: hydrogen atom transfer 
(HAT) (β-carotene/linoleic acid assay) and single electron transfer (SET) (2,2‟-
diphenylpicrylhydrazyl (DPPH) free radical scavenging assay and ferric reducing antioxidant 
power (FRAP) assay) reaction-based assays.  Potent antioxidant effects were observed for certain 
crude methanolic orchid extracts.  Generally, there was a dose-dependent change in radical 
scavenging activities of crude extracts from which EC50 values were determined.  The root 
extracts of all species, except that of E. petersii, had consistently more effective radical 
scavenging activity than that of other plant parts within each species.   The pseudobulb extract of 
E. petersii, was the most potent extract (EC50 1.32±0.86 mg/ml).  In the β-carotene-linoleic acid 
assay, based on the oxidation rate ratio (ORR), the leaf extract of T. tridentata and the root 
extracts of C. arcuata and E. hereroensis exhibited the best antioxidant effects (0.02, 0.023 and -
0.15 respectively).  Similarly, the average antioxidant activity (%ANT) of these samples was 
greater than that of BHT (95.88±6.90%) and all other samples.  Bulbophyllum scaberulum leaf, 
pseudobulb and root extracts, E. petersii pseudobulb extract and T. tridentata root extract also 
exhibited a greater capacity to prevent β-carotene oxidation when compared to BHT.  All crude 
orchid extracts tested demonstrated a general dose-dependent response in the ferric reducing 
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power assay.  The reducing power of ascorbic acid (0.08 mM) and BHT (0.05 mM), as measured 
as absorbance, was 1.12±0.12 and 0.73±0.08 respectively.  At 6.25 mg/ml, A. africana root and 
E. petersii pseudobulb extracts were the most effective in reducing power activity. 
 
The short-term bacterial reverse mutation Ames Salmonella/microsome mutagenicity (ASMM) 
assay, which makes use of mutant histidine-dependent Salmonella typhimurium strains, was used 
to determine the mutagenicity and toxicity of crude orchid extracts.  In the presence of a mutagen 
S. typhimurium TA98 strain detects frameshift events while the TA100 and TA102 strains detect 
base-pair substitutions.  In the absence of metabolic activation, mutagenic extracts were observed 
against the TA98 strain only.  All A. africana DCM leaf and stem extracts tested, the DCM root 
extract (0.5, 0.05 mg/ml) and EtOH leaf, stem and root extracts at 5 mg/ml exhibited mutagenic 
effects.  The EtOH root extracts (5, 0.5 mg/ml) of B. scaberulum exhibited mutagenic indices 
(MI) comparable to that of 4NQO (17.00 and 13.00, respectively).  Eulophia petersii PE 
pseudobulb extract demonstrated mutagenic potential at 5 mg/ml.  The ethanolic root extracts of 
T. tridentata showed mutagenic effects at 5 and 0.5 mg/ml.  The mutagenicity index (MI) with 
metabolic activation (S9) was determined using only the TA98 strain; where no mutagenic 
effects were observed. 
 
In the phytochemical evaluation of crude methanol orchid extracts, the Folin-Ciocalteu assay for 
total phenolics, butanol-HCl assay for condensed tannins, rhodanine assay for gallotannins and 
vanillin assay for flavonoids revealed a quantitative chemical profile of the tested samples.  The 
correlation between observed biological effects and chemical compounds present was found to 
be generally significant.  The significant antimicrobial, anthelmintic, anti-inflammatory and 
antioxidant activity of E. petersii pseudobulb extracts and E. hereroensis tuber and root extracts 
may be attributed to their high total phenolic content.  Alternatively, the significant levels of 
gallotannin content in E. hereroensis may have contributed to the bioactivity.  The flavonoid 
content of B. scaberulum and T. tridentata may explain the potent activity observed in the anti-
inflammatory, antioxidant and acetylcholinesterase inhibitory assays; while the flavonoid content 
C. arcuata may have contributed to the potent anthelmintic and antioxidant activities.  The 
significantly higher levels of gallotannin content may explain the significant anti-inflammatory 




A number of biologically active compounds have been isolated from certain Orchidaceae species 
around the world on the basis of their traditional medicinal uses.  The traditional uses of these 
orchid species were scientifically validated.  No pharmacological research has been previously 
conducted on South African medicinal orchids; therefore the current investigation has produced 
novel findings on the efficacy and safety of these orchid species and promotes the continued 
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Humanity‟s evolution is a direct result of our valuable relationship with nature.  The 
simultaneous development of science and research methods has contributed to a more 
knowledgeable civilisation.  Despite this, a great majority of our population remain 
malnourished, ill, and merely surviving in diseased and poor living conditions.  The situation is 
characterised by recurring infections, incidences of associated disorders and the emergence of 
new diseases.  This, coupled with a lack of effective medicines and/or medicines with various 
side effects, reduces the quality of life for many generations, and impedes our growth and 
development as humans.  Therefore our immediate and urgent attention is necessary.    
 
How do we all progress further under such challenging conditions?  While the answer at times 
seems impossible, programs which advocate for the provision of adequate, accessible, effective 
and safe healthcare is a step in the right direction.  Such programs recognise the value of our 
human and natural resources and address the short and long term outcomes of healthcare.  
Primary or conventional healthcare is the current most recognised system in most countries, and 
favours the use of synthetically derived medicines.  However, plant derived products have 
contributed greatly to this system.   
 
Medicinal plant research has revealed the value of indigenous knowledge systems and is 
accomplished by a systematic evaluation of natural plant resources.  The continued development 
of the human race depends on the efficient management of our human and natural resources, and 
recognition of the value of knowledge contained around and within them.   
 
1.2. THE WAY FORWARD 
 
„Health for All‟ is a World Health Organisation (WHO) initiative which has placed a great deal 
of importance on the access to healthcare.  The campaign is based on the view that health is a 
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fundamental right (PATEL, 1983).  Presently, conventional health care systems are inadequate 
and inaccessible to facilitate this right in various developing and developed regions.  The WHO 
facilitates yet another programme which identifies traditional medicine (a medical system 
already in use in many developing parts of the world) as an integral health-care resource that can 
improve the health status in those areas (HILLENBRAND, 2006). On a global scale the 
promotion of the Traditional Medicine Programme places emphasis on the formulation of 
national policies on traditional medicine, increased investigations into potential therapeutic 
activity, toxicity, enhancing the knowledge of all stakeholders (which includes the traditional 
healers and conventional practitioners) and to activate educational efforts to enlighten the public 
in the member states (WHO, 2002a).  The Declaration of Alma Ata in 1978 at the „International 
Conference on Primary Health Care‟ held in the USSR was a form of global recognition of 
traditional medicine and the potentially beneficial role it could play were it integrated into the 
primary healthcare system (PHC).   
 
Traditional medicine, which comprises both indigenous knowledge and medical systems, has 
survived through the ages and remains to be the preferred medical system to conventional 
medicine (WHO, 2002a).  With dependence and preference weighing heavily in favour of 
traditional medicine, the strategy to integrate the two medical systems in countries such as South 
Africa would greatly benefit patients (mostly indigenous people) who subscribe to traditional 
medicine.  Traditional healers are trusted members of their communities and are therefore well 
positioned to educate their communities (KING and HOMSY, 1997).  With formal registration, 
the advice and medication dispensed by traditional healers would be appropriately recognized, 
regulated and adequately supported by the different disciplines of science (CLARKE, 1998; 
RICHTER, 2003).  Certain aspects of traditional medicine such as safety and efficacy of the 
medicine are still to be addressed.   
 
In South Africa, the integration of the two medical systems requires more time, as traditional 
medicine needs to be adequately regulated (SINDIGA et al., 1995).  By applying modern 
scientific techniques, such as pharmacological evaluation to traditional medicine, and continually 
developing our technologies we will be able to address issues of safety, availability and a have 
broader application of the natural plant products indigenous to our country (DRAFT 
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NATIONAL POLICY ON AFRICAN TRADITIONAL MEDICINE FOR SOUTH 
AFRICA, 2008).  By formally documenting indigenous knowledge, conducting scientific 
investigations on medicinal and related plants to validate their use and providing adequate and 
suitable governmental support, African Traditional Medicine may become globally recognized as 
an established medical system (DRAFT NATIONAL POLICY ON AFRICAN 
TRADITIONAL MEDICINE FOR SOUTH AFRICA, 2008). 
 
1.3. PLANT DRUGS IN MODERN MEDICINE 
 
Modern conventional medicine has had significant breakthroughs over the years.  A number of 
herbal remedies have served as templates for some clinical drugs used in modern medicine 
(FABRICANT and FARNSWORTH, 2001).  Today, a large proportion of clinically used drugs 
and new formulations are derivatives of natural plant products (HARVEY, 2008; KINGSTON, 
2010).  Familiar examples include:  artemisinin, aspirin, atropine, bulbocapurine, cocaine, 
codeine, colchicines, ephedrine, hyoscyamine, ipecac, morphine, papverine, physostigmine, 
picrotoxin, pilocarpine, pseudoephedrine, quinidine, quinine, reserpine, scopolamine, strychnine, 
theophylline and d-tubocaranine (COX, 1994; COX and BALICK, 1994; COX, 1995; VAN 
WYK et al., 1997).   
 
A report by FABRICANT and FARNSWORTH (2001) states that, 122 bioactive compounds 
from an estimated 94 plant species are currently consumed as clinical drugs.  It was further 
established that approximately 80% of these drugs are derived from plants already in use for 
similar purposes in traditional medicine.  In 1991, as reported by O’NEILL and LEWIS (1993), 
clinical drugs from natural products and or their derivatives represented a major portion of the 
best selling pharmaceuticals in that year.  In 1996, six of the top 20 dispensed drugs were natural 
products (PHILLIPSON, 2001).  Other reports claim that, of the 119 plant-derived clinical 
drugs reported by FARNSWORTH et al. (1985), 12 featured in the top 25 best selling 
pharmaceuticals (VERPOORTE, 1998).   
 
It is obvious that modern medicine is closely linked to the continuous development of more 
effective and safe drugs.  Judging from the list of familiar clinical drugs above, plants are an 
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important source of compounds that are ultimately used for drug development.  High-value 
secondary metabolites have also been applied in pharmaceutical, food and agricultural industries.  
Therefore, the potential of medicinal plant research is immense.   
 
1.4. MEDICINAL PLANT SPECIES OF INTEREST 
 
An estimated 49 indigenous orchid species from 20 orchid genera are currently being informally 
traded and used in South African traditional medicine (HUTCHINGS et al., 1996). They are 
used primarily for medicinal and cultural purposes, especially by the Zulu community in South 
Africa (GERMISHUIZEN and MEYER, 2003; HUTCHINGS et al., 1996). 
 
1.5. AIMS AND OBJECTIVES 
 
The current investigation addressed the broader aims of medicinal plant research by determining 
the efficacy, safety and chemical profile of seven indigenous orchid species used in South 
African traditional medicine and practices.   
 
The biological and toxic effects of orchid plant extracts were assessed using established 
pharmacological bioassays.  The phytochemical evaluation of the seven orchid plant extracts 
provided insight into the classes of chemical compounds present and their possible role in the 
observed biological activities.  The potential of plant extracts from seven orchid species 










2.1.1. Medicinal plants 
 
Man‟s dependence on the Plant Kingdom seems to parallel our evolutionary history.  Our basic, 
domestic, cultural and health needs have all been catered for by plants, and through the ages our 
dependence has hardly decreased.  The medicinal value of plants was realised by early 
civilisations and the traditional use of plants as medicine is still in practice today 
(VERPOORTE, 1998).  Some of the earliest indications of mankind‟s dependence on medicinal 
plants and their applications are documented in ancient pharmacopeias (PAGE et al., 1997; 
CRAGG and NEWMAN, 2001).  UNESCO (1996) and WHO (2002a) reported widespread 
usage of medicinal plants within the practice of traditional medicine in developing countries.  
Historically, plants were the only source of medication and they continue to demonstrate their 
therapeutic usefulness by being a part of, possibly the only primary health care system in certain 
regions (RIBEIRO et al., 2010).   
 
The more established traditional health care systems found in India, China, America and Europe, 
have extensive well preserved and detailed documentation in pharmacopoeia.  For example, of 
the approximately 8 000 higher plant species catalogued as having medicinal uses in India, more 
than 1 500 are known to be used across the four major traditional medical systems practised in 
India (Ayurveda, Siddha, Tibetan and Unani) (SUBRAT et al., 2002). Similarly, the Chinese, 
Far East and South American nations still subscribe to their traditional medical systems.  They 
are well integrated and widely studied in their respective countries and have made significant 







2.1.2. Drug discovery process 
 
In traditional medical practices plant based medicines are administered in their crude form.  Drug 
development, however, requires the extraction and isolation of pure bioactive compounds.  The 
earliest record of compound isolation is that of the alkaloid morphine from Papaver somniferum 
in 1805 (Sertürner), closely followed by quinine (bark of Cinchona) in 1820 (Caventon and 
Pelletier) (RAY, 1960; BUTLER, 2005). 
 
Differences between crude and pure plant extracts include their consistency in activity.  With 
crude extracts if individual constituents are active only when acting synergistically, then various 
factors such as physiological, environmental, geographic variation (among others) may impact 
on activity (FIGUEIREDO et al., 2008).  Additional factors known to impact on the efficacy or 
potency post harvest include:  collection techniques, storage and preparation conditions.  When 
compared, there may be more variability and inconsistency in crude plant extracts than in pure 
compounds.  Advantages of pure compound isolation include the ability to determine an accurate 
and effective dose and proper identification of compounds which could lead to the possible 
chemical synthesis of the compound.  This has the added benefit of relieving stress on natural 
plant sources.  Also, one would be able to trace how and where the compound may be involved 
in the different/ relevant biological processes (CANNELL, 1998).  The chemical modification of 
bioactive compounds is carried out in an attempt to produce fewer side effects.  A good example 
of an isolated compound is aspirin which is an effective analgesic and anti-pyretic.  Salicylic acid 
(naturally occurring in the bark of willow (Salix alba) and the poplar tree was isolated and a 
synthetic acetyl derivative was produced from which aspirin was modeled (COLEGATE and 
MOLYNEUX, 1993; HARBOURNE et al., 2009).  Upon isolation and or identification, active 
compounds need to undergo meticulous toxicological, pharmacokinetic and metabolic studies to 
determine their precise effectiveness and safety.  These final steps in the drug development 
process often pose many problems and determine the outcome of studies into naturally derived 
plant products.  
 
The extensive use of drugs such as artemisinin and taxol are indicative of their efficacy.  It also 
draws attention to the therapeutic value and potential of plants as sources of novel bioactive 
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agents.  Unfortunately, this potential is yet to be fully exploited (KINGHORN, 2008).  In 
addition, BALANDRIN et al. (1993) and KINGHORN (2008) showed that plants already 
investigated, were tested for very few types of biological activity.  KINGHORN (2008) 
cautioned that phytochemical studies alone may not reveal all potentially bioactive constituents.  
The advent of high-throughput bioassays has allowed for more in depth research (HOUGHTON 
et al., 2007).  Some of the advantages include a smaller sample size and the ability to investigate 
many plants at a time.  Bioassays, though convenient, need to be sensitive to the presence of 
bioactive agents while at the same time preventing false positives.  There is the added possibility 
of false negative results when using low concentrations of crude extracts (RASOANAIVO and 
RATSIMAMANGA-URVERG, 1993).  RASOANAIVO and RATSIMAMANGA-URVERG 
(1993) and HOUGHTON et al. (2007) caution that false negatives may also be a result of loss 
of synergistic effects when active compounds are separated out in methods such as bioassay 
guided fractionation.  Therefore, as highlighted by VERPOORTE (2000), a combined approach 
by the various disciplines would be advantageous.  Often, however, very few laboratory tested 
active compounds appear on the shelves as clinical drugs.  
 
Natural plant products are still widely used and the demand is steadily growing.  However, only 
94 plant species are represented in the 122 plant-derived pharmaceuticals used today 
(FABRICANT and FARNSWORTH, 2001).  Based on the extensive historic and global use of 
plants as medicine, as well as their availability (≈250 000 higher plant species), there is a great 
possibility of uncovering useful bioactive compounds within the Plant Kingdom (NEWMAN 
and CRAGG, 2007).  This in turn could result in the formulation of new drugs.   
 
 
2.1.3. Secondary metabolites 
 
Secondary metabolites are often considered to be the source of bioactive compounds within 
plants (BALANDRIN et al., 1993).  The valuable role of secondary metabolites as bioactive 
agents has become more apparent over recent years.  Unlike macromolecules, such as nucleic 
acids, proteins and carbohydrates, that are necessary for the proper functioning of the plant; 
secondary metabolites are known to be synthesised for various reasons including, in response to 
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a biological attack and lack of nutrients (CANNELL, 1998).  They are also considered to be 
unique to certain species, with some serving a particular purpose such as antiherbivory effects, 
sexual stimuli and/or antibiotic effects; while others have no apparent purpose (CANNELL, 
1998).  These chemical structures may be produced at different stages of a plant‟s life with a 
variation in type and quantity.  Such intra-specific variation may be due to differences in: genetic 
make-up, growth conditions, habitat, stage in life-cycle or the plant organ being investigated 
(FIGUEIREDO et al., 2008).  In 1998, VERPOORTE reported that there was in excess of 100 
000 known secondary metabolites, however only a few of these have been studied.  He further 
emphasised the immense potential of discovering bioactive compounds.  New chemical 
structures may be present with different modes of action, better activity, or perhaps fewer side 
effects than those already known and used in clinical drugs.  Therefore, there is significant 
potential for the discovery of substances with therapeutic value from traditionally used plants.   
 
 
2.1.4. Traditional medicine 
 
Traditional medicine can be defined as encompassing “diverse health practices, approaches, 
knowledge and beliefs [that] incorporate plant and animal, and or mineral based medicines, 
spiritual therapies, manual techniques and exercises applied singularly or in combination to 
maintain well being as well as to treat, diagnose or prevent illness” (WHO, 2002a).  Through 
the ages many cultural groups around the world have incorporated and practiced such medical 
practices into their cultures, which has been passed down to the next generation as part of their 
cultural heritage (WHO, 2002a).  In developing countries traditional medicine is more widely 
practiced when compared to Western medicine.  The World Health Assembly acknowledged the 
dependence of developing nations on traditional medicine for primary health care in their 
declarations.  UNESCO (1996) reported a widespread usage of medicinal plants within the 
practice of traditional medicine in developing countries.  It is estimated that up to 80% of the 
world‟s population depend on traditional medicine to cater for their primary health care 
(ABELSON, 1990; HILLENBRAND, 2006).  However, traditional medicine should not be 
considered to be a primary healthcare alternative found only in developing countries.  A later 
report showed an increased dependence by developed countries on natural plant products (in the 
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form of plant derived clinical drugs/herbal remedies) (KUHN, 2002; RASKIN et al., 2002).  
Twenty five percent of clinical drugs contain bioactive compounds extracted from plants 
(FARNSWORTH, 1984; FARNSWORTH, et al., 1985; CAMERON et al., 2005).  The 
WHO reported in 2008 that little over 70% of European, North American and other developed 
countries‟ population has used various forms of alternative/complementary therapies (VAN DER 
WATT et al., 2008; WHO 2008). 
 
Traditional medicine may be considered a more holistic system where both the physical and 
mental aspects of an illness are considered.  The WHO 2001 report, lists some of the advantages 
of traditional medicine over conventional medicine:  accessibility, affordability, wider 
acceptance by the developing nations, increasing popularity in developed countries.  In Africa 
the number of people using traditional medicine varies greatly with that of those that use 
conventional medicine.  Take for example the relative ratio of patients to practitioners in Ghana:  
224 people: 1 traditional healer compared to 21 000 people: 1 orthodox practitioner and in 
Swaziland:  110 people:  1 traditional healer compared to the 10 000 people: 1 orthodox 
practitioner (RUKANGIRA, 2001).  According to Statistics South Africa, there are an estimated 
200 000 traditional healers in South Africa (cited in MOAGI, 2009).  This estimate includes 
diviners (sangoma) and herbalists (inyanga) as well as traditional birth attendants and surgeons 
(WREFORD, 2007).   
 
With regard to African Traditional Medicine, a medicinal plant may also be consumed as food so 
there is no impression of it being toxic as it contains therapeutic properties.  Unfortunately 
though, clinical drugs which are often produced synthetically with very specific and potent 
therapeutic activity have been associated with numerous, often severe, side effects.  The 
iatrogenic effects of modern drugs made available to communities that rely on traditional 
medicine may be due to the lack of information on its use, misadministration of the drugs or even 
drug abuse.  A medicinal plant on the other hand may not exhibit such high potency (as the 
active compound is present in its crude form) but there have been few reports of severe side 




Natural products have played an integral role in treating infectious diseases (CRAGG et al., 
1997; MAHADY et al., 2008).  Earlier discoveries of therapeutic agents from natural resources 
are an indication of the value of natural products/nature.  The vast number of illnesses that affect 
communities in developing countries like Africa can be attributed, in part, to unhygienic 
practices and living conditions and the lack of food and safe drinking water (BLACK et al., 
2003; WEISS and McMICHAEL, 2004; COKER et al., 2011).  PELEG and HOOPER 
(2010) call attention to the chronic worldwide crises of ineffective treatment for emerging and 
re-emerging infectious diseases and the constant development of antibiotic resistance (AR).   
 
However, it makes more economic sense for pharmaceutical companies based in developed 
countries to conduct extensive research on ailments such as heart disease and cancer.  This is 
often in response to market/population demands.  So, with hardly any buying power, 
communities in the developing countries have not been able to influence/motivate for research 
initiatives towards ailments that most affect them (SHAH, 2010).  With traditional medicine 
being a well supported industry and considering the wealth of natural resources, a more focused 
and meaningful approach to research should be to assess traditional medicinal plants for potential 
therapeutic compounds.  This would allow for the validation of use of those species.   
 
 
2.1.5. Traditional medicine in South Africa 
 
The African continent is home to a multitude of habitats which comprise a wide range of plant 
species.  The African medical system draws on this resource to treat a large proportion of the 
population that prefers to consult a traditional healer rather than a conventional medical 
practitioner.  RASKIN et al. (2002) estimated that 75% of the population from developing 
countries depend on plant-based remedies. 
 
A major sector of the South African population subscribe to the use of medicinal plants to attend 
to their health needs.  The preference for traditional medicine over conventional medicine was 
thought to be due to medication being accessible and a cheaper option. According to MANDER 
et al. (2007) however, the use of traditional medicine is not limited to regions and/or persons that 
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are poor and uneducated.  He goes on further to state that “traditional medicine was often more 
expensive than at local government clinics”.  This trend is not surprising though as, the practice 
and consumption of African Traditional Medicine is based primarily on the cultural beliefs and 
traditions of the African community.  The Southern African region supports approximately 30 
000 higher plant species of which an estimated 3 000 are used in traditional medicine (VAN 
WYK et al., 1997). 
 
MANDER (1998) reported on the extent of traditional medicine usage in KwaZulu-Natal.  Since 
then statistics on the trade of traditional medicines in South Africa have not changed much.  
MANDER et al. (2007) revealed similar estimates; with about 27 million consumers, more than 
133 000 persons employed and over 700 plant species traded.  Another report by VAN WYK et 
al. (2009) indicated the national position with around 3 000 plants being used for medicine, with 
only 350 species used more commonly/traded more often.  VAN WYK et al. (2009) also 
reported that an estimated 200 000 indigenous traditional healers in South Africa consult with a 
large sector of the population (providing primary healthcare alternatives).  It is because of this 
high number and their location, that they are more available and accessible to communities in 
rural and remote parts of South Africa (LIVERPOOL et al., 2004).  Previously, the South 
African Medical Association estimated that in South African cities there is 1 orthodox medical 
practitioner to 700 patients.  In rural areas however, that ratio is 1:10 000.  These kinds of 
statistics reveal why there may be such a heavy reliance on traditional medicine at present.  More 
recent data published by BUSIA (2005) show ratios of 1:1639 and 1:700-1200 for orthodox 
doctor:patient and traditional medical doctor:patient respectively.  
 
South African traditional medicine, however, is at risk of losing vital indigenous knowledge.  
Unlike Indian and Chinese traditional medicine, knowledge has not been captured in documents 
or pharmacopeias detailing the use, preparation and administration of the medication.  Instead, 
African cultural heritage, which includes knowledge about traditional medication, has been 
passed down by word of mouth from generation to generation (MOROLONG, 2007).  This 
tradition of oral history has the risk of future misinterpretation and loss of information.  
However, there have been significant ethnobotanical contributions over the years by various 
authors which serve as the only available documented information on African traditional 
12 
 
medicine, at times detailing the uses, preparations and administration of South African plants in 
the African medical system.   
 
It is mainly the elders of a rural community that hold significant knowledge of herbal medicine 
(LALONDE, 1993).  However, VAN WYK et al. (1997) are quick to point out that, though 
traditional medicine is deeply rooted in ancient tradition, it is adaptable and open to change 
through modern developments.  SIMON and LAMIA (1991) reported the dispensation of 
effective conventional medication such as penicillin by traditional healers.  They have also 
shown keen interest in primary health care training programmes (RICHTER, 2003).   
Another positive development is the renewed interest in the medicinal plants used.  Recent 
research efforts address two main topics:  the conservation of the more commonly used plants 
and their cultivation; and the pharmacological evaluation of the plants to verify their medicinal 
value and efficacy.  
 
 
2.1.6. Conservation issues 
 
There has been renewed interest in traditional practices, drugs originating from plants around the 
world, and plants used for ethnomedicinal uses since the 1990s.  This renewed respect for the 
indigenous people and the wealth of knowledge they hold is mainly due to conservation concerns 
and the increased demand by the public for alternative medicines (IDRC FACTSHEET).   
South Africa boasts great plant biodiversity, yet there are a number of factors contributing to 
their decline.  One of these factors is the incorrect and/or over-harvesting of vulnerable 
medicinal plant species.  Historically, plant material was harvested in a sustainable manner 
mostly by the healer himself (VAN WYK et al., 1997). It has however, become modern practice 
to purchase these plants from informal/untrained gatherers trying to generate an income.  This 
impacts negatively on the natural/wild plant resources as there is no sustainable harvesting 
(MANDER et al., 2007) and it is an obvious threat to South Africa‟s plant biodiversity.  The 
practice of traditional medicine is not widely accepted due to the dire conservation status of 
many medicinal plants.  The harvesting of plant species for traditional medical practices is 
however, not considered the greatest threat to biodiversity.  According to the Living Planet Index 
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(which “reflects the state of the planet‟s ecosystems”) in the LIVING PLANET REPORT 
(2008) habitat loss, land changes and fragmentation due to agriculture are the chief 
anthropogenic factors that negatively impact on natural ecosystems.  Other threats are grouped as 
either overexploitation, pollution, spread of invasive species or genes and climate change; in 
order of severity.  Accordingly, HINRICHSEN and ROWLEY (1999) predict that up to 60 000 
plants could become extinct by the year 2025.  It has also been suggested that there is significant 
economic value attached to plant-based drugs and those that are yet to be discovered 
(PRINCIPIE, 1996).   
 
Given the vast plant biodiversity and rich cultural heritage of South Africa, the renewed interest 
in medicinal plant research and conservation concerns; we are obliged to conduct exact and 
responsible scientific research.  Medicinal plants and holders of indigenous knowledge are 
valuable resources to our society.  While South Africa is unique in many ways, the 
environmental, social and economic difficulties we face are not new.  Medicinal plant research 









The Orchidaceae make up the largest and most diverse family of flowering plants.  They are 
popular, often expensive, ornamentals.  They are widespread, with a broad range of 
ethnobotanical applications. Their medicinal use and corresponding pharmacological and 
phytochemical properties have been extensively investigated globally.  However, the biological 
activity and chemical composition of South African medicinal orchid species is yet to be 
explored fully. There is very limited documented information on South African medicinal orchid 
species; no formal pharmacopoeia outlining ethnobotanical uses; and ethnobotanical and 
distribution records are either scarce or inconsistent and plant populations are becoming 
gradually smaller.  In this Chapter the potential for South African species is highlighted by 
reviewing pharmacological and phytochemical research done globally on other orchid species. 
 
 
3.2. THE FAMILY 
 
The Orchidaceae is the largest Angiosperm family and boasts a worldwide distribution of an 
estimated 20 000 species and 796 genera (CHASE et al., 2003; DRESSLER, 1993b). More 
recent estimates are in the region of 35 000 species (CRIBB et al., 2003).  Currently, there are 
five accepted subfamilies, Apostasioideae (earliest orchids), Cypripedioideae, Vanillioideae, 
Orchidioideae and Epidendrioideae (largest and most evolved) (SMITH and READ, 2008a).  
Most orchids are either epiphytic or terrestrial with some orchid species having other growth 
forms such as epilithic or lithophilic (attached to rocks) and saprophytic (feeding on dead 







3.3. MORPHOLOGY AND REPRODUCTIVE BIOLOGY 
 
The Orchidaceae are monocotyledonous plants with very distinguishing characteristics 
(SEIDENFADEN and WOOD, 1992; DRESSLER, 1993a; 
HTTP://WWW.KEW.ORG/SCIENCE/ORCHIDS/ORCHIDSTRUCTURE.HTML).  
Morphologically, orchids are unique with zygomorphic flowers that contain a labellum or lip 
(highly modified and enlarged petal) and varying lengths of spurs (elongated perianth lobes or 
median and lateral sepals).  The lip is considered to be an adaptation that facilitates cross 
pollination.  Another distinctive feature of an orchid flower is the gynostemium (column) which 
is a combination of the pistil and remaining stamen/s (female and male reproductive organs).  
There is vast evolutionary history associated with this particular fused organ.  The anther found 
at the tip of the column has a sticky mass – viscidium to which pollinia (separate masses of 
pollen) are attached via a stipe in most epiphytic orchids or a caudicle in most terrestrial orchids.  
The stigma is ventrally positioned in the column.  Pollinia are generally transferred to the stigma 
via a rostellum (modified stigma lobe).  Most orchid flowers undergo resupination at the inferior 
ovary, where the flowers rotate 180°, to ensure that the lip is positioned below the column and to 
allow more efficient and successful pollination.  Resupination, however, seems to have been lost 
in some genera, while in some genera, the flower may rotate 360°.  Post pollination, ovules 
develop into minute „dust-like‟ seeds which are suitable for wind dispersal.  Other significant 
structures include the inflorescence (structure on which flowers are presented), pseudobulbs 
(modified stem that perform the role of a water storage organ), tubers (underground structures 
that endure the dry seasons), velamen (a protective layer found on the older section of the roots) 
and a symbiotic relationship with mycorrhiza at the root soil interface (which facilitates uptake 
of nutrients).   Such valuable features have enabled the different genera to colonise many diverse 





Orchids have adapted to a wide range of habitats around the world, occurring mainly in the 
tropical and subtropical regions and at altitudes ranging from sea level up to 5 000 m.  They are 
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particularly dominant in a nutrient-deficient environment and more than half the world species 
are epiphytic.  The tropics of South America support the highest number of speices (±6400), 
followed by Asia (±4000) and Africa (±1500) (BRUMMIT, 2001; McMURTRY et al., 2008).  
Comparatively, Africa is less well endowed, however, southern Africa accounts for a third of the 
1500 orchid species and can therefore be considered rich in orchid diversity.  In southern Africa, 
orchids are widely represented, with 55 genera and approximately 494 epiphytic and terrestrial 
species (GERMISHUIZEN and MEYER, 2003).  A high frequency of endemism is also a 
feature with approximately 75% being endemic to the region, occupying a very restricted 
distribution range (STEWART et al., 1982).  For those genera found in other regions, the 
majority of their species are endemic in southern Africa. 
 
 
3.4.1. Distribution pattern in South Africa 
 
An orchid distribution map posted on the Plantzafrica website shows the presence of orchid 
populations across the greater part of the country (POWRIE and KURZWEIL, 2000).  The 
northwestern region however, reveals a much reduced occurrence of orchid species.  In South 
Africa, 35 species are terrestrial, 17 epiphytic and 1 epilithic.   
 
The species used for traditional medicine in South Africa are distributed mainly in the eastern 
and northern regions of the country (Table 3.1. Chapter 3).  This distribution pattern is probably 
dictated by seasonal rainfall patterns.  Species such as Ansellia africana Lindl., Disa aconitoides 
Sond., Eulophia clavicornis Lindl. var. clavicornis, E. ensata Lindl. share similar distribution 
patterns across the south eastern coast towards the northern Provinces of South Africa.  Some 
species are found across the border into neighbouring countries such as Zimbabwe and 
Mozambique (E. tenella Rchb.f. and D. polygonoides Lindl.  respectively), or as far north as 
tropical Africa (Diaphananthe xanthopollinia (Rchb.f.) Summerh. Synonym:  Rhipidoglossum 
xanthopollinium (Rchb.f.) Schltr. and E. angolensis (Rchb.f.) Summerh.).   
 
Seven species were investigated in this study; two belong to the pantropical terrestrial Eulophia 
genus, E. petersii and E. hereroensis.  The epiphytic Ansellia genus which also occurs in these 
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habitats is considered rare due to overharvesting.  Cyrtorchis arcuata and Tridactyle tridentata, 
two epiphytic species share similar distribution patterns across Africa.  Another well represented 
genus in the southern African region is the epiphytic/lithophytic Polystachya.  Polystachya 
pubescens is found more commonly in forest and bushland regions.  Bulbophyllum scaberulum, 
another lithophyte can be found in large masses on trees and rocks.  
 
 
3.5. ETHNOBOTANICAL USES OF ORCHIDS AROUND THE WORLD 
 
 
3.5.1. Medicinal uses 
 
It is a broadly known concept that orchids are used for medicinal purposes around the world.  
The medicinal value of orchids was realised by the early civilizations and they were 
subsequently used as therapeutic agents to treat common ailments.  BULPITT (2005) described 
the widespread medicinal use of orchids.  In early European history, Theophrastus (372-286 BC) 
derived the word orchid from the Greek word orchis (as the tubers of many European terrestrial 
orchids resembled testicles).  Orchids were therefore used initially to treat testicular diseases and 
as an aphrodisiac (BULPITT, 2005). LANGHAM (1579) described anti-pyretic; anti-
consumption; and anti-diarrhoeal effects.  The mucilaginous nature of salep served as a 
demulcent and nutritive to sooth gastrointestinal irritations (BULPITT, 2005).  The Americans 
make extensive use of the vanilla orchid as a flavourant and perfume, a tradition passed on from 
the ancient Aztecs to modern civilizations.  The vanilla aroma is used to detect Alzheimer‟s 
disease (FLADBY et al., 2004).  Vanillin (active compound isolated from vanilla) is also 
reported to have antimicrobial activity (FITZGERALD et al., 2003).  The Australian aborigines 
and early settlers mainly used the Cymbidium and Dendrobium species to treat dysentery, as an 
oral contraceptive, to relieve pain/poultice, and to cure ringworm infection.  Some species were 
consumed as a food source.  BULPITT (2005) also makes reference to other regions such as 




In India, the Ayurvedic Pharmacopoeia currently consists of seven volumes and is a legal 
document of standards for the quality of Ayurvedic drugs used since the Vedic era. Tonics such 
as Ashtawarga which comprise of eight drugs include four orchid species – Malaxis muscifera 
(Lindl.)Kuntze, M. acuminate D.Don, Habenaria intermedia D.Don and H. edgeworthi Hook.F.  
There is record of 40 other species used in traditional Indian medicine (SINGH et al., 2007; 
RAO, 2004).  These species represent approximately 21 genera; all identified as important 
medicinal sources:  Acampe, Bulbophyllum, Calanthe, Coelogyne, Cymbidium, Cypripedium, 
Dactylorhiza, Dendrobium, Epipactis, Eria, Eulophia, Filckingeria, Habenaria, Liparis, Luisia, 
Malaxis, Pecteilis, Pholidota, Rhynchostylis, Satyrium and Vanda (SINGH et al., 2007).  
Chinese traditional medicine, which is just as ancient as Ayurvedic medicine, has many 
references to orchid use for medicinal treatment.  BULPITT et al. (2007) highlighted the five 
major traditional medicines of which orchids are key ingredients – Shi-Hu (five Dendrobium 
species) used to treat deficiency disorders in the kidney, lung and stomach, Tian-Ma (Gastrodia 
elata) used to relieve dizziness, convulsions, hypertension and to treat stroke patients, Bai-Ji 
(Bletilla striata) used to treat haemorrhagic disorders as well as cancers; Jin-Xian-Lian (two 
Anoectochilus species) used mainly to treat nephritis, cystitis and pneumonia and Shan-Ci-Gu 
(Cremastra appendiculata) used to treat tonsillitis, hypertension and cancers. 
 
On the African continent there are many examples for use; for instance Malawians use about 12 
species for medicinal purposes, of which approximately nine species are used to treat stomach 
ailments and two more cater for fertility problems.  Cyrtorchis arcuata is used to treat diabetes 
and skin infections; epilepsy is prevented by using E. cucullata and psychological disorders such 
as madness is treated with T. tricuspis (BULPITT, 2005).  While there is an awareness of 
medicinally used orchids around the world; the extensive use of certain southern African orchids 
for medicinal and magical purposes is not known to most people, illustrated in Table 3.1. 
(Chapter 3).  The African medical system lacks significant detail on the therapeutic uses, 







3.5.2. Non-medicinal uses 
 
Globally orchids are appreciated for their ornamental appeal and therefore considered as 
significant horticultural plants.  BULPITT (2005) reported on some other economic and cultural 
uses of orchids.  Salep (dried and powdered orchid tubers), famously known in European 
countries, was originally produced by 16th century Europeans for use in beverages and ice cream.  
It is a key ingredient in a popular Turkish dish – salep dondurma (orchid ice cream) and is 
considered to be nutritious.  
 
In Africa, KURZWEIL (2000) confirmed the use of some orchids as food.  The tubers of some 
Disa and Satyrium species in central and eastern Africa are common sources of food for 
communities in rural areas.  Other South African species from these genera are used to produce a 
sweet juice from their roots and tubers while Neobolusia tysonii and Eulophia species. are 
sources of food (KURZWEIL, 2000).   
 
 
3.6. ETHNOBOTANICAL USES OF ORCHIDS IN SOUTH AFRICA 
 
An estimated 49 indigenous orchid species from 20 orchid genera are currently being informally 
traded and used in South African traditional medicine (Table 3.1. Chapter 3) (HUTCHINGS et 
al., 1996). They are used primarily for medicinal and cultural purposes, especially by the Zulu 
community in South Africa (HUTCHINGS et al., 1996; GERMISHUIZEN and MEYER, 
2003). 
 
Informal market surveys, in the greater Pietermaritzburg, Umlazi, and Nongoma regions of 
KwaZulu-Natal, indicated that a number of medicinal orchid species share the same vernacular 
name (e.g.: the vernacular iphamba refers to 12 different species Cyrtorchis arcuata, 
Diaphananthe millarii, D. xanthopollinia, Eulophia ensata, E. ovalis, E. leontoglossa, 
Microcoelia exilis, Mystacidium capense, M. venosum, Polystachya transvaalensis, Tridactyle 
bicaudata, T. tridentata).  It is unclear if this relates to the shape of the plant organs being sold, 
locality from which it was collected, or for its claimed therapeutic use.  Traders were interviewed 
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in their vernacular language and in English about the uses of plants listed in Table 3.1. (Chapter 
3).  Traders recognised plants when using the vernacular names and from pictures of dried 
herbarium samples.  Interviews with plant traders rarely produce congruent answers; with some 
traders not even recognizing the plant or vernacular name at all. Plant traders may also sell 
substitutes for certain orchids; if there are alternative plants with the same/similar vernacular 
name or therapeutic value as the one requested, or if the plant requested is not available.  None of 
the traders interviewed referred to the plant species by their scientific names.   
 
Our observations, of KwaZulu-Natal herbal markets, have indicated that the rate of trade in 
medicinal orchids, as well as the volume traded is higher for species such as A. africana (whole 
plants); which are sold mainly for their aphrodisiac properties. Eulophia streptopetala (tubers 
and roots) is traded at a similar rate, but at a slightly lower volume. Species from the genus 
Eulophia are often sold interchangeably due to their appearance and common use in the 
treatment of infertility. E. petersii (whole plants) is sold frequently, in smaller volumes, as it is 
used both medicinally and culturally. 
 
 
3.6.1. Medicinal uses 
 
3.6.1.1. Inflammatory disorders 
 
From the literature it is evident that approximately 14 orchid species from seven genera are used 
medicinally in South Africa (Table 3.1: Section A Chapter 3). Nearly 50% of these species 
belong to the genus Eulophia.  Three Eulophia species and one Polystachya species are used to 
treat inflammatory related disorders in South African traditional medicine. In South Africa, the 
burnt tuber powder of E. ovalis is rubbed into incisions made on limbs affected by pain 
symptoms (HUTCHINGS et al., 1996). Polystachya ottoniana (plant part not specified) is used 
to produce a soothing effect for teething babies (BATTEN and BOKELMANN, 1966). The 
Malawians use cooked roots of E. cucullata as a poultice (WATT and BREYER-
BRANDWIJK, 1962). In Zimbabwe, the tubers of E. petersii are prepared as an infusion and 
21 
 
used to treat dropsy (GELFAND et al., 1985). The Pedi community uses a root infusion of A. 




3.6.1.2. Intestinal disorders 
 
Polystachya ottoniana (plant part not specified) is used to produce a soothing or curative effect 
for patients with diarrhoea (BATTEN and BOKELMANN, 1966). For those patients diagnosed 
as having intestinal worms, a strong infusion of pounded Satyrium bracteatum tuberous roots 
mixed with milk is used as an enema-type anthelmintic (HULME, 1954).  
 
3.6.1.3. Neurological disorders 
 
For persons that have lost their speech mainly due to an illness (possibly a stroke), an infusion of 
the tubers of D. polygonoides is administered (HULME, 1954).  The Xhosa people use a boiled 
liquid preparation (decoction) of the roots of B. ovata for people inflicted with symptoms of 
madness (BATTEN and BOKELMANN, 1966). Hysterial outbursts are treated with an emetic 
prepared from certain Eulophia species (plant part not specified) (GERSTNER, 1941). An 
infusion of the leaves and stem of A. africana is prepared by the Zambians in the Mpika district 
to treat symptoms of madness (HUTCHINGS et al., 1996). In certain South African regions the 
seeds of P. ottoniana are used as snuff (BATTEN and BOKELMANN, 1966). These seeds 
could be producing a psychoactive or hallucinogenic effect which is used in some aspects of 
African traditional culture. 
 
3.6.1.4. Reproductive disorders 
 
A root infusion of D. aconitoides is administered as an emetic for women; to promote conception 
(HULME, 1954). The Sotho use a cold water infusion of a few Eulophia species (E. clavicornis 
(plant part not specified) and E. tenella (tubers)) to treat infertility (WATT and BREYER-
BRANDWIJK, 1962). JACOT GUILLARMOD (1971) reported a similar use for tuber 
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infusions of E. ovalis. An E. cucullata bulbous root infusion is ingested in small doses by 
married couples if the wife is considered barren (HULME, 1954). Alternatively, a decoction of 
the bulbous root of E. cucullata is ingested by men to treat impotence (BRYANT, 1966). A 
decoction of A. africana is used as an aphrodisiac by women (WATT and BREYER-
BRANDWIJK, 1962). GELFAND et al. (1985) documented a similar use for A. africana in 
Zimbabwe. 
 
3.6.1.5. Other medicinal uses  
 
The therapeutic information, administration and preparation of E. ensata is not entirely 
descriptive and the specific ailment for which this orchid is prescribed is not clear. However, it is 
mentioned that in the Transkei (Eastern Cape) infant ailments are treated with E. ensata (plant 
part not specified) (BATTEN and BOKELMANN, 1966).  Emetics are prepared to cause 
emesis, that is to either induce vomiting or nausea. In African traditional medicine, emetics are 
widely used to facilitate the removal of what is thought to be the cause of the ailment. One would 
be expected to cough up phlegm or mucus that is produced. This practice is particularly common 
in the use of orchids for cultural purposes. Root infusions of E. speciosa are prepared as emetics 
for both humans and animals (GERSTNER, 1941). Similarly, root infusions of H. epipactidea 
are used to induce vomiting (WATT and BREYER-BRANDWIJK, 1962). 
 
 
3.6.2. Non-medicinal uses 
 
Love charms are used extensively in African traditional culture. Approximately 18 orchid 
species from 10 genera are used for such purposes (Table 3.1: Section B Chapter 3). Forty 
percent of these species belong to the genus Eulophia. 
 
3.6.2.1. Love charms 
 
A love charm emetic infusion of Acrolophia cochlearis roots is ingested by young men 
(HULME, 1954). Aerangis mystacidii (plant part not specified) is recorded as being used for a 
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similar purpose in traditional medicine (CUNNINGHAM, 1988). The roots of A. africana may 
be prepared as an infusion and administered as an emetic (GERSTNER, 1941), while the leaves 
are used by men as a courting charm (HUTCHINGS et al., 1996). Cyrtorchis arcuata (plant part 
not specified) is the key ingredient in an emetic that is administered by the man to the young lady 
to make her love him (HULME, 1954). The tuber of E. angolensis is prepared as an emetic 
infusion which is consumed by young men (HULME, 1954). Eulophia cucullata bulbous roots 
are prepared as an emetic infusion (GERSTNER, 1941). The tubers of E. ensata and E. ovalis 
are prepared as emetic infusions which are used by young men (HULME, 1954). The whole 
plant of E. parviflora is vaguely mentioned as a love or protective charm (CUNNINGHAM, 
1988). The tubers of E. petersii are prepared as a sprinkling infusion love charm (HUTCHINGS 
et al., 1996). Other Eulophia love charm emetic infusions may be prepared from E. streptopetala 
(HUTCHINGS et al., 1996) and from tubers of E. welwitschii; which are used by young men 
(HULME, 1954). The tuber infusion prepared from E. tenella is used by young men to wash 
with and is used as a courting charm (HUTCHINGS et al., 1996). The preparation and 
administration of the following species is not entirely descriptive and lacks vital information. 
Two Liparis species, L. bowkeri and L. remota are used as love or goodluck charms (plant part 
not specified) in traditional medicine (HUTCHINGS et al., 1996). An infusion of Microcoelia 
exilis or an emetic of Mystacidium capense is also used as love charms (plant part not specified) 
(HUTCHINGS et al., 1996). A tuber infusion of Oeceoclades mackenii is taken by young men 
(HULME, 1954). Similarly, an emetic prepared from tubers of S. parviflorum is ingested by 
young men (HULME, 1954). 
 
3.6.2.2. Fertility charms 
 
More specific charms are prepared to either prevent or promote fertility. Ansellia africana is 
used by young men to prevent women from having children if their love is not returned (WATT 
and BREYER-BRANDWIJK, 1962). The tubers of two Eulophia species E. clavicornis 
(HUTCHINGS et al., 1996) and E. ovalis (JACOT GUILLARMOD, 1971) are used 
separately to create dolls that represent fertility. Whole plant decoctions of unspecified 




3.6.2.3. Protective charms 
 
Protective charms may be used for bad dreams, to ward off evil, to protect one from lightening 
and to protect the home. Ansellia africana leaves are prepared as an infusion to treat persons 
experiencing bad dreams (HUTCHINGS et al., 1996). Alternatively one can inhale the smoke 
of its burning roots for the same purpose (HUTCHINGS et al., 1996). The tubers of certain 
orchids are used as an infusion that is sprinkled around the home to ward off evil: B. ovata, 
Brachycorythis species, Eulophia clavicornis, S. longicauda and S. parviflorum (HULME, 
1954). Dried, burnt powder of whole plants of H. epipactidea is mixed with sheep fat which is 
applied to pegs put into the ground of a new homestead (HULME, 1954). Whole plant infusions 
may also be prepared from D. stachyoides and D. versicolor for sprinkling around the home to 
ward off evil, while the roots of Corycium nigrescens are prepared as an emetic infusion that is 
ingested (HULME, 1954). An enema-type tuber infusion from E. tenella is used to neutralise 
evil charms put in the food or drink (HULME, 1954).  A whole plant infusion of D. stachyoides, 
a tuber infusion of E. leontoglossa, a root and stem infusion of E. speciosa or a bulb and leaf 
infusion of H. dregeana (HULME, 1954) may also be used to protect against lightening. Dried 
burnt powder from H. epipactidea whole plants mixed with sheep fat may also be applied to 
incisions cut into the wrists, foreheads and ankles of every member of the homestead as 
protection from storms (HUTCHINGS et al., 1996). 
 
The preparation and administration of other orchid-derived protective charms is not clear e.g.: E. 
streptopetala. Similarly, the following species are merely listed as emetic protective or love 
charms:  M. venosum, P. ottoniana, P. pubescens, P. sandersonii, P. transvaalensis 
(HUTCHINGS et al., 1996); while the following species are simply recorded as being used in 
traditional medicine as a charm in southern Africa, unless otherwise stated: A. africana in 
Zimbabwe (GELFAND et al., 1985), E. clitellifera (CUNNINGHAM, 1988), D. millarii 
(HUTCHINGS et al., 1996), D. xanthopollinia (HUTCHINGS et al., 1996), Rangaeris 
muscicola (CUNNINGHAM, 1988), T. bicaudata, T. tridentata and Vanilla roscheri 
(HUTCHINGS et al., 1996). Whole plants of Bolusiella maudiae are vaguely known to be used 




3.6.2.4. Lethal charms 
 
A death charm, used to induce lethal effects, is prepared from the dried powder of Habenaria 
dives Rchb.f. (inhluthi yotshani) tubers, which is mixed with other herbs (HULME, 1954). 
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Table 3.1.:  Description, distribution and conservation status of orchids used for medicinal, cultural and ritualistic purposes in southern Africa 
Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
(Section A) Medicinal Uses     
Ansellia africana Lindl.  
 
Tough, stiff alternate leaves (250-
1000 × 30 mm) with parallel veins; 
Yellow or yellow marked with 
reddish brown flowers (lip is 
brighter yellow) (30-50 mm wide) 
arranged on branching 
inflorescence (±500 mm) (Jun-Nov) 
Imfe-nkawu Aphrodisiac  
Madness  
Coughs  
Tropical Africa (MLW, 
MOZ, ZAM, ZIM, 
BOT, NAM, SWZ) 






(egg-shaped) Perrenial herb; 
crowded sharp-tipped leaves 
(±70×22 mm); Pale pink to purple 
flowers with white keel and purple 
spotted lip; 3 lobed with no spur 
(±13 mm wide) arranged on a 
crowded inflorescence with lower 




Madness Tropical Africa (MLW, 
ZAM, ZIM, SWZ) 
South Africa (CPP, 




Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Disa aconitoides Sond.  
 
(monk‟s hood) Perennial herb; 
Many overlapping leaves; 15-70 
white to pale mauve with darker 
spots flowers with a thick upward 
pointing spur (±10 mm) that is 




Conception Ethiopia, Tropical 
Africa (MLW, MOZ, 
ZAM, ZIM, SWZ) 
 South Africa (CPP, 
NAT, OFS, TVL) 
LC  
Disa polygonoides Lindl.  
 
(knot-grass)Perennial herb; Erect 
clasping leaves (±150×15 mm); 
Red orange flowers on dense 
spikelike inflorescence (±170×20 
mm) with slender spur (± 4,5 mm) 
that faces down. (Oct-May) 
Ihlamvu elibomvu 
Umklakleshe 
Lost speech MOZ, ZIM, LES, SWZ  
South Africa (CPP, 
NAT, OFS, TVL) 
LC  
Eulophia clavicornis 
Lindl. var. clavicornis 
 
(Horn) Perennial herb; Partly to 
fully developed leaves at flowering 
(50-730 mm); green to purplish 
brown sepals with white to pale 
pink or pale blue petals and a lip as 
long as the median sepal (9-18 
mm); cylindrical spur (14-89 mm) 





Infertility ZIM, MOZ, SWZ 





Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Eulophia cucullata (Afzel. 
ex Sw.) Steud.  
 
(Hooded) Perennial herb; Leaves 
may be absent or partly grown at 
flowering and ±300×10 mm at 
maturity; 3-15 large flowers (±30 
mm diameter) and petals and sepals 
(±27 mm) with bright pink to white 
tinged pale purplish pink petals and 
lip, inner surface of lip yellow with 
orange and purple spots; purplish 









Tropical Africa (MWL, 
MOZ, ZAM, ZIM) 
 Madagascar 
South Africa (NAT) 
LC  
Eulophia ensata Lindl.  
 
(Sword-shaped) Perennial herb; 
Stiff, erect, pleated, tapering partly 
to fully grown leaves at flowering 
(±900×15 mm); 6-30 pure yellow 
flowers (±20 mm) with 3 lobed 
blunt lip (±25×12 mm) and slender 
spur (±7 mm) (Sep-Feb) 
Iphamba yentaba 
Mahlane 
Infant ailments  MOZ, SWZ  




Eulophia ovalis Lindl. 
subsp. ovalis 
 (Oval) Perennial herb; Fully 
developed leaves at flowering 
(±600×30 mm); ±18 smaller 
flowers with white petals tinged 
yellow or purple, with fleshy lip 
and peg-like outgrowths and 1-5 




ZIM, LES, SWZ  
South Africa (CPP, 




Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Eulophia petersii (Rchb.f.) 
Rchb.f. 
 
Perennial herb; Thick, spreading 
leaves with rough margins 
(±400×44 mm); flowers arranged 
on well spaced inflorescence with 
branching stem, large flowers, 
sepals (19-33 mm), petals and 
sepals curled back, greenish 
purplish brown, white lip (±30×15 
mm) with purplish pink crests; 2-8 
mm spur (Nov-Apr) 





MLW, MOZ, ZAM, 
ZIM, SWZ,  

















Not Applicable Not Applicable 
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Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Eulophia speciosa (R.Br. 
ex Lindl.) Bolus 
 
(Beautiful) Perennial herb; Stiff, 
smooth and thick mature leaves at 
flowering (±600×20 mm); 10-30 
flowers arranged on inflorescence with 
small pale green sepals, large spreading 
bright yellow petals (±20×15 mm) and 
a blunt spur (Aug-Jan) 
Amabelejongosi 
Umlunge omhlope 
Emetic  Ethiopia - Arabian 
Peninsula 
MLW, MOZ, ZAM, 
ZIM, BOT, NAM, 
SWZ 
South Africa (NAT, 
TVL) 
Lower Risk – Near 
Threatened 
Declining  
Eulophia tenella Rchb.f. 
 
(Tender) Perennial herb; leaf 
dimensions (100-420×2-6 mm); 
Small flowers with green to brownish 
purple sepals (±9 mm) and creamy 
yellow petals, midlobe of lip is bright 
yellow with stout spur (2-3 mm) 
(Nov-Jan) 
Untongazibomvana Infertility  South Tropical Africa 
(MOZ, ZIM) 












(Similar to Epipactus) Perennial 
herb; overlapping ribbed leaves that 
clasp the stem and grade into bracts 
(±100×20 mm); creamy green 
flowers with white lip arranged on 
dense inflorescence (±120 mm) 
with erect bracts  ±40×10 mm, 
midlobe of lip ±15 mm hair-like 
side lobes, ±30 mm slender spur 




Emetic  Ethiopia, ZIM, BOT, 
LES, NAM, SWZ 






Perennial herb; Epiphyte; Vertically 
flattened pseudobulb and tapering 
to one end (±25×15 mm); 2-4 blunt 
notched leaves (±80×10 mm); 1-6 
white to pinkish or yellow flowers 
(10-14 mm wide) on slender, erect 
inflorescence, 3 lobed, curled lip 
with yellow mid stripe with pink 






South Tropical Africa 
(MOZ, ZIM, SWZ) 





Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Satyrium bracteatum (L.f.) 
Thunb.  





South Africa (CPP, 
NAT, TVL) 
LC  
(Section B) Cultural and Ritualistic Uses    
Acrolophia cochlearis 
(Lindl.) Schltr. & Bolus 
 
(shell-like) Perrenial herb, 4-9 
leaves arranged in 2 ranks; Small 
(<10 mm wide) flowers coloured 
greenish brown, white with tinge of 
purple arranged on a widely 
branced inflorescence (Aug – Jan) 




(Rchb.f.) Schltr.  
 
Flat leathery, oblong/ wider at 
bilobed tip, dark green leaves 
arranged in a fan; 2-6 (±280 mm) 
inflorescence with 4-14 (up to 24) 
flowers (±20×25 mm wide) that are 
white tinged pink; Spur 60-80 mm 
(Feb-Jun) 




MLW, MOZ, ZAM, 
ZIM, SWZ 





Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Ansellia africana Lindl.  
 
Tough, stiff alternate leaves (250-
1000 × 30 mm) with parallel veins; 
Yellow or yellow marked with 
reddish brown flowers (lip is 
brighter yellow) (30-50 mm wide) 
arranged on branching 
inflorescence (±500 mm) (Jun-Nov) 
Imfe-nkawu Courting 
charm  
Bad dreams  
Love charm  
Bad dreams  
Charms  
 Tropical Africa (MLW, 
MOZ, ZAM, ZIM, 
BOT, NAM, SWZ) 
South Africa (NAT, 
TVL) 
 




(Bolus) Schltr.  
 
Rare, thin short roots; Short stems; 
3-10 dark green fleshy, succulent 
leaves that overlap at base in a fan 
arrangement (Feb) (20-30×5-8 
mm); 20-30mm wide flowers 
partially hidden by bracts; with lip 
3 lobed at base and short rounded 
spur. 




Tropical Africa (MLW, 
ZAM) 










(egg-shaped) Perrenial herb; 
crowded sharp-tipped leaves 
(±70×22 mm); Pale pink to purple 
flowers with white keel and purple 
spotted lip; 3 lobed with no spur 
(±13 mm wide) arranged on a 
crowded inflorescence with lower 




Ward off evil  Tropical Africa (MLW, 
ZAM, ZIM, SWZ) 
South Africa (CPP, 
NAT, OFS, TVL) 
LC  
Brachycorythis species  Ilabatheka 
elikhulu 




Perennial herb; Erect (±200 mm) 
overlapping leaves; small rounded 
brown to black flowers in dense 
inflorescence, lateral sepals mostly 
joined, lip appendage (±4 mm); 
Bracts have long slender points 
(Dec-May) 
Umabelebuca Ward off evil  Southern Tanzania, 
LES, SWZ 
South Africa (CPP, 








(Lindl.) Schltr.  
 
(bent like a bow) Perrenial herb; 
epiphyte; with whitish roots with 
greenish orange tips; ±400×10 mm 
wide stems; strap-shaped leathery 
wide stiff leaves (110-160×25-30 
mm); Large cream flowers (±50 
mm  wide) with 40-60 mm spur 
arranged on 2-6 hanging 





Love charm Tropical Africa (MLW, 
MOZ, ZAM, ZIM, 
SWZ) 




(Bolus) H.P.Linder  
 
Perennial herb; epiphyte; Rare; (4-
5mm) diameter Roots grey- green 
with elongated white dots; ±25 mm 
stems; 3-10, 70-120×15-17 mm 
stiff, velvety leaves with 
conspicuous veins; 1-2 hanging 
inflorescence (±27 mm) with 7-13 
(±12 mm) diameter flowers with 
rounded sepals, green anther caps, 






















(yellow pollinia) Perennial 
herb;Epiphtye; branched stems (120 
mm); ±16 (40-100×6-9 mm) 
leathery, thin, straight leaves with 
rounded lobes at tip; 10-25 
yellowish green flowers (6-12 mm 
diameter) with very broad lip, 
slightly curved lip (±5 mm) on 




Uganda, MLW, MOZ, 
ZAM, ZIM 
South Africa (CPP, 
NAT) 
LC  
Disa stachyoides Rchb.f. 
 
(Wound wort) Perennial herb; 
pointed leaves (±80×10 mm); Small 
purple flowers with white lip, 2-6 
mm broad, flat almost horizontal 
spur; arranged on dense 
inflorescence (±100 mm) (Nov-Jan) 
Ihlamvu elimpofu 
Lasenkangala 
Ward off evil 
and lightening  
LES, SWZ  
South Africa (CPP, 




Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Disa versicolor Rchb.f. 
 
(Changing colour) Perennial herb; 
3-5 folded basal leaves (±200×20 
mm) from separate shoot; sheathing 
stem leaves (±100×15 mm); dull 
red to pink or fading greenish 
brown flowers with hook spur (5-7 
mm) arranged on dense 
inflorescence (±150 mm) with 
bracts longer than flowers; vanilla 
scented (Dec-Feb) 
Ihalmvu elibomvu Ward off evil  Southern Tropical 
Africa (MOZ, ZIM, 
LES, SWZ) 
South Africa (CPP, 





Perennial herb; Stiff, erect, pleated 
leaves (±900×50 mm); 4-10 bright 
lemon yellow with purplish brown 
or olive tinged flowers (± 26 mm) 
with large blunt tipped sepals and 
poorly developed spur arranged on 
±300 mm inflorescence; sweetly 
scented (Oct-Apr) 
Amabelejongosi Love charm   Tropical Africa (MLW, 
MOZ, ZAM, ZIM, 
BOT) 










Lindl. var. clavicornis 
 
(Horn) Perennial herb; Partly to 
fully developed leaves at flowering 
(50-730 mm); green to purplish 
brown sepals with white to pale 
pink or pale blue petals and a lip as 
long as the median sepal (9-18 
mm); cylindrical spur (14-89 mm) 





Ward off evil  
Fertility charm  
ZIM, MOZ, SWZ 




(Rchb. f.) Bolus 
 
(Small pack saddle) Perennial herb; 
Leaves may be absent or ±40 mm at 
flowering with mature thick, stiff 
leaves (±240×13 mm); 5-25 small 
white to pale yellow with reddish 
purple lined flowers, petals and 
sepals spreading (4-9 mm), bright 
yellow crest on lip with ±4 mm spur 
(Jul-Nov) 




Tropical Africa (MOZ, 
ZAM, ZIM) 
Madagascar 
South Africa (CPP, 




Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Eulophia cucullata (Afzel. 
ex Sw.) Steud. 
 
(Hooded) Perennial herb; Leaves 
may be absent or partly grown at 
flowering and ±300×10 mm at 
maturity; 3-15 large flowers (±30 
mm diameter) and petals and sepals 
(±27 mm) with bright pink to white 
tinged pale purplish pink petals and 
lip, inner surface of lip yellow with 
orange and purple spots; purplish 






Love charm  
 
Tropical Africa (MWL, 
MOZ, ZAM, ZIM) 
Madagascar 
South Africa (NAT) 
 
LC  
Eulophia ensata Lindl. 
 
(Sword-shaped) Perennial herb; 
Stiff, erect, pleated, tapering partly 
to fully grown leaves at flowering 
(±900×15 mm); 6-30 pure yellow 
flowers (±20 mm) with 3 lobed 
blunt lip (±25×12 mm) and slender 
spur (±7 mm) (Sep-Feb) 
Iphamba yentaba 
Mahlane 
Love charm  MOZ, SWZ  











(Tongue like a lion) Perennial herb; 
Stiff; erect; partly to fully grown 
leaves at flowering (±450×9 mm); 
7-35 (±16 mm) white to lemon 
yellow to pink tinged green flowers; 
pale yellow, pink, or white petals; 
yellow to brown crests on lip; 
slender spur (3-5 mm) with 
overlapping bracts (Aug-Feb) 
Iphamba Protection 
from storms  
LES  
South Africa (CPP, 
NAT, OFS, TVL) 
LC  
Eulophia ovalis Lindl. 
subsp. ovalis 
 
(Oval) Perennial herb; Fully 
developed leaves at flowering 
(±600×30 mm); ±18 smaller 
flowers with white petals tinged 
yellow or purple, with fleshy lip 
and peg-like outgrowths and 1-5 
mm spur (Oct-Apr) 
Iphamba Love charm  
Infertility 
charm  
ZIM, LES, SWZ 
South Africa (CPP, 








(Lindl.) A.V. Hall 
 
(With small flowers) Perennial 
herb; Partly developed leaves at 
flowering, leathery, and (250×16 
mm) at maturity; 5-30 flowers with 
blunt petals and sepals, (7-20 mm), 
sepals are brownish green on the 
outside and orange-brown on the 
inside and pale yellow petals with 
brownish red veins, yellow midlobe 
with broad fleshy ridges and 2-5 
mm spur (Aug-Dec) 




Africa (MOZ, ZIM, 
SWZ) 
South Africa (CPP, 
NAT, TVL) 
LC  
Eulophia petersii (Rchb.f.) 
Rchb.f. 
 
Perennial herb; Thick, spreading 
leaves with rough margins 
(±400×44 mm); flowers arranged 
on well spaced inflorescence with 
branching stem, large flowers, 
sepals (19-33 mm), petals and 
sepals curled back, greenish 
purplish brown, white lip (±30×15 
mm) with purplish pink crests; 2-8 
mm spur (Nov-Apr) 
Isaha                
Isaka 
Love charm  Eritrea, MLW, MOZ, 
ZAM, ZIM, SWZ, 
Arabian Peninsula 





Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 







Love charm  
Protective 
charm  
Not Applicable Not Applicable 
Eulophia speciosa (R.Br. 
ex Lindl.) Bolus 
 
(Beautiful) Perennial herb; Stiff, 
smooth and thick mature leaves at 
flowering (±600×20 mm); 10-30 
flowers arranged on inflorescence 
with small pale green sepals, large 
spreading bright yellow petals 






from storms  
Ethiopia, MLW, MOZ, 
ZAM, ZIM, BOT, 
NAM, SWZ, Arabian 
Peninsula 














(Twisted petals) Perennial herb; 
Thin pleated partially developed 
leaves at flowering (±750×70 mm); 
30-50 flowers arranged on simple 
or branching inflorescence with 
green sepals mottled purplish 
brown (±20 mm) and yellow 
roundish petals, side lobes of lip are 
streaked red-brown, with stout spur 
(1-2 mm) (Sep-Feb) 
Amabelejongosi Love charm  
Protective 
charm  
Eritrea, MLW, MOZ, 
ZAM, ZIM, NAM, 
SWZ, South-west 
Arabian Peninsula 






Eulophia tenella Rchb.f. 
 
(Tender) Perennial herb; leaf 
dimensions (100-420×2-6 mm); Small 
flowers with green to brownish purple 
sepals (±9 mm) and creamy yellow 
petals, midlobe of lip is bright yellow 
with stout spur (2-3 mm) (Nov-Jan) 




Africa (MOZ, ZIM) 






Perennial herb; Stiff, erect, pleated 
leaves (±700×23 mm); 4-5 large, 
pale creamy lemon to bright yellow 
flowers (25(46)×12 mm), petals and 
sepals not spreading, side lobes of 
lip reddish purple with slender spur 
(3-7 mm) (Nov-Feb) 
Umlunge Love charm  Zaïre, ZAM, SWZ 





Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Habenaria dives Rchb.f. 
 
(Rich) Perennial herb; Stiff leaves, 
prominent veins and clasping at 
base (±150×20 mm); small white 
flowers with green veined sepals 
arranged dense inflorescence (±300 
mm), 3 lobed lip with 8-15 mm 
spur; short slender stalks (Dec-Mar) 
Inhluthi yotshani Death charm  LES, SWZ  
South Africa (CPP, 





Perennial herb; Two basal leaves 
(±85 mm), leaves on stem taper to 
hair-like tip (±20 mm); hooded 
greenish flowers arranged on a 
dense inflorescence, 3 lobed lip 
with a slightly longer middle lobe, 
wide mouthed spur which is thicker 
at tip (±10 mm) (Oct-Apr) 
Intelezi ye-zulu Protection 
from storms  
Uganda, ZIM, LES, 
SWZ 
South Africa (CPP, 










(Similar to Epipactus) Perennial 
herb; overlapping ribbed leaves that 
clasp the stem and grade into bracts 
(±100×20 mm); creamy green 
flowers with white lip arranged on 
dense inflorescence (±120 mm) 
with erect bracts  ±40×10 mm, 
midlobe of lip ±15 mm hair-like 
side lobes, ±30 mm slender spur 






from storms  
Ethiopia, ZIM, BOT, 
LES, NAM, SWZ 
South Africa (CPP, 
TVL) 
LC  
Habenaria species  Ihlamvu Birth of a son  Not Applicable Not Applicable 
Liparis bowkeri Harv. 
 
Perennial herb; epiphytic or 
terrestrial; soft green pseudobulbs 
in closely packed surface groups 
(20-70 mm); 2-4 pale green soft 
leaves with side veins (±70×60 
mm); 4-12 translucent yellowish 
green fading brown flowers on a 
slender stem with flat side sepals 
(±12 mm) and very narrow petals, 
6-8 mm broad lip (Dec-Mar) 
Not Available Love 
Goodluck 
charm  
Ethiopia, MLW, ZAM, 
ZIM, SWZ 





Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Liparis remota J.Stewart 
& Schelpe 
 
Similar to Liparis bowkeri with an 
extended rhizome between 
pseudobulbs 
Not Available Love / 
Goodluck 
charm  
Southern Cape Province 
– Swaziland 
LC  
Microcoelia exilis Lindl. 
 
(Thin/Weak) Perennial herb; 
Epiphyte; Leafless; 20-80 tiny 
white flowers (±2 mm) on 
numerous slender inflorescences 
(60-120 mm), flower throughout the 
year. 
Iphamba Love charm  Kenya, MLW, MOZ, 







(Of the Cape) Perennial herb; 
Epiphyte; Pale grey with elongated 
white dots on roots (4-6 mm 
diameter); Long, flat, stiff leaves 
(30-130×10-15 mm) unequally 
bilobed; 6-14 white flowers (±23 
mm) widely spaced on 2-4 hanging 
inflorescences (60-100 mm), pale 
green spur (40-60 mm) (Sep-Jan) 
Iphamba Love charm  SWZ 









Harv. ex Rolfe 
 
(Having veins) Perennial herb, 
Epiphyte; Stemless; Grey-green 
mass of roots with white streaks 
and green tips (4-5 mm diameter); 
Leaves absent or stunted with 
distinctive veins if present (30-
50×8-11 mm); 4-7 white flowers 
(15-20 mm diameter) on 1-2 





South Africa (CPP, 
NAT, TVL) 
LC  
Oeceoclades mackenii (Rolfe 
ex Hemsl.) Garay & P.Taylor 
synonym: Oeceoclades 
maculata (Lindl.) Lindl. 
 
Rare Perennial herb; Dark purplish 
green pseudobulbs; thick 
horizontal, blade-like leaves 
(±150×15 mm) on short mottled 
grey-green stalk; ±30 pink and 
cream flowers arranged on single or 
branched inflorescence, side lobes 
of lip marked pinkish red and 2 red 
blotches in front, club-shaped spur 
(Feb-Apr) 
Impimpi encane Love charm  Africa (MLW, MOZ, 
ZIM) – introduced in 
Tropical America 










Perennial herb; Epiphyte; Vertically 
flattened pseudobulb and tapering 
to one end (±25×15 mm); 2-4 blunt 
notched leaves (±80×10 mm); 1-6 
white to pinkish or yellow flowers 
(10-14 mm wide) on slender, erect 
inflorescence, 3 lobed, curled lip 
with yellow mid stripe with pink 




South Tropical Africa 
(MOZ, ZIM, SWZ) 









(Downy/ Slightly hairy);  Clustered 
pseudobulbs (20-60×1-15 mm); 
Leaves are not fully developed until 
after flowering 2-3 (±100×17 mm); 
8-20 golden yellow flowers (±23 
mm) with side sepals (±12 mm 
wide) streaked with dark red lines, 
red veined lip, lobes covered with 


















Short pseudobulbs (±30×15 mm); 
2-3 small leaves (±100×15 mm); 6-
12 yellowish green and brownish 
orange flowers(±13 mm wide), 
narrowly triangular side sepals with 
a velvety smooth outer surface, 3 
lobed creamy white lip (heavily 











2-6 Blunt blade-like leaves 
(±150×20 mm); ±12 yellowish 
green tinged reddish brown on the 
outer surface flowers arranged on 
short erect inflorescence (±60 mm), 
median sepal ±12 mm, white lip 
with faint purple streaks on the side 
lobes only (Oct-Jan) 
Iphamba Protective/love 
charm  
Cameroon – Kenya, 
MLW, ZAM, ZIM, 
SWZ 











(Growing on / near mosses) 
Perennial herb; Epiphyte; 4-6 mm 
grey roots; woody stem ±25×10 
mm; Erect, deeply keeled, curving 
leaves with unequally bilobed tips 
(70-120×10-13 mm); 5-15 white 
flowers (±25 mm diam) with a 
triangular lip and pointed tip, spur 
50-90 mm (Dec-Mar) 
Not Available Protective/love 
charm  
Tropical Africa (MLW, 
MOZ, ZAM, ZIM) 




Lindl. var.longicauda x 
Satyrium neglectum Schltr. 
subsp. woodii (Schltr.) 
A.V.Hall 
 
(Long-tailed) Perennial herb; 1-2 
basal leaves(±200 mm) prostrate / 
partly erect found on a separate 
shoot from the flowering stem or 
may be absent; ±60 flowers (±20 
mm) on ±200 mm inflorescence, 
deep pink to red flowers, hairy flap 











Species Botanical description Vernacular term Use General distribution 
range 
Conservation status 
Satyrium parviflorum Sw. 
 
(Small flowers) Perennial herb; 2-3 
basal leaves (±300×100 mm) from 
separate shoot or at base of 
flowering stem; ±100 small densely 
packed yellowish green tinged olive 
to dark maroon flowers on ±300 






Ward off evil  
Love charm  
LES, SWZ 
South Africa (CPP, 





(Two-tailed lip) Perennial herb; 
Lithophyte; grey roots and rough 
stems; Leaf dimensions (60-
160×10-15 mm); 12-16 flowers 
(12-16 mm diam), arranged in 2 
rows on ±6 stems (60-80 mm), 3 
lobed lip with fringed side lobes 
spur (10-18 mm) (Oct-Apr) 
Iphamba Protective 
charm  
Tropical Africa (MLW, 
MOZ, ZAM, ZIM, 
SWZ) 














(Three-toothed); Perennial herb; 
Epiphyte; forms large dense 
masses; grey roots; round stems (±3 
mm); 10-14 narrow, round and 
fleshy leaves (50-100×2-4 mm) 
which are widely spaced, pointed 
and slightly grooved on upper 
surface; Flowers (5-8 mm) arranged 
in spikes (3-5 flowers/ spike) 
opposite leaves, coloured pale waxy 
cream, 3-toothed lip, narrow spur 
(±8 mm) (Nov-Mar) 
Iphamba Protective 
charm  
Tropical Africa (MLW, 
MOZ, ZAM, ZIM) 
South Africa (CPP, 
NAT) 
LC  
Vanilla roscheri Rchb.f. 
 
Perennial herb; liana; Imperfectly 
developed leaves, scale-like and 
papery brown (±30 mm); Creamy 
white flowers are arranged spirally 
on terminal or axillary 
inflorescences; succulent stems 
±200 mm; roots arise at nodes that 
clasp vegetation or absorb nutrients 
from the soil 










BOT - Botswana, CPP - Cape Provinces, LES - Lesotho, LC – Least concern, MWL - Malawi, MOZ - Mozambique, NAT - Natal, NT 
- Not Threatened, OFS - Orange Free State, SWZ - Swaziland, TVL - Transvaal, ZAM - Zambia, ZIM - Zimbabwe  
Description and Vernacular name reference:  HUTCHINGS et al. (1996) 
Distribution references (unless otherwise stated):  BRUMMIT (2001); GOVAERTS (2003) 
Conservation status (unless otherwise stated):  RAIMONDO et al. (2009) 
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3.7. PHARMACOLOGICAL AND PHYTOCHEMICAL RESEARCH OF ORCHIDS 
 
There are a number of marketable high-value secondary metabolites currently used in the 
pharmaceutical, food and agricultural industries (RAO and RAVISHANKAR, 2002).  Various 
research initiatives are geared towards maintaining reliable sources of these and other useful 
primary and secondary metabolites.  These include the continuous search for novel compounds, 
identification of biosynthetic pathways and improvement in synthetic production; making use of 
chemical, biotechnological and molecular research techniques.  Medicinal plant research forms 
an integral part of this greater scheme of things as the chemistry of the majority of plant species 
are yet to be determined, novel compounds are often identified and; their therapeutic and 
commercial potential is made apparent. 
 
The information on South African orchid species has been extensive in certain areas of interest, 
such as biology, classification, and conservation of orchids (LINDER and KURZWEIL, 1999).  
Botanical research in this region has achieved significant progress over the years, with 
distribution patterns, morphology and orchid-environment relationships for numerous species 
being established (LINDER and KURZWEIL, 1999).  The same authors however, pointed out 
the lack of information in certain aspects, such as pollination biology and ecology of South 
African orchids. In addition, with the recent taxonomic revisions in orchid classification, 
complete updated information on some genera is difficult to locate.   
 
Taxonomic relationships within the Orchidaceae family are often described in relation to their 
chemical profiles with specific reference to certain classes of compounds such as alkaloids 
(LAWLER and SLAYTOR, 1969) or flavonoids (WILLIAMS, 1979).  More recently, the 
chemicals and molecular mechanisms involved in the diverse pollination systems have been of 
interest; where chemical mimicry or deceit is used to encourage visits from pollinators 
(NILSSON, 1992; BRODMANN et al., 2008; SCHLÜTER and SCHIESTL, 2008; TSAI et 
al., 2008).  Research has also focused on factors that affect germination and propagation of 
orchids (SMITH and READ, 2008b); as well as how biotechnology can be applied to produce 





3.7.1. Global research 
 
International pharmacological and phytochemical research has elucidated a number of active 
compounds from exotic orchids.  Extensive phytochemical research has been conducted on 
orchids originating from India resulting in the isolation of polyphenols, ligans, alkaloids, 
monoterpenes, triterpenes and stilbenoids such as bibenzyls and phenanthrenes (GARO et al., 
2007).  At times, further studies to determine the biological activity of isolated compounds 
validated the traditional uses of the plant species.  For other compounds such determinations are 
lacking.  MAJUMDER et al. (1987) for example isolated two bibenzyl derivatives – amoenylin 
and isoamoenylin as well as moscatilin (4,4‟-hydroxyl-3,3‟,5-trimethoxybibenzyl) from the 
orchid Dendrobium amoenum.  For certain bibenzyl derivatives, PETTIT et al. (1988) reported 
antimitotic activity for certain bibenzyl derivatives; while other bibenzyl derivatives are 
documented as being effective endogenous plant growth regulators (GORHAM, 1980).  Such 
activity is yet to be determined and/or confirmed for amoenylin and isoamoenylin as well as 
moscatilin (4,4‟-hydroxyl-3,3‟,5-trimethoxybibenzyl).  
 
Summarised below are pharmacological and phytochemical findings on orchid species used for 
traditional medicinal purposes. 
 
3.7.1.1. Anti-inflammatory/immunomodulatory activity 
 
Over expression of tumour necrosis factor alpha, interleukins and nitric oxide could result in 
various inflammatory disorders and autoimmune diseases.  D. chrysanthum is commonly used as 
an antipyretic and immunoregulatory plant in Chinese traditional medicine (BARLOCCO, 
2006).  Ethyl acetate stem extracts produced phenanthrene dendrochrysanene and eight other 
known compounds.  The anti-inflammatory effects of dendrochrysanene were confirmed by a 
concentration dependent inhibition of mRNA expression of interleukins and free radicals 
(YANG et al., 2006).  Of the two phenanthraquinones isolated from D. moniliforme stems, 
moniliformin and denbinobin, the latter exhibited strong anti-inflammatory effects (LIN et al., 
2001).  Denbinobin has been isolated from D. nobile, Ephemerantha lonchophylla and E. 
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fimbriata with cytotoxic effects (TALAPATRA et al., 1982; TEZUKA et al., 1991; TEZUKA 
et al., 1993; LEE et al., 1995).  Denbinobin (1 μg/ml) significantly inhibited TNF-α and 
prostaglandin E2 (PGE2) formation by 62 and 43% respectively, while affecting the release of 
histamine and ß-glucuronidase in mast cells.  These results validate the traditional uses of D. 
moniliforme to treat colds, fever and heat stroke. 
 
Scaphyglottis livida and Maxillaria densa dichloromethane:methanol (1:1) whole plant extract 
produced antinociceptive and anti-inflammatory effects. These plants are used traditionally in 
Mexico to treat inflammatory disorders.  Both extracts demonstrated significant antinociceptive 
effects in the writhing test, however only S. livida extract produced significant antinociceptive 
effects, in terms of thermal latency, in the hot plate test.  A concentration dependent inhibitory 
effect was noted in the carrageenan-induced paw edema inflammation test for S. livida extract 
but not for M. densa extract.  Of the four compounds, triterpenoid LLD (5α-lanosta-24,24-
dimethyl-9(11),25-dien-3β-ol), cyclobalanone, gigantol (3,4‟-dihydroxy-5,5‟-
dimethoxybibenzyl) and DTB, isolated from Scaphyglottis livida extract, only LLD and DTB 
exhibited antinociceptive and anti-inflammatory effects.  Fimbriol A and erianthridin, isolated 
from M. densa extract, produced similar antinociceptive effects to that of LLD and gigantol in 
the writhing test.  Gigantol and LLD (25-100 mg/kg) exhibited significant anti-inflammatory 
effects; which was concentration dependent for gigantol (DÉCIGA-CAMPOS et al., 2007). 
 
Sesquiterpene glycosides dendroside A and dendronobilosides A and B were detected in D. 
nobile stem extracts.  An immunostimulatory effect was observed for dendroside A and 
dendronobiloside A where, dendroside A stimulated the production of T lymphocytes at 10-7 M 
and both dendroside A and dendronobiloside A produced a significantly higher stimulatory effect 
on B lymphocyte production (at 10-5 and 10-6 M).  Alternatively, dendronobiloside B exhibited 
inhibitory effects on T lymphocyte production at concentrations between 10-7 and 10-5 M 
(ZHAO et al., 2001). 
 
Comparatively, three polysaccharides from D. aphyllum (Roxb.) C.E. Fischer stem extract 
produced immunostimulatory activity (ZHAO et al., 1994).  There has been biological 
development of carbohydrates and their application in the pharmaceutical industry.  Two species, 
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Cyrtopodium andersonii R. Br. and C. cardiochilum are used traditionally in Brazil to treat chest 
colds, tuberculosis (TB) and haemoptysis (BARRETO and PARENTE, 2006).  Cyrtopodium 
cardiochilum hot water pseudobulb extract produced a polysaccharide referred to as 
Cyrtopodium cardiochilum polysaccharide (CCP).  It was found to significantly increase the 
phagocytic index when compared to the standard (Zymosan) and exhibited similar significant 
anti-inflammatory effects when compared to Indomethacin (10 mg/kg body weight).  An 
increase in vascular permeability is one of the early signs of an inflammatory response.  CCP 
glucomannan suppressed vascular permeability by approximately 20% of the control 
(BARRETO and PARENTE, 2006). 
 
Chinese Materia Medica mention Shi-Hu traditionally used to treat throat inflammation, fever, 
curing cataract or as a tonic that promotes production of body fluid.  Various primary and 
secondary metabolites have been isolated and their pharamacological activities determined.  Hot 
water stem extract of D. huoshanense produced a polysaccharide isolate that stimulated the 
immune response by increasing macrophage cytokine tumour necrosis factor alpha (TNF-α) and 
lymphocyte cytokines interferon λ (IFN-λ).  At 200 µg/ml, polysaccharide HPS-1B23, enhanced 
TNF-α production up to 1130.4 pg/ml and stimulated IFN-λ release close to 1300 pg/ml (ZHA et 
al., 2007). 
 
Traditionally used to treat inflammatory disorders such as rheumatism, G. elata EtOH extract 
demonstrated considerable anti-angiogenic effects in the chorioallantoic membrane (CAM) assay 
(vascular development inhibition of 55.0 and 71.7% at 1 and 3 μg/egg extract) while the n-
butanol fraction showed dose-dependent activity at IC50 0.47 μg/egg.  In vivo vascular 
permeability, an early sign of inflammatory response, was significantly inhibited; while strong 
analgesic and anti-inflammatory activity was observed.  It was postulated that such activity was a 
result of inhibited NO production and cyclooxygenase-2 expression.  Compounds such as 4-
hydroxybenzyl alcohol and 4-hydroxybenzaldehyde, isolates of G. elata, are thought to be 
responsible for the effects (AHN et al., 2007).   
 
Nitric oxide, a free radical gaseous signalling molecule in the body, is involved in the 
maintainence of blood vessels by relaxing smooth muscle (resulting in vasodilation), inhibiting 
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platelet aggregation and leukocyte adhesion to the endothelium.  Nitric oxide is often associated 
with physiological and pathological processes such as chronic or acute inflammation.  
Occasionally, in the event of an infection there is an increased production of NO.  The result is 
excessive vasodilation and hypotension which often progresses to septic shock.  The inhibition of 
NO, therefore, is considered to be of therapeutic benefit.   
 
Bulbophyllum odoratissimum contains bulbophyllispiradienone which inhibits NO release from 
macrophages (YAO et al., 2005a; b; CHEN et al., 2008b).  Both dendroflorin and nobilone 
isolated from D. nobile stem extracts exhibited inhibitory effects (IC50 13.4 and 38.1 μM 
respectively), with dendroflorin being more active than resveratrol (23.5 μM).  Traditional 
medicines such as Shi Hu could be producing curative effects via antioxidant effects or inhibition 
of NO production. (ZHANG et al., 2007). 
 
3.7.1.2. Neuroprotective and antioxidant activity 
 
Anti-inflammatory effects are also related to various neuroprotective and antioxidant effects.  
Neurodegenerative disorders such as Alzheimer‟s, Parkinson‟s and Huntington‟s disease have 
often been associated with mitochondrial oxidative damage and effects of reactive oxygen 
species (ROS) (BEAL, 2004; HARMAN, 1994). 
 
Dendroflorin, moscatilin and nobilone, a 2,7-dihydroxy-4-methoxy-9-fluorenone, were isolated 
from D. nobile 60% EtOH stem extracts (ZHANG et al., 2007).  The antioxidant activity was 
determined using DPPH free radical scavenging and ORAC assays.  Dendroflorin and moscatilin 
exhibited significant scavenging activities when compared to for Vitamin C (IC50 16.2±0.2 and 
14.5±0.3) in the DPPH assay.  There was markedly higher peroxyl radical scavenging activity 
for dendroflorin, nobilone and moscatilin than for Vitamin C in the ORAC assay (0.596±0.003, 
0.432±0.005 and 0.625±0.013 µM Trolox equivalent/µM).  EtOH 
 
Of the 70 herbal medicines tested for their active-oxygen scavenging activity D. plicatile 
methanol stem extract was one of those that demonstrated potent activity (72% inhibition) 
against superoxide anion radical (·O2-)  (OHSUGI et al., 1999).  The rhizome of Gymnadenia 
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conopsea R. Br. found in China and Nepal, traditionally referred to as Wangla, has been used in 
Tibetan medicine for coughs, asthma and as a tonic in Chinese medicine.  Antioxidant and anti-
hepatitis B effects have been established (PCT INT. APPL. WO 2004, 2004, CAI et al., 2006).  
Dichloromethane extract of the aquatic orchid H. repens yielded habenariol (bis-p-
hydroxybenzyl-2-isobutylmalate).  A structurally similar 2-[1-methylpropyl]malate ester was 
isolated from the rhizomes of the non-aquatic orchid, Galeola faberi (WILSON et al., 1999; LI 
et al., 1993).  Habenariol has been characterized as an antifeedant (WILSON et al., 1999).  Like 
most phenolic compounds, habenariol has also demonstrated antioxidant properties in the human 
low density lipoprotein (LDL) lipid peroxidation model.  The model records the delay in the 
onset of conjugated lipid hydroperoxide formation.  When compared to the more effective α-
tocopherol, habenariol (25 μM) produced a maximum oxidation rate of 0.0048 with a lag-phase 
time of 180 minutes and a concentration dependent inhibition of copper-induced lipid 
hydroperoxide production (IC50 35 μM) (JOHNSON et al., 1999).  
 
Active constituents of G. elata rhizome, gastrodin and p-hydroxybenzyl alcohol, have proven 
antioxidant (free radical scavenging) activities which is believed to be responsible for their 
neuroprotective effects (LIU and MORI, 1992; 1993; KIM et al., 2001 and YU et al., 2005).  
The effect of ageing on memory and performance is often associated with neurodegenerative 
processes.  Increased production of free radicals is believed to be the main cause of such 
processes.  The impairment of any one of the major aspects of memory; acquisition, 
consolidation and retrieval, leads to undesirable effects.  In each phase, the various 
neurotransmitter levels are varied.   
 
Memory consolidation impaired with a protein synthesis inhibitor, cycloheximide (CXM), was 
positively affected by gastrodin (50 mg/kg) and p-hydroxybenzyl alcohol (1-25 mg/kg).  
Memory retrieval impaired with a dopaminergic receptor agonist, apomorphine (APO), was also 
positively affected by gastrodin (1-25 mg/kg) and p-hydroxybenzyl alcohol (0.1-5 mg/kg).  The 
effect of p-hydroxybenzyl alcohol on memory and learning was found to be significantly 
superior to that of gastrodin.  Gastrodin is known to pass through the blood-brain barrier and 
decompose into p-hydroxybenzyl alcohol.  The mechanisms via which the different compounds 
facilitate these processes include decreasing dopamine and other monoamine concentrations and 
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prevention of DNA degradation (HSIEH et al., 1997).  Other studies propose alternative 
mechanisms (SUN et al., 2004).  The learning ability and memory retention in rats was 
positively affected by G. elata extract; where the number of electric strokes in rats performing 
the Y-maze test was significantly reduced (P < 0.01) after the second and third month.  
Gastrodia elata extract also prevented damage to the ultrastructure of the rat hippocampus (HU 
et al., 2003a; b). 
 
Anticonvulsant properties are believed to be linked to the antioxidant effects on lipid 
peroxidation in the brain, and a result of antioxidant enzymes (LIU and MORI, 1992; 1993; 
MORI et al., 2004).  Also known to treat convulsive disorders like epilepsy, the significant 
inhibition of lipid peroxide production in vivo, as well as the significant free radical scavenging 
properties observed in vitro, suggests antioxidant activity to be responsible for the antiepileptic 
result (LIU and MORI, 1992).  In addition to a reduction in epileptic seizures and free radicals, 
there is microglia activation and apoptosis which suggest a protective effect against neuronal 
damage (HSIEH et al., 2005). 
 
Steamed and dried tubers of G. elata (Tian-ma) are traditionally used in China to treat 
rheumatism, paralysis and neuralgic diseases (CHIANG SU NEW MEDICAL COLLEGE 
AND SHANGHAI SCIENTIFIC TECHNOLOGIC, 1977).  p-Hydroxybenzyl alcohol and 
vanillin, constituents of G. elata, demonstrated antioxidant and pro-oxidant effects in various 
cellular and molecular models which suggest their contribution to the overall antioxidant effect 
(LIU and MORI, 1993).  Vanillin and p-hydroxybenzyl significantly inhibited calcium influx 
and apoptosis, which is suggestive of its effect on the calcium signaling pathway (LEE et al., 
1999).  In terms of anti-epileptic research, the anticonvulsant effect of gastrodin is believed to act 
on the γ-aminobutyric acid (GABA) metabolic pathway by, inhibiting the GABA shunt; thereby 
increasing the concentration of GABA in the brain (AN et al., 2003). The inhibition of GABA 
transaminase enzyme prevents the degradation of GABA into the neurotransmitter glutamate. 
Elevated levels of glutamate cause excitotoxicity in cells whereby an increase in calcium influx 
activates enzymes that can damage cell structures.  4-Hydroxybenzaldehyde, from G. elata, 
significantly inhibited GABA transaminase (<0.05 moles/mg protein/h NADPH) when compared 
to a positive control, Valproic acid (±0.1 moles/mg protein/h NADPH).  Vanillin was shown to 
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significantly scavenge free radicals (LIU and MORI, 1993); and increased binding of GABA at 
the GABAA receptor complex (OJEMANN et al., 2006).  Seeing that the regulation of GABA 
levels in the brain is related to antiepileptic and anticonvulsant effects, such inhibitory activity 
highlight the potential of such compounds (HA et al., 2000).  
 
Other studies found an increased expression of antioxidant proteins (disulfide isomerase, 1-Cys 
peroxiredoxin) following transient focal cerebral ischemia, in the presence of both G. elata crude 
extract and active compound p-hydroxybenzyl alcohol.  This suggests a neuroprotective role 
(YU et al., 2005).  Gastrodin is another neuroprotective compound present in G. elata (LI et al., 
2003).  When tested in an Alzheimer‟s disease cellular model, gastrodin was found to promote 
cerebral cortical and hippocampal cell survival and significantly decrease lactate dehydrogenase 
production which is suggestive of a neuroprotective effect (LIU et al., 2005).  Alzheimer‟s is 
characterized by senile plaques, cerebrovascular amyloidisis, neurofibrillary tangles, and 
selective neuronal loss (KIM et al., 2003).  The insoluble amyloid ß-peptide is thought to be 
responsible for the neuronal loss or cell death.  The ethyl ether fraction of G. elata, significantly 
reduced neuronal cell death by 92% (KIM et al., 2003).   Vanillin (4-hydroxy-3-
methoxybenzaldehyde), a constituent of Tian ma, also contributes to the observed 
pharmacological activities (WU et al., 1989).   
 
Apoptosis or programmed cell death is a natural developmental process within cells.  It is 
associated with neuronal cell death in various neurodegenerative disorders.  The process is 
activated by the lack of certain serum or nerve growth factors.  Mitogen-activated protein kinases 
(MAPKs) are well-known in cell signaling pathways within cells.  Methanol extracts (75%) of G. 
elata were found to inhibit cell apoptosis in serum deprived rat pheochromocytoma (PC12) naïve 
cells as observed in the MTT assay and under Hoechst staining.  The protective effect observed 
was a result of the activation of the serine/threonine kinase dependent pathway and a suppression 
of stress activated c-Jun NH2-terminal kinase (JNK) activity (HUANG et al., 2004) 
 
The enzyme acetylcholinesterase breaks down the neurotransmitter acetylcholine.  A shortage of 
acetylcholine and its transmission is characteristic of Alzheimer‟s disease.  Therefore the 
restoration of acetylcholine levels, by inhibiting the action of AChE in the brain, is the current 
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treatment for the disease.  4-Hydroxybenzaldehyde, an active compound isolated from G. elata 
exhibit potent antioxidant activity and GABA transaminase inhibitory effects but weak AChE 
inhibitory activity.  Researchers, looking for compounds with more extensive biological 
activities, produced a new class of active and selective AChE inhibitors by introducing amino 
acid moieties into the backbone of 4-hydroxybenzaldehyde.  The resultant compounds exhibited 
more potent AChE inhibitory activity.  Two compounds 4b (IC50 0.19 μM) and 4i (IC50 0.28 μM) 
performed better than galanthamine (IC50 0.55 μM), and 4i was selective for AChE (WEN et al., 
2007). 
 
Monoamine oxidases are involved in the breakdown of neurotransmitters such as serotonin, 
dopamine, adrenalin and nor-adrenalin.  Found in the mitochondrial membrane of neuronal and 
non-neuronal cells, they catalyse the oxidative deamination of primary, secondary and tertiary 
amines to imines and release by-product hydrogen peroxide (H2O2).  The two isoforms MAO-A 
and MAO-B have different substrate preferences, inhibitor specificity and tissue distribution.  
The inhibition of MAO-B increases dopamine levels which is therapeutically beneficial in 
anxiety disorders and other neurological diseases such as Alzheimer‟s and Parkinson‟s. When 
compared to 27 different plant extracts G. elata tuber extract (50% EtOH) exhibited poor MAO-
A and MAO-B inhibitory effects with IC50 (<50 mg/ml) and had showed no selectivity to MAO-
B (LIN et al., 2003). 
 
A sedative effect can be defined as a general reduction in the activity of the central nervous 
system (CNS).  The dried rhizome of Gastrodia elata is used for such a purpose in Chinese, 
Japanese and Korean medicine, during paralysis, epilepsy, vertigo and tetanus.  It is considered 
to be an essential ingredient in the formulation that is prepared (JUNG et al., 2006).  Gastrodia 
elata EtOH (75%) root extracts were found to exhibit strong antidepressant activity in animal 
behavioural models.  At 300 mg/kg the extract significantly decreased the time of immobility 







3.7.1.3. Anti-angiogenic / Anti-tumour 
 
Anti-angiogenic drugs are currently used to inhibit growth of blood vessels in cancer cells.  In 
the presence of certain growth factors the growth of blood vessels may be stimulated. Currently, 
cancer research looks into the use of what is termed angiogenesis-based tumour therapy – using 
angiogenesis inhibitors from both natural and synthetic sources.  Also, the production and 
development of endothelial cells is associated with tumour growth and development.  The 
inhibition of angiogenesis prevents neoplasms (abnormal tissue growth) and inflammation, 
therefore, angiogenesis research is also vital for cardiovascular and inflammatory disorders.   
Erianin, isolated from the Chinese medicinal orchid D. chrysotoxum, exhibited antitumour 
activity (ZHANG et al., 2005).  In determining the various mechanisms involved, significant in 
vivo and in vitro anti-angiogenic effects, selective inhibition of endothelial cell generation (EC50 
34.1±12.7 nM) and cytoskeletal disruption of endothelial cells were observed (GONG et al., 
2004).   
 
Very similar potent antitumour and anti-angiogenesis effects were noted for moscatilin isolated 
from D. loddigesii (TSAI et al., 2010.)  Research on compounds such as moscatilin; with known 
anti-inflammatory, cytotoxic, anti-platelet aggregation and anti-proliferative properties; and 
erianin, provide insight into the mechanisms involved in cancer progression.  Antitumour 
activities have been detected in compounds from the Bulbophyllum genus (YAO et al., 2005a; 
b), with B. odoratissimum, in particular, containing cytotoxic phenolics (CHEN et al., 2008b).  
Calanquinone A isolated from Calanthe arisanensis also exhibited cytotoxic activity (LEE et al., 
2008).  Whole plant extracts of D. chrysotoxum are used in Chinese traditional medicine.  
Dendrobium chrysotoxum EtOH stem extracts as well as isolated compounds such as erianin, 
chrysotoxine and confusarin produced antitumour activities (WANG et al., 1997; GONG et al., 
2006); while the aerial parts of D. nobile were found to contain antitumoral phenanthrenes (in 
vitro and in vivo) (LEE et al., 1995). Moscatilin, a bibenzyl compound, demonstrated potential 
antimutagenic activity (MIYAZAWA et al., 1999).  Dendrobium cariniferum DCM whole plant 
extracts revealed dendronone, a phenanthrequinone (CHEN et al., 2008a).  Another 
Dendrobium species (D. thyrsiflorum) exhibited significant cytotoxic effects due to the presence 




Cremastra appendiculata is the only orchid species to have a triphenanthrene isolated from its 
tubers.  Cremastra appendiculata is used in Chinese medicine to treat various cancers (XUE et 
al., 2006).  The ethanolic extracts of the tubers were found to be inactive against various human 
cancer cell lines in cytotoxic assays (IC50 > 5 μg/ml).  Pure compounds such as 
cirrhopetalanthrin however were selectively active against lung (17.8 μM), ovarian (13.2 μM), 
hepatoma (8.4 μM), stomach (10.5 μM), colon (11.2 μM) and breast (12.5 μM) cancer cell lines. 
 
3.7.1.4. Antiviral and antimicrobial activity 
 
In vitro antiviral activity of lectins from a Cymbidium hybrid, Listera ovata and Epipactis 
helleborine against severe acute respiratory syndrome coronavirus (SARS-CoV) and feline 
infectious peritonitis virus (FIPV) were determined to be (EC50) 4.9±0.8, 2.2±1.3 and 1.8±0.3 
µg/ml against SARS-CoV and 4.5+2.6, 0.7±0.3 and 1.6±0.9 µg/ml against FIPV.  Listera ovata 
mannose-specific lectin produced the most effective antiviral activity against coronavirus (FIPV) 
(KEYAERTS et al., 2007).  KEYAERTS et al. (2007) established that, of the 33 plant lectins 
investigated, mannose-binding lectins produced the strongest anti-coronavirus activity.  This 
effect could be a result of the sugar specificity of these lectins (VAN DAMME et al., 1998; 
KEYAERTS et al., 2007).  Previous in vitro studies on mannose-specific plant lectins from 
these three species revealed antiviral activities against human immunodeficiency virus (HIV) 
type 1 and type 2 in MT-4.  Considerable antiviral activity was also noted in HEL, HeLa and 
MDCK cells when testing against anti-human cytomegalovirus (CMV), respiratory syncytial 
virus (RSV) and influenza A virus (BALZARINI et al., 1992). 
 
Carbohydrate binding proteins or glycoproteins = lectins or agglutinin are well documented and 
characterised.  Mannose binding lectins are common in monocotyledons.  Their high specificity/ 
affinity gives rise to their characteristic biological activities which are being investigated to be 
applied against viruses, cancer cells and in crop protection.  As mentioned earlier, antiviral 




Cypripedium macranthos var. rebunense seeds demonstrated antifungal properties at various 
growth phases as a mechanism to facilitate germination (SHIMURA et al., 2007).  Dendrobium 
officinale agglutinin 2 demonstrated significant antifungal properties against Gibberella zeae 
which suggests its possible use for crop plants (CHEN et al., 2005).  French botanist, Noel 
Bernard observed acquired immunity in Orchis morio and Loroglossum hircinum against 
Rhizoctonia repens, an endomycorrhizal fungus.  Phytoalexins are defined as low molecular 
weight antimicrobial compounds synthesised and accumulated in plants post-exposure to 
microorganisms (STOESSL and ARDITTI, 1984).  Orchinol (2,4-dimethoxy-7-hydroxy-
dihydrophenanthrene) isolated from O. militaris, loroglossol and hircinol (2,5-dihydroxy-4-
methoxy-dihydrophenanthrene) isolated from L. hircinum exhibited antimicrobial properties 
(BÖLLER et al., 1957; HARDEGGER et al., 1963).  Hircinol and orchinol were considered to 
be non-specific antimicrobials as they produced varying activities against a range of fungi and 
bacteria (GÄUMANN et al., 1960; URECH et al., 1963; FISCH et al, 1973).  Loroglossol, an 
isomer of orchinol, was found to exhibit similar effects.  (WARD et al., 1975).   
 
The amino acid sequence of gastrodianin, the major antifungal component of G. elata, shared 
strong homology to that of monomeric mannose-binding proteins of orchids such as E. 
helleborine and L. ovata.  Such mannose-binding proteins have proven in vitro antifungal 
activity; therefore, gastrodianin-like proteins are considered a novel group of antifungal proteins 
(WANG et al., 2001).  It was established that gastrodianin has a stable structure with potent 
inhibitory activity against certain fungal strains (XU et al., 1998). 
 
Dengue viral infection is common in tropical and subtropical regions.  The infection can progress 
to haemorrhagic fever and dengue shock syndrome which are lethal.  Heparan sulfate 
proteoglycan found on the surface of all mammalian cells has a heparan sulfate chain that 
facilitates infection.  Sulfated polysaccharides are currently being researched as potential anti-
dengue drugs.  The sulfated derivatives of polysaccharides WGEW and AGEW (two α-D-
glucans) from G. elata exhibited potent anti-dengue virus activities with WSS45 being selective 
for type-2 dengue virus.  Also, it was observed that with an increase in the degrees of 




The aromatic molecule, vanillin (4-hydroxy-3-methoxybenzaldehyde) has been extensively 
studied and applied in the food, chemical, pharmaceutical and cosmetic industries (WALTON et 
al., 2003).  This versatile aromatic compound is used widely and more commonly in the culinary 
industry as a flavourant (CHOMCHALOW, 1996).  It is naturally obtained during the ageing 
and alcoholic extraction (fermentation) of green vanilla pods (Vanilla planifolia Andrews, syn. 
V. fragrans Ames).  Vanillin exhibits antioxidant and antimicrobial properties against certain 
Gram-positive and Gram-negative bacteria known to spoil food and is therefore used as a food 
preservative (KRUEGER and KRUEGER, 1983; BURRI et al., 1989; CERRUTTI, et al., 
1997; DAUGSCH and PASTORE, 2005). 
 
Genetic modification is a relatively new method used to maintain orchids commonly traded as 
potted plants for a longer period.  This is accomplished by conferring antimicrobial properties 
into orchid species like Oncidium by introducing a plant ferredoxin-like protein (PFLP) (LIAU 
et al., 2003). 
 
3.7.1.5. Phytotoxic activity 
 
Erianthridin and gymnopusin, two phenanthrene derivatives from Maxillaria densa 
methanol:chloroform (1:1) whole plant extract, contributed to the moderate phytotoxic effect 
(growth inhibition, electrolyte leakage, and chlorophyll reduction) observed on duckweed tissue.  
Gymnopusin was found to exhibit a more potent effect over a shorter period.  Growth inhibitory 
activity, measured by inhibition of radical elongation of Amaranthus hypochondriacus, was 
observed for gymnopusin and erianthridin (IC50 330 and 58.2 μM respectively).  The overall 
results suggested a non-specific mechanism; however specific lysis of the tonoplast membrane 
by gymnopusin implied a different and specific mode of action.  The herbicidal potential of 
gymnopusin is weak as it displayed cytotoxic effects in vitro against four mammalian cell lines 
thioguanin-resistant rat hepatoma cells (H4TG) (IC50 13.0±0.9 µM),MDCK (IC50 11.0±0.5 µM), 
NIH Swiss mouse embryo fibroblasts (NIH3T3) (IC50 12.0±1.0 µM), and Kirsten strain of 
Moloney sarcoma virus-transformed 3T3 cells (KA31T) (IC50 21.0±0.5 µM) (VALENCIA- 
ISLAS et al., 2002).  Interestingly, other researchers had previously determined various 
approaches to synthetically produce gymnopusin (WANG and SNIECKUS, 1991).  
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Collectively, such information can benefit further research efforts dealing with bioherbicides and 
their safety.  
 
WILSON et al. (1999) were the first to identify the defense mechanism in the form of the 
phenolic compound habenariol from a perennial freshwater orchid H. repens.  Phenolics are 
generally shown to possess antioxidant activity with curative and preventative properties (LIU et 
al., 1992).  The lipophilic secondary metabolite habenariol is produced naturally by the plant to 
prevent omnivorous crayfish from grazing on the water plant.  A further example of a feeding 
deterrent was discovered in Phalaenopsis hybrids in the form of two 1,2-saturated pyrrolizidine 
monoesters (FRÖLICH et al., 2006).  Investigators established that the young and developing 
tissues contained the highest concentration of these alkaloids, thus serving as a preventative 
measure (FRÖLICH et al., 2006).  Pyrrolizidine alkaloids, potent antifeedants for most 
herbivores, are highly conserved alkaloids found only in five plant families.  In Orchidaceae, 
these are represented in eight genera:  Liparis, Malaxis, Cysis, Phalaenopsis, Vanda, Vandopsis 
(HARTMANN and WITTE, 1995), Pleurothallis (BORBA et al., 2001), and Cremastra 
(IKEDA et al., 2005).  Taxonomically speaking, these genera belong to five tribes within the 
subfamily Epidendroideae only (CAMERON, 2004); which emphasises the conserved nature of 
this alkaloid occurrence.  Pyrrolizidine alkaloid phalaenopsine T from Phalaenopsis hybrids is 
also known to exhibit growth inhibitory properties (FUJIEDA et al., 1988). 
 
3.7.1.6. Spasmolytic activity 
 
The spasmolytic effect or inhibition of smooth muscle contraction by natural plant extracts has 
been widely used in traditional medicine to treat hypertension, stomachache and prevent 
abortion.  In Mexico, M. densa and S. livida are used for such purposes.  Five compounds 
isolated from S. livida demonstrated concentration-dependent spasmolytic effects in vitro similar 
to that of papaverine.  Researchers also determined that the NO/cGMP pathway is the 
mechanism via which 3,4‟-dihydroxy-5,5‟-dimethoxybibenzyl acts (ESTRADA et al., 1999). 
 
Gigantol and 3,7-dihydroxy-2,4-dimethoxyphenanthrene also isolated from S. livida were found 
to have concentration-dependent vasorelaxing activity.  Mechanisms thought to mediate their 
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activity include increased levels of NO and or cGMP (ESTRADA-SOTO et al., 2006).  The 
spasmolytic activity of stilbenoids isolated from M. densa (2,5-dihydroxy-3,4-
dimethoxyphenanthrene, fimbriol-A, nudol, gymnopusin and erianthridin) was found to be 
similar to that of papaverine.  However, activity was established to be not as a result of nitric 
oxide mechanism or calcium influx (ESTRADA et al., 2004). 
 
Laelia autumnalis (Lex.) Lindley methanol extract demonstrated vasorelaxant properties (IC50) 
34.61±1.41 µg/mL (Emax) 85.0±4.38% in intact rat aortic endothelium rings.  In endothelium-
denuded rings the extract induced relaxation at IC50 45.11±4.17 µg/mL (Emax 80.0±12.1%).  
Also, a significant decrease in systolic and diastolic blood pressure and heart rate in 
spontaneously hypertensive rats was observed.  Antihypertensive and vasorelaxant effects were 
found to be a result of calcium (Ca2+) channel blockage (VERGARA-GALICIA et al., 2008). 
Similar vasorelaxant effects were observed for L. autumnalis used in traditional Mexican 
medicine for hypertension and related diseases, validating their traditional uses (AGUIRRE-
CRESPO et al., 2005).   
 
Gigantol and 3,7-dihydroxy-2,4-dimethoxyphenanthrene isolated from S. livida used to treat 
stomachache and prevent abortion, exhibited vasorelaxant properties as a result of more than one 
mechanism (ESTRADA-SOTO et al., 2006).  The vasorelaxant effect reduces hypertension and 
promotes muscle relaxation, which supports the traditional uses of this plant.   
 
Of the five muscarinic acetylcholine receptor subtypes, M3 directs the contraction of smooth 
muscle and mucous secretion in mucous glands.  Selective blockage of M3 receptors is 
suggested to offer relief in respiratory disorders such as chronic obstructive pulmonary disease, 
gastrointestinal disorders such as irritable bowel syndrome and urinary tract disorders such as 
urinary incontinence.  There is a need for selective receptor subtype substitutes to prevent 
adverse side effects found in current medication.  Cremastra appendiculata is used in Chinese 
medicine to treat various cancers (XUE et al., 2006).  The bulb extract was originally found to 
be active, and further investigation found cremastrine, a pyrrolizidine alkaloid, to selectively 





3.7.1.7. Other activities 
 
3.7.1.7.1. Anti-platelet aggregation effects 
 
The Chinese prepare a (Yin) tonic from various Dendrobium stems which is used to treat fever 
symptoms, increase body fluid production and as nourishment.  Dendrobium densiflorum DCM 
stem extracts produced anti-platelet aggregation active compounds such as gigantol, moscatilin, 
homoeriodictyol, scoparone and scopoletin; in vitro.  Scoparone proved to be the most effective 
and was used as a positive control.  When compared to the control, at 100 µM, percentage 
inhibition for gigantol, moscatilin, homoeriodictyol, scoparone and scopoletin was, 31, 36, 50, 
64, 21, respectively.  (FAN et al., 2001). 
 
Methanol stem extract of D. loddigesii Rolfe inhibited platelet aggregation.  Three compounds 
(moscatilin, moscatin and moscatilin diacetate) obtained from a fraction of the extract also 
exhibited potent concentration dependent antiplatelet aggregation activities.  Moscatilin, 
moscatin and moscatilin diacetate inhibited arachidonic acid (AA)-induced platelet aggregation 
at IC50 61.8, 37.2, 11.2 μM, respectively.  Thromboxane A2, a signalling molecule that triggers 
platelet aggregation and is produced in the presence of AA, may have been the target for 
moscatilin and moscatin, while moscatilin diacetate may have had a more direct intracellular 
effect (CHEN et al., 1994). 
 
3.7.1.7.2. Inhibition of cell-surface glycoside cleavage 
 
Various classes of flavonoids such as anthocyanins, flavonols and C-glycosylflavones have been 
isolated from orchids.  C-glycosylflavones are known to inhibit cell-surface glycoside cleavage 
(TOVAR-GIJÓN et al., 2006).  Glycosides contribute to pigments; form the basis of certain 
antibiotics and cardiac glycosides.  Glycosides are converted into glycosyl (carbohydrate) and 
aglycone components by hydrolytic cleavage (addition of water). By inhibiting glycoside 
breakdown, plant pigments are preserved; and mechanisms involved in glycoside production and 




3.7.1.7.3. Inhibition of kainic acid binding to brain glutamate receptors 
 
S-(4-hydroxybenzyl)-glutathione, isolated from aqueous extracts of G. elata, was found to inhibit 
kainic acid from binding to glutamate receptors (IC50 2 x 10-6 M) with less effectiveness than 
glutamate (IC50 2 x 10-7 M) and glutathione (IC50 8 x 10-7 M) (ANDERSSON et al., 1995).  
Kainic acid is considered an excitatory neurotoxin (MCGRAW-HILL CONCISE 
DICTIONARY OF MODERN MEDICINE, 2002) and is effective when binding and upon 




Scientific research of exotic orchids have also allowed for the expansion of the cosmetic 
industry.  The utilization of orchid extracts and other such natural cosmetic products are 
becoming more popular among the American population (MINTEL COSMETIC 
RESEARCH).  Some companies attribute the beautifying effects to compounds found in the 
roots of certain orchid species (GUERLAIN COSMETIC COMPANY).  The identities of the 
orchids are not often revealed however, the emphasis is on the protective properties of the 
extracts such as:  fighting free radicals, increase in skin immunity, enrichment in naturally 




Synthetically produced vanillin is used for chemical and pharmaceutical applications as the 
natural extraction process is approximately 250 times more expensive.  Uncured beans of the 
vanilla orchid were used medicinally by the Mayan civilization to treat venomous insect bites 
and to heal wounds.    Studies on vanillin revealed additional biological activities which include 
anti-carcinogenic (ability to inhibit tumour formation), anti-mutagenic effects and anti-
clastogenic (inhibition of chromosomal damages) (KESHAVA et al., 1998; ZABKOVA et al., 
2006).  Vanillin‟s curative properties have also been showcased against sickle cell disease – as 
an effective inhibitor of red blood cell sickling.  ZHANG et al. (2004) provided details on the 
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vanillin prodrug MX-1520, which was synthesized to treat red blood cell sickling with vanillin, 
in vivo. 
 
It is evident from the literature that there is no pharmacological research on South African 
medicinal orchids (CHINSAMY et al., 2011). However, there have been significant 
developments in medicinal orchid research worldwide. The ethnobotanical approach used to 
select the abovementioned species for pharmacological and phytochemical research yielded 
valuable biological compounds. A similar approach can therefore also be applied to South 
African medicinal orchids, with potentially favourable results. 
 
 
3.8. ORCHID CONSERVATION 
 
The conservation status of medicinal plants is often associated with indiscriminate harvesting 
and demand when used for traditional medicine practices (ARNOLD et al., 2002).  According to 
HILTON-TAYLOR (1996), the reason a large number of species became extinct in the 
southern African region was attributed to the large number of persons using them for traditional 
medicines.  Generally, orchids have been fiercely protected on the basis that they are „rare‟ and 
under threat from excessive collection.  However, according to McMURTRY et al. (2008), the 
collection of plants for cultivation and or horticultural purposes was the original threats to orchid 
populations.  Currently orchid populations are most affected by the loss of suitable habitats due 
to industrial practices (timber plantations, mining and agriculture) and urbanization (DIXON et 
al., 2003; McMURTRY et al., 2008).  Comparatively, the collection of orchids for herbal trade 
features as one of the lesser threats to orchid populations.  In the South African context, the 
conservation status of most medicinally used orchid species (Least Concern – LC) is indicative 
of this (Table 3.1. Chapter 3).  DIXON et al. (2003) mention that medicinal orchids often have 
small flowers and are of little horticultural value – therefore the threat to various medicinal 
species needs to be separated from that imposed by collection for horticultural purposes.  The 
conservation status of South African medicinal orchid species (Table 3.1. Chapter 3) could 
either reflect a negligible impact by collection for medicinal and cultural uses or, it could 
indicate a lack of knowledge on such orchids.  Earlier it was mentioned that there are „gaps‟ in 
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our knowledge of orchids (CRIBB et al., 2003).  The authors also allude to the fact that orchid 
conservation is „multi-faceted‟ – ethnobotanical, pharmacological and phytochemical studies of 
medicinally used orchids in South Africa will contribute positively to the conservation goals by 
presenting data that add value to medicinal and related orchid species.  Also, the increased 
protection of orchids will in turn allow for the protection of other species that occur in the same 
regions.  The conservation status of Vanilla roscheri (Endangered – Table 3.1. Chapter 3) in 
South Africa could be associated with their use in African traditional practices.  According to 
BRUMMIT (2001), the presence of V. roscheri is prolific from south-west Ethiopia to north-
east KwaZulu-Natal.  Therefore it would be more reasonable to assume that the conservation 
status, with respect to local IUCN Red List ratings of V. roscheri, is due to a lack of availability 
of suitable habitat within South Africa.  While certain orchids are valued for their horticultural 
appeal, certain species often hold medicinal, cultural, commercial, and or nutritional value in the 
regions where they occur and deserve the necessary scientific attention and protection. 
 
 
3.9. QUO VADIS 
 
It is evident that medicinal research of orchids has surged ahead in some regions.  Often their 
indigenous uses are validated, novel compounds are identified and potential uses in industries are 
discussed.  The ethnobotanical uses of orchids in South Africa (Table 3.1. Chapter 3) have not 
been exploited pharmacologically (CHINSAMY et al., 2011).  Scientific validation is essential 
as the uses are indigenous and unique to South African orchids.  
 
Common reasons for the lack of research on South African medicinal orchids include; orchids 
have mostly been appreciated for their horticultural appeal and medicinal orchids mostly have 
insignificant/ unpretentious flowers – reducing their appeal for further study. Also, as mentioned 
earlier, the generally accepted conservation status of most orchid species could discourage 
researchers from studying these specific species.  Only a small percentage of South African 
orchid species is used in African traditional practices (49 out of ±500 in southern Africa).  Often 
there are some morphological and ecological clues as to the chemistry of certain plants.  
Colourful flowers are suggestive of high flavonoid content.  In the case of South African orchids 
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a considerable number of species are white or green which should suggest their lack of certain 
secondary metabolites – often responsible for observed pharmacological effects.  Also, 
secondary metabolites are responsible for attracting pollinators, in the case of South African 
orchids most are pollinated by moths, which do not require a chemical stimulus. Therefore, the 
few species actually used in traditional medicine may represent a refined list of most active 
species or genera with bioactive compounds.  Finally, the use of traditional medicine is still not 
fully recognised in South Africa and abroad, and the medicinal plant research field is still 
establishing itself in our country, therefore orchids have not featured as yet. 
 
Literary resources on ethnobotanical uses of South African (Table 3.1. Chapter 3) have 
provided the initial impetus for medicinal orchid research in South Africa. The relatively small 
number of species found in South Africa (±500) is said to be a result of biology and not 
taxonomic bias.  Taxonomic bias could either be an underestimate or an inflation of species 
number.  South African orchid species numbers are not a result of taxonomic bias.  Inflation of 
species number is a problem in regions like Europe and the distribution and occurrence of orchid 
species in South Africa is relatively well known.  Endemism is the result of very limited factors 
that makes a habitat suitable for particular organisms or plants.  Given that geographical location 
of species is one of the determining factors in the type and quantity of secondary metabolites 
produced; and that 75% of orchids in the southern African region are endemic (STEWART et 
al., 1982) it could be assumed that their unique geographical location would have some influence 
on the chemical composition of these species.  The potential of revealing bioactive compounds 
that are unique to South African orchids is great. 
 
Scientific validation is necessary as these species are still being used for traditional medicine. 
During preliminary market surveys, a constant trade and demand for certain orchids was 
observed. This demand could imply therapeutic or beneficial effects. The toxicology of 
medicinal plants needs equal consideration in medicinal plant research. Most of the orchid 
species used for cultural practices are administered as emetics. It would be important to know 
what the effects of these orchid-derived medicines are on the human body and more especially 
their safety, in terms of toxicity.  Pharmacological and phytochemical investigations of South 
African medicinal orchids may reveal bioactive compounds that could add value to medicinal 
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and related orchid species.  These could be further developed into much needed therapeutic 








The earliest inhabitants of the earth, bacteria, are ubiquitous mainly due to their adaptable nature.  
It was not until the late 17th century that they became more apparent to the scientific community.  
They are morphologically diverse and while some benefit the ecosystem others are pathogenic.  
This chapter investigates the effect of crude orchid extracts on various test organisms like 
bacteria and fungi which are known to cause widespread diseases.    
 
One third of all deaths of children under five occur in sub-Saharan Africa (HILL et al., 1999).  
The annual death toll of this group of the world‟s population is an estimated 11 million.  Over 
90% of these deaths occur in developing countries; nearly 70% result from communicable 
diseases, such as respiratory infections, malaria and diarrhoea (HILL and AMOUZOU, 2006).  
PINNER et al. (1996) revealed that between 1981 and 1992 infectious diseases had moved from 
the 5th to the 3rd leading cause of mortality.  A later report by IWU et al. (1999) showed that half 
of all deaths in tropical countries were a result of infectious diseases.  According to the 
Millennium Development Goals a reduction of 4.3% of the U5MR, between 1990 and 2015, is 
required in the sub-Saharan region.  Contrary to common belief, even populations in developed 
countries experience under five mortalities due to communicable diseases (BLACK et al., 
2010).   
 
Worldwide, 33 million persons are infected with HIV (WILLIAMS, 2010).  Two million die 
every year (WILLIAMS, 2010).  In 2008 more than 70% of all AIDS-related deaths worldwide, 
occurred in the sub-saharan African region (UNAIDS, 2009).  With the nearly two million new 
infections in 2008 there are approximately 22.4 million persons (67% of the global infected 
population) living with HIV in this region.  By 2007 it was established that the largest population 
of persons living with HIV (5.7 million) occurred in South Africa (UNAIDS, 2009).  
Immunodeficient persons are more susceptible to opportunistic infections (KAPLAN et al., 
1998; SASSI, 2011).   
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Immunodeficient populations include transplant recipients, elderly and HIV-infected persons.  
KAPLAN et al. (1998) and GOUWS and KARIM (2010) report TB as the most prevalent 
opportunistic infection. In immunocompromised transplant recipients, infections such as invasive 
candidiasis, TB and resistant Gram-negative bacteria are prevalent. Aged persons are more prone 
to post-operation infection and during long periods in hospital. In recent times, the most common 
AIDS-related diseases include pneumonia, diarrhoea, TB and hepatitis C (SASSI, 2011).  
According to SASSI (2011) 90% of all AIDS-related deaths were a result of opportunistic 
infections. 
 
Fungi from the genus Candida form part of our natural microflora found on skin, mucous 
membranes and the gastrointestinal tract, yet C. albicans is the main contributor of mucosal 
infections and systemic mycoses (MORSCHHÄUSER, 2002; WROBLEWSKA et al., 2002). 
Candida albicans can turn pathogenic and cause oral, vaginal and systemic infections (De 
BACKER et al., 2000).  According to hospital admissions, the rate of invasive fungal infections 
(IFIs) in America almost doubled in just 10 years (1980- 1990) (BECK-SAGUÉ and JARVIS, 
1993).  In Europe a similar pattern emerged with a 1.6% frequency in the period 1978-1982 to a 
4.1% in 1988-1992 (GROLL et al., 1996).  Such statistics are indicative of the alarming 
increase in frequency of severe IFIs in organ and bone marrow transplant recipients as well as 
patients infected with HIV (MEYERS, 1990).   
 
In the case of persons who are immunocompromised Candida species cause opportunistic 
infections (WROBLEWSKA et al., 2002).  Mucosal and systemic fungal infections are 
prevalent in patients with AIDS (LOEFFLER and STEVENS, 2003).  The colonization of the 
mouth, pharynx and esophagus (oral candidiasis) may be present in up to 84% of patients 
suffering from HIV (MAENZA et al., 1997; MARTINS et al., 1997).  In immunocompromised 
patients there is the threat of superficial infections such as oropharyngeal candidiasis (OPC) and 
more serious systemic infections (MORSCHHÄUSER, 2002).  Cancer patients most commonly 
present with C. albicans fungal infections (WINGHARD, 1995), while, C. albicans and C. 
parapsilosis feature as the most common IFIs in pediatric and neonatal cases (BLYTH et al., 
2007).  The most prevalent mycosis in hospitals is candidiasis (WROBLEWSKA et al., 2002).  




VISCOLI and CASTAGNOLA (1999) list some common problems encountered when treating 
patients presenting with fungal infections:  i) difficult to confirm diagnosis until late stage of the 
disease; ii) some fungi have intrinsic or acquired resistance to antifungal drugs; and iii) there is 
the risk of drug toxicity. 
 
 
4.1.1. Antibacterial agents 
 
Considerable effort has been made to reduce infection rates.  Conventional medicine had a major 
breakthrough in the fight against infectious diseases with the serendipitous discovery of 
penicillin by Fleming (1928).  This perhaps was the basis for the original definition of an 
antibiotic – “substance produced by one microorganism which is capable of inhibiting growth 
or killing another microorganism”.  Subsequent antibiotic discoveries included the isolation of 
erythromycin and the family of tetracyclines (among others) from various microorganisms 
(LAURENCE and BENNETT, 1980).  Over the years this definition has been modified to 
accommodate other antibiotic sources that have been discovered.  For a while in the 20th century 
the advent of antibacterial drugs were considered one of the most crucial therapeutic 
contributions to the healthcare system of man and animals (PAGE et al., 1997).  An antibacterial 
drug (or chemotherapeutic agent) may be defined as a drug that is used to treat an infectious 
disease by either removing or destroying the infective agent without harming the host.   
 
The action of an antibiotic may be described as either bacteriostatic (inhibition of bacterial 
growth) or bactericidal (ability to kill the bacterium) (PAGE et al., 1997).  Many of the major 
antibacterial drugs have specific target sites (a) bacterial cell wall biosynthesis; (b) protein 
synthesis; (c) DNA replication and repair.  Antibiotics are therefore further classified according 
to their mode of action, for example, β-lactams and glycopeptides represent 2 classes of 
antibiotics that inhibit bacterial growth by targeting bacterial cell wall synthesis.  Other major 
classes of antibiotics involve certain modes of action such as:  inhibition of protein synthesis; 
nucleic acid metabolism; intermediary metabolism and the disruption of cytoplasmic membranes 




4.1.2. Antifungal agents 
 
Antifungal drugs are often prescribed in both conventional and traditional medical systems.  
ROGERS (2002; 2006) highlights the concern over limited clinical drugs currently available, 
whilst it is clear that there is an increasing incidence of IFIs especially in immunocompromised 
patients.  Antifungal agents have been used extensively in HIV-positive patients for treatment of 
OPC and cryptococcosis.  There are different classes of antifungal agents (KONTOYIANNIS 
and LEWIS, 2002; ROGERS, 2002):   
 Polyenes – this group includes the broad spectrum acting Amphotericin B and nystatin 
drugs.  Polyenes target fungi by interacting with ergosterol which is the major sterol in 
the fungal plasma membrane.  This action creates pores and channels in the plasma 
membrane which allows for the leakage of potassium and other cell constituents and 
ultimately cell death (VANDEN BOSSCHE et al., 1994).  Amphotericin B may be 
administered orally to produce a topical effect which decreases intestinal colonisation in 
addition to the treatment of OPC and gastrointestinal candidiasis.  Amphotericin B, 
however, is known to cause nephrotoxicity and its use has therefore been limited.  
Nystatin, which is considered even more toxic, has been prescribed only for topical 
infections. 
 Azoles – included in this group are the triazoles, fluconazole and itraconazole as well as 
the imidazoles.  These also act by affecting the sterols in the plasma membrane but 
particularly inhibit ergosterol biosynthesis.  Fluconazole has exhibited specific activity 
against C. albicans and Cryptococcus neoformans but not against Aspergillus species.  
Whereas itraconazole, which exhibited more broad spectrum activity, is less palatable.  
This group has shown both fungistatic and fungicidal activity in vivo. 
 Fluoropyrimidines – Flucytosine acts by inhibiting DNA and RNA synthesis as it 
transgresses the fungal cell membrane using a cytosine permease.  These drugs have 
shown activity against Candida species and Cryptococcus neoformans.  They are more 
commonly used in combination therapy with polyenes like Amphotericin B (FRANCIS 
and WALSH, 1992).  This combination therapy is either to increase potency or to 
counter Amphotericin B toxicity.  Combination therapy of Amphotericin B and 
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flucytosine has the risk of developing flucytosine-related toxicity (FRANCIS and 
WALSH, 1992).  Alternatively, flucytosine could be combined with azoles to reduce 
toxicity while preventing drug resistance (HOSPENTHAL and BENNETT, 1998).  
Flucytosine resistance in C. albicans isolates has ruled out the option of using this drug in 
monotherapy for fatal yeast infections. 
 Other groups include:  Allylamines (Lamisil) which target the precursory steps of 
ergosterol biosynthesis while echinocandins (Cancidas) inhibit beta-(1,3)-glucan 
synthase.  Both classes have shown significant potential in their respective applications. 
 
The triazole fluconazole is the fourth most prescribed antifungal drug in the world (DENNING 
et al., 1995).  The new triazoles are now considered effective treatment (GOA and 
BARRADELL, 1995).  They are fungistatic (inhibit fungal growth) and are considered to be less 
toxic than the polyene Amphotericin B and more active against yeasts, yeast-like fungi and 
dimorphic fungi.  This however, often results in a recurrent infection (REX et al., 1995).  
MORSCHHÄUSER (2002) states that, the emergence of the fluconazole-resistant C. albicans 
strain is the result of long-term, low dose fluconazole treatment of recurring OPC in AIDS 
patients (ODDS, 1993; HUNTER et al., 1998; LOPEZ et al., 2001).   
 
There is a worldwide incidence of rising severe fungal infections (GOLDMAN et al., 2004).  
The development of resistance in previously susceptible Candida strains has been reported for 
patients with AIDS.  It has been hypothesised that the systemic use of antifungal drugs has 
affected the epidemiology of fungal infections, of which drug resistance is a direct result 
(ROGERS, 2002).  In light of the number of persons with HIV and AIDS suffering from 
opportunistic fungal infections, there is an urgent requirement for effective antifungal agents 
(GEORGOPAPADAKOU, 1998).  Unfortunately, there are only a few classes of antifungal 







4.1.3. Drug resistance and contributing factors 
 
All things considered, antibiotics are the preferred drug when treating infectious diseases.  
PAGE et al. (1997), however, pointed out that the over-prescription and excessive use of 
antibiotics has resulted in the promotion and development of antibacterial drug resistance.  
Various bacterial strains have become resistant to available antibacterial drugs.  The structure of 
microbes affects their reaction to antimicrobial agents (WHITE and McDERMOTT, 2001).  
Gram-positive bacteria lack the outer membrane present in Gram-negative bacteria; they are 
therefore, generally more vulnerable to antibacterial agents.  Alternatively, as a consequence of 
certain antimicrobial mode of activity, Gram-negative bacteria may exhibit greater susceptibility 
than Gram-positive bacteria (WHITE and McDERMOTT, 2001). 
 
PAGE et al. (1997) classified AR as being a result of one of 2 mechanisms:  innate (or intrinsic) 
AR, which depends on the properties of the drug whereas acquired AR depends on the genetic 
adaptation of the bacteria concerned.  All presently available antibiotics are susceptible to 
acquired AR (KIMBALL, 2008a).  LAURENCE and BENNETT (1980) observed 2 general 
types of drug resistance:  (a) drug tolerance (infective organism multiplies (growth) in the 
presence of the drug) and (b) drug destroying (bacteria able to inactivate the drug).  PELEG and 
HOOPER (2010) present a summary of the seven known resistance mechanisms found in Gram-
negative bacteria and their effects on the antibiotics:  loss of porins, use of β-lactamases, 
transmembrane efflux pumps, antibiotic-modifying enzymes, mutation of target sites, ribosomes 
and lipopolysaccharides and metabolic bypass mechanisms.  
 
Clinical antifungal drugs may be susceptible to drug resistance; however, other contributing 
factors such as: impaired drug adsorption; accelerated drug metabolism; antagonism, high fungal 
load and a constant case of being immunocompromised may be involved.  HIV-positive patients 
with OPC are known to be affected by the latter two factors (REX et al., 1995; MAENZA et al., 
1996).  Like with AR, the mechanism of resistance may either be intrinsic or acquired.  Some 
mechanisms known to be used by infecting fungi against triazoles include:  i) The use of efflux 
pumps to reduce drug accumulation; ii) Alteration of membrane sterol composition and; iii) 
Alteration of concentration and or structure of target fungal proteins (SANGLARD and ODDS, 
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2002).  The most recent resistance mechanism to be discovered was the use of bacterial efflux 
systems (POOLE, 2007).  It was observed as tetracycline resistance in E. coli.  Efflux 
mechanisms are both drug-specific and multidrug which causes them to impact on the treatment 
of infectious diseases. 
 
The potentially fatal mycoses commonly observed in patients with immunocompromised 
conditions occur systemically not superficially.  In 1998 reports by REVANKAR et al. (1998) 
and MARTINS et al. (1998) showed a decrease in rate of oral candidiasis in AIDS patients 
using antiretrovirals and the result is a decrease in azole-resistant isolates from these patients.  In 
vitro and clinical antifungal resistance may be defined differently.  In vitro resistance is 
determined by establishing the degree of susceptibility of fungal species to certain antifungal 
drugs.  The fungi can be further classified as possessing either intrinsic or acquired resistance.  
However, if a fungal infection persists while the patient is on a regulated antifungal drug 
treatment, then it is considered as clinical resistance.   
 
With an increasing number of patients presenting with infectious diseases and the alarmingly 
high incidences of AR in recent years, the search for new therapeutic drugs is a necessary 
measure.  The available conventional medication is under pressure to treat the new and re-
emerging diseases such as the increasing number of opportunistic infections often found in 
patients with AIDS.  The „National Committee for Clinical Laboratory Standards (NCCLS)‟ 
produced a revised and certified in vitro susceptibility test that determines the minimum 
inhibitory concentration of antifungal agents against Candida species.  Currently there are 
numerous studies investigating the molecular mechanisms involved in antifungal drug resistance.  
Once these mechanisms elucidate the mode of action of fungi in drug resistance, more specific 
recommendations can be made during drug development and design. 
 
4.1.4. Antibacterial evaluation techniques 
 
HEWITT and VINCENT (1989) defined a microbiological assay as a “technique whereby the 
potency or concentration of a chemical substance may be determined by its effect on the 
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growth of a microorganism”.  They went on further to stress that such assays are essential tools 
for detecting and developing suitable antimicrobial agents/ drugs. 
 
VALGAS et al. (2007), CHOMA and GRZELAK (2010) describe three broad groups of 
bioassays suitable when testing for antibacterial activity (a) diffusion; (b) dilution; (c) 
bioautographic: 
 (a) Diffusion – a common technique which is suitable for preliminary evaluation especially 
of pure compounds.  The disc-diffusion bioassay allows for a higher throughput of crude 
plant extracts to be tested against various bacteria.  The bioassay does not require an 
immediate homogenous dispersion of extract however; if the extract is insoluble in water 
then the technique is not suitable as there would be poor extract diffusion.  Results are scored 
based on inhibition zones around the test extract.  There are certain limiting factors which 
include the solubility or molecular size of the sample or the growth rate of the test 
microorganism that may not allow for sensitive/ accurate reproducible results for crude plant 
extracts.   
 (b) Microdilution – is an ideal preliminary test when using a few test organisms and testing 
crude extracts.  The technique requires the homogenous dispersion of a small quantity of test 
sample in water.  It is a more rigorous and precise evaluation of a crude plant extract and 
enables one to determine either the minimum inhibitory concentration (MIC) or minimum 
bactericidal or lethal concentration (MBC; MLC) i.e. the concentration value necessary to 
inhibit bacterial growth or to kill bacteria respectively for a given microorganism.  PAGE et 
al. (1997) indicate that there may be a 2-8 times difference between the abovementioned 
determinants.  It is quick, sensitive and reproducible (ELOFF, 1998).  The use of indicators 
p-iodonitrotetrazolium violet (INT) and [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide] (MTT) to visualize inhibition zones is a beneficial feature 
(HOSTETTMANN et al., 1995; GIBBONS and GRAY, 1998). 
 (c) Bioautography – is a more rapid approach.  It is an ideal technique where the use of 
bioassay-guided fractionation allows for easy detection of those compounds which exhibit 
biological activity.  The use of indicators to visualize inhibition zones is an added advantage 




VALGAS et al. (2007) and CHOMA and GRZELAK (2010) cited external factors such as 
extraction procedure, volume of inoculum used, culture medium, composition and pH of the 
medium and incubation temperature that may influence MIC values.  The authors CHOMA and 
GRZELAK (2010) also impress that when using any evaluation technique to test for 
antibacterial activity in crude extracts the results may vary.  In addition to the factors mentioned 
above, other factors include the actual assay technique, bacterial strain used, the source of the 
plant material, the age of the plant, condition of the plant material (fresh/dried), and the 
concentration of extract tested (JANSSEN et al., 1987).  Due to the high number of factors that 
may result in variability the formulation of a standard protocol remains difficult.   
 
During the early stages of drug development, crude extract concentration is very important.  One 
may assume that an extract is inactive while using a concentration that is too low.  There is the 
possibility that the active ingredient is present at very low concentrations in the plant and should 
be tested at a higher concentration.  However, in traditional medicine, plant material cannot be 
ingested in bulk to obtain the benefits of an active constituent that is present at low 
concentrations.  This investigation therefore simply serves as a means to validate the use of 
orchids in traditional medicine.  Extracts that lacked any significant activity may in fact show 
greater activity at higher concentrations.  Also, scientific evaluations often reveal crude plant 
extracts that have potential antimicrobial activity.  A suitable dose can thereafter be determined 
for a therapeutic drug for use in the future. 
 
 
4.2. MATERIALS AND METHODS 
 
4.2.1. Plant collection 
 
Leaves, stems and roots of Ansellia africana Lindl. (MC 01NU); leaves, pseudobulbs and roots 
of Bulbophyllum scaberulum (Rolfe) Bolus (MC 02NU); leaves and roots of Cyrtorchis arcuata 
(Lindl.) Schltr. (MC 03NU); tubers and roots of Eulophia hereroensis Schltr. (MC 04NU); 
leaves, stems, pseudobulbs and roots of Eulophia petersii (Rchb.f.) Rchb.f. (MC 05NU); 
pseudobulbs and roots of Polystachya pubescens (Lindl.) Rchb.f. (MC 06NU); leaves and roots 
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of Tridactyle tridentata (Harv.) Schltr. (MC 07NU) were purchased from herbal markets in 
Nongoma, Pietermaritzburg and Umlazi (KwaZulu-Natal).  Voucher specimens were deposited 
at the University of KwaZulu-Natal Herbarium. 
 
4.2.2. Extraction of plant extracts 
 
For the current investigation, all plant material was dried at 37 °C in an incubator, for 72 h and 
subsequently macerated into fine powders using an electric blender.  The powdered plant 
material was stored in air-tight containers and stored in the dark at room temperature, until 
further use.  Four solvents of varying polarity (PE, DCM, 80 % EtOH and water) were used in a 
sequential extraction process.  In order of increasing polarity, 5 g powdered plant material were 
soaked in 100–200 ml cold solvent, sonicated for 1 h in an ultra-sound water bath, left to saturate 
overnight, and then filtered under vacuum using Whatman No. 1 filter paper.  The resultant 
extract was concentrated using either a rotary evapourator or freeze-drier. 
 
4.2.3. Resuspension of plant extracts 
 
Antibacterial assay:  Plant material extracted in PE, DCM and 80 % EtOH were re-suspended in 
80 % EtOH to a concentration of 50 mg/ml.  Plant material extracted with distilled water was 
resuspended in such to produce an aqueous extract. 
Antifungal assay:  Plant extracts were re-suspended in dimethyl sulfoxide (DMSO) and distilled 
water to produce organic solvent and aqueous extracts respectively to a concentration of 100 
mg/ml. 
 
4.2.4. Test organisms used in biological assays 
 
Plant extracts were screened for activity against four bacterial strains and one fungal strain 
obtained from the American type culture collection (ATCC).  Two Gram-positive bacteria: 
Staphylococcus aureus (ATCC 12600) and Bacillus subtilis (ATCC 6051), and two Gram-
negative bacteria: Escherichia coli (ATCC 11775) and Klebsiella pneumoniae (ATCC 13883) 
were employed.  These cultures were maintained on Mueller-Hinton (MH) nutrient agar and 
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stored at 4°C.  Cultures of the fungal strain Candida albicans (ATCC 10231) were, maintained 
on Yeast Malt (YM) agar and stored at 4°C. 
 
4.2.5. Microdilution antibacterial assay 
 
This method is more sensitive than the previously used disc-diffusion bioassay.  The aim of the 
assay is to determine the Minimum Inhibitory Concentration (MIC) values (mg/ml) of plant 
extracts over a period of 24 h (ELOFF, 1998).  The micro-dilution assay was used to test the 
antibacterial activity of orchid plant material.  An added advantage of this method is that it could 
be used for bioassay guided fractionation (post-purification). 
 
Materials prepared in advance under aseptic conditions included McCartney bottles (2 bottles for 
each bacterial strain), MH broth, a steel trough covered in foil, pipette tips, Eppendorf tubes and 
100 ml distilled water.  Each bacterial strain was aseptically prepared in MH broth and kept 
overnight in an orbital shaker at 37 °C.  The following day, optical density readings of the 
overnight bacterial cultures were taken with a VARIAN® CARY 50 Conc Spectrophotometer.  
Overnight bacterial cultures were diluted with MH broth 1:100 (i.e. 200 μl in 19.8 ml).  Sterile 
distilled water (100 μl) was added to each well of a 96-well microplate.  To this, 100 μl of each 
plant extract were added and serially diluted in a two-fold dilution.  Subsequently, 100 μl of the 
dilute bacterial cultures were added to the respective wells of the microplate.  Additional 
microplates filled with just MH broth or water and no bacteria, with no extract and with just 
solvents served as the negative controls.  Neomycin served as a positive control and was 
prepared by adding 20 μl of neomycin to 480 μl of distilled water in an Eppendorf tube to make a 
500 μl solution.  One hundred microlitres of this solution were used to prepare a 2-fold serial 
dilution to test for the MIC of each bacterial strain being tested.  The microplates were then 
sealed with parafilm and stored in an incubator overnight at 37°C.  After 24 h a 0.2 mg/ml stock 
solution of the (Sigma®) INT indicator was prepared and 50 μl was added to each well.  The 
microplates were again incubated at 37 °C for 1 h and observed.  The indicator is reduced to a 
red colour (tetrazolium salt) when acted upon by biologically active organisms.  This indicates a 
lack of antibacterial activity.  Antibacterial activity is recorded as the minimum inhibitory 




4.2.6. Antifungal bioassay 
 
A microdilution protocol (where MIC values (mg/ml) were determined) was performed, however 
a combination of ELOFF (1998); MOTSEI et al. (2003) and MASOKO et al. (2007) protocols 
was used as fungal growth differs from bacterial growth.  Cultures of Candida albicans (ATCC 
10231) fungus were prepared in Yeast Malt (YM) broth and incubated overnight in a water bath 
set at 37 °C.  Subsequent to this, the absorbance readings of 1 ml 0.5 McFarland barium sulphate 
standard solution was taken, followed by, 1 ml of 4 ml sterile saline:400 μl of a 24 h old fungal 
culture mixture.  The percentage absorbance was read at 530 nm.  The absorbance reading for the 
Candida saline solution was adjusted with sterile saline to match that of the McFarland standard 
(0.2500 – 0.2800).  Once this was accomplished the resultant fungal solution was further diluted 
in YM broth 1:1000 (i.e. 10 μl stock yeast culture: 10 ml broth) (MOTSEI et al., 2003).   
 
According to the technique used by ELOFF (1998), 100 μl of sterile distilled water was added to 
each well of a 96-well microplate.  Plant extracts (100 μl) were added and a serially diluted in a 
two-fold dilution.  Thereafter, 100 μl of the dilute fungal cultures were added to each well.  
Samples containing just YM broth or water and no fungus, with no extract and with just solvents 
served as the negative controls.  The positive control was performed as a serial dilution of 25 µl 
antibiotic Amphotericin B (25 mg/ml) (prepared by weighing out 5 mg of Amphotericin B into 
an Eppendorf and dissolving it in 195 µl of DMSO) inoculated with fungi.  Fifty microlitres (50 
µl) of growth indicator, (Sigma®) INT, was added during the assay – to serve as an indicator of 
fungal growth after 24 and 48 h periods.  Microplates were sealed with parafilm and incubated 
overnight at 37°C.  Minimum inhibitory concentrations were recorded after 48 h, after which, 40 
µl of YM broth was administered to each well to determine if there was fungicidal/fungistatic 









Results for the antibacterial and anti-candidial activity of crude extracts for seven orchid species 
are shown in Table 4.1. (Chapter 4).  Significant inhibitory and lethal effects were scored at less 
than 1 mg/ml.  Tridactyle tridentata aqueous root extract produced the most effective 
antibacterial activity against S. aureus (0.049 mg/ml).  All T. tridentata organic root extracts 
produced significant inhibitory activities against both Gram positive bacteria.  Eulophia petersii 
DCM pseudobulb extracts significantly inhibited all bacterial strains tested (0.78 mg/ml against 
B.s., E.c., and K.p. and 0.39 mg/ml against S.a.).  Eulophia hereroensis 80% EtOH root extract 
was the only other extract to exhibit significant inhibitory effects against Gram-negative bacteria, 
specifically K.p. (0.65 mg/ml).  After 48 h C. albicans was most susceptible to P. pubescens 
aqueous pseudobulb extract (0.0816 mg/ml).  Eulophia petersii DCM pseudobulb extract 




Table 4.1.:  Antibacterial and antifungal activity of crude extracts from seven South African medicinal orchid species against standard 
bacterial and fungal strains from ATCC. 
Species Plant part Extraction solvent Bacterial strains (MIC mg/ml) Candida albicans (mg/ml) 
    B.s. S.a. E.c. K.p. MIC (48 h) MFC(72 h) Ansellia africana Leaves PE 5.21 4.72 4.69 4.17 12.5 >12.50 
  DCM 2.15 2.67 2.86 2.6 8.33 12.5 
  Ethanol 2.05 1.85 2.6 2.08 12.5 12.5 
  Water >12.50 >12.50 >12.50 >12.50 6.25 6.25 
 Stems PE 2.03 3.44 3.75 2.19 6.25 6.25 
  DCM 0.39 2.19 2.81 2.81 6.25 6.25 
  Ethanol 2.34 5.63 4.38 2.5 12.5 12.5 
  Water >12.50 >12.50 >12.50 >12.50 >12.5 >12.5 
 Roots PE - - 3.13 - 12.5 12.5 
  DCM 0.46 3.12 2.08 2.08 2.08 2.08 
  Ethanol 1.95 2.34 2.34 1.95 3.13 4.17 
  Water >12.50 >12.50 >12.50 >12.50 2.08 >12.50 
Bulbophyllum scaberulum Roots DCM 0.15 0.0735 4.69 4.69 0.78 3.13 
  Ethanol 0.26 0.26 6.25 4.17 1.56 6.25 
  Water 6.25 6.25 >12.50 12.5 >12.50 >12.50 Cyrtorchis arcuata Leaves PE 1.56 1.56 3.13 1.56 6.25 6.25 
  DCM 0.78 1.56 3.13 3.13 3.13 4.69 
  Ethanol 2.08 3.13 3.13 2.08 6.25 6.25 
  Water >12.50 2.08 12.5 3.13 3.13 3.13 
 Roots PE 2.34 1.56 3.13 3.13 6.25 6.25 
  DCM 0.59 0.59 3.13 3.13 6.25 6.25 
  Ethanol 2.6 3.13 3.13 4.17 6.25 6.25 
  Water >12.50 1.95 >12.50 3.13 >12.50 >12.50 
Eulophia hereroensis Tubers PE 3.13 1.56 3.13 3.13 - - 
  DCM 2.08 3.13 1.56 3.13 - - 
  Ethanol 4.17 6.25 3.13 3.13 - - 
  Water >12.50 12.5 12.5 10.42 >12.50 >12.50 
 Roots DCM 0.39 1.56 6.25 6.25 - - 
  Ethanol 0.13 0.42 1.3 0.65 - - 
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Species Plant part Extraction solvent Bacterial strains (MIC mg/ml) Candida albicans (mg/ml) 
    B.s. S.a. E.c. K.p. MIC (48 h) MFC(72 h) Eulophia petersii Leaves PE 1.56 0.39 3.13 1.56 >12.50 >12.50 
  DCM 3.13 3.13 3.13 3.13 1.56 6.25 
  Ethanol 2.6 0.91 3.13 3.13 3.13 3.13 
  Water - - - - 8.6 >12.50 
 Stems PE 0.78 0.39 3.13 3.13 12.5 12.5 
  DCM 1.56 1.56 1.56 1.56 0.78 0.78 
  Ethanol 1.3 1.56 6.25 2.08 2.6 10.42 
  Water >12.50 >12.50 >12.50 >12.50 >12.50 >12.50 
 Pseudobulbs PE 0.098 0.2 3.13 3.13 3.13 3.13 
  DCM 0.78 0.39 0.78 0.78 0.65 0.65 
  Ethanol 1.56 2.08 6.25 6.25 0.78 6.25 
  Water >12.50 3.13 6.25 5.21 >12.50 >12.50 
 Roots PE 0.78 0.39 3.13 3.13 >12.50 >12.50 
  DCM 0.33 0.2 1.3 1.3 1.04 1.3 
  Ethanol 3.13 4.17 3.13 4.17 3.13 12.5 
  Water >12.50 >12.50 12.5 12.5 >12.50 >12.50 
Polystachya pubescens Pseudobulbs PE 0.78 1.56 1.56 1.56 3.13 6.25 
  DCM 0.29 0.39 3.13 3.13 3.13 3.13 
  Ethanol 1.56 2.08 3.13 2.08 3.13 6.25 
  Water - - - - 0.0816 3.13 
 Roots DCM 1.17 1.17 3.13 3.13 6.25 6.25 
  Ethanol 1.56 1.56 3.13 2.6 1.56 3.13 
  Water 6.25 3.13 12.5 3.13 >12.50 >12.50 Tridactyle tridentata Roots PE 0.2 0.59 3.13 2.34 6.25 6.25 
  DCM 0.0653 0.0816 5.21 5.21 2.6 5.21 
  Ethanol 0.65 0.91 3.13 3.13 3.13 3.13 
  Water 3.13 0.049 >12.50 12.5 3.13 3.13 Neomycin (µg/ml)  0.012 0.78 0.39 0.098 - - Amphotericin B (µg/ml)  - - - -  49.0 B.s. - Bacillus subtilis; E.c. - Escherischia coli; K.p. - Klebsiella pneumoniae; S.a. - Staphylococcus aureus. The values presented are 





The current list of medicinally and culturally used orchid species in South African traditional 
practices (Table 3.1. Chapter 3) may represent a refined list of species that were observed by 
the traditional healers and traders to be most therapeutically beneficial (CHINSAMY et al., 
2011).  Certain classes of compounds have specific biological activity, which may have been 
harnessed when used in traditional medical practices.   
 
Phytoalexins are defined as low molecular weight antimicrobial compounds synthesised and 
accumulated in plants post-exposure to microorganisms (STOESSL and ARDITTI, 1984).  This 
is in accordance with the observation made by French botanist, Noel Bernard; who revealed an 
acquired immunity in orchid species O. morio and L. hircinum against R. repens, an 
endomycorrhizal fungus.  Other orchid species with functional uses of their antifungal properties 
include C. macranthos var. rebunense seeds which demonstrated antifungal properties at various 
growth phases as a mechanism to facilitate germination (SHIMURA et al., 2007).  Dendrobium 
officinale agglutinin-2 demonstrated significant antifungal properties against G. zeae which 
suggests its possible use for crop plants.  (CHEN et al. 2005).  
 
The pseudobulb aqueous extract of P. pubescens, which shares the vernacular name with P. 
ottoniana (amabelejongosi) and may be sold a replacement, significantly inhibited C. albicans 
after 48 h (0.0816 mg/ml).  This was the only aqueous extract to have such an effect on C. 
albicans.  The stem and pseudobulb DCM extract of E. petersii exhibited a more moderate but 
persistant antifungal effect.  While the antimicrobial use of Polystachya species in African 
traditional medicine is validated; a more comprehensive evaluation of the antifungal properties 
and chemistry of Polystachya species of South Africa may reveal novel phenanthrene and 
dihydro phenanthrene compounds with possibly novel modes of action.  Similar studies on E. 
petersii may uncover interesting results.   
 
Phenanthrenes and their dihydro phenanthrene derivatives constitute the major phytoalexins in 
orchids (KOVÁCS et al., 2008).  Orchinol (2,4-dimethoxy-7-hydroxy-dihydrophenanthrene) 
isolated from O. militaris and loroglossol and hircinol (2,5-dihydroxy-4-methoxy-
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dihydrophenanthrene) isolated from L. hircinum exhibited antimicrobial properties (BÖLLER et 
al., 1957; HARDEGGER et al., 1963).  Hircinol and orchinol were considered to be non-
specific antimicrobials as they produced varying activities against a range of fungi and bacteria 
(GÄUMANN et al., 1960; URECH et al., 1963; FISCH et al., 1973).  Hircinol (100 ppm) 
exhibited fungistatic effects against C. lipolitica over three days; while loroglossol was found to 
be inactive.  Orchinol (100 ppm) demonstrated a more potent antifungal effect by completely 
inhibiting growth of C. lipolitica over six days (KOVÁCS et al., 2008).   
 
Alternatively, future studies should look into the antifungal activity of lectins.  Mannose binding 
lectins are commonly found in higher plant families; Orchidaceae, Amaryllidaceae, Alliaceae, 
Araceae, Iridaceae and Liliaceae.  They are involved in recognition of high-mannose type 
glycans of foreign microorganisms or predators. Orchid species from which mannose binding 
lectins have been isolated include L. ovata, E. helleborine, and Cymbidium hybrid (VAN 
DAMME et al., 2000).  Gastrodianin, a stable structure with potent inhibitory activity against 
certain fungal strains (XU et al., 1998) was isolated from G. elata as the main antifungal 
compound.  It was found to be closely related to the antifungal mannose-binding proteins of 
orchids such as E. helleborine and L. ovata; therefore, gastrodianin-like proteins are considered a 
novel group of antifungal proteins (WANG et al., 2001).   
 
According to KOVÁCS et al. (2008) phytoalexins such as phenanthrenes and 
dihydrophenanthrenes are the defence compounds present in orchid species to counter microbial 
attack.  Bulbophyllum scaberulum is one of the less frequently sold orchids in herbal markets.  
There is no record of B. scaberulum being used in African traditional medicine in the available 
ethnobotanical literature.  The DCM root extract was most effective against S.a. (Table 4.1 
Chapter 4).  The organic root extracts were particulary active against Gram-positive bacteria.  A 
large number of phenanthrenes have been isolated from the genus Bulbophyllum (KOVÁCS et 
al., 2008).  These include: bulbophyllanthrin, cirrhopetalanthrin, coelonin, confusarin, 
erianthridin, fimbriol-B, flavanthrin, flavanthrinin, gymnopusin, isoreptanthrin, nudol, 
reptanthrin.  A more extensive evaluation of Bulbophyllum species in South Africa may uncover 




With regard to the current investigation, E. petersii is used by the Zimbabweans as a tuber 
infusion to treat edema (GELFAND et al., 1985); the pseudobulb DCM extract significantly 
affected all test organisms (Table 4.1. Chapter 4); while the PE and DCM root extracts 
significantly inhibited only Gram-positive bacteria.  While this may not be a direct correlation 
with the use of the plant, active constituents in this non-polar extract may have other protective 
properties not previously known.  The total phenolic content of the pseudobulb was significantly 
higher than other extracts (Figure 6.3 A).  The therapeutic effect of this plant may include 
prevention of opportunistic infections.  Different species of the Eulophia genus are traded under 
one vernacular name.  Such substitution might imply similar uses, therapeutic effect and/or lack 
of knowledge on the different species.  The use of E. hereroensis (syn. E. junodiana Kraenzl., E. 
undulata Rolfe and E. pillansii Bolus) in African traditional medicine has never been previously 
reported.  The DCM and 80% EtOH root extracts exhibited significant antibacterial activity 
against certain test organisms (Table 4.1. Chapter 4).  This was the only other species tested 
(other than E. petersii) that exhibited a significant effect against a Gram-negative bacterium.  A 
more complete phytochemical and broad pharmacological assessment of the South African E. 
petersii species, and Eulophia genus, might reveal similarities and/or differences to that of the 
Yemen species.   
 
A phytochemical report by BLITZKE et al. (2000) revealed five phenanthrenes and several 
phytosterols from the roots of E. petersii collected in Yemen.  KOVÁCS et al. (2008) reviewed 
the phytochemical and pharmacological research on phenanthrenes from orchids.  Of the 
phenanthrenes found in E. petersii (coelonin, lusianthridin, lusianthrin, eulophiol) lusianthridin 
was found to be active against Gram-positive bacteria but with poor effect against certain fungi 
(KOVÁCS et al., 2008).  In Chinese medicine, Bletilla striata is used to treat 
„pneumonorrhagia‟ and „pneumonopthisis‟.  Gram-positive bacteria were found to be susceptible 
to lusianthridin, isolated from the methanol extract of B. striata.  The same compound was also 
found to have cytotoxic activity in vitro and in vivo, anti-tumour effects and increase 
contractions (KOVÁCS et al., 2008).  Biphenanthrenes, blestriarene A, B and C were 
particularly active against S. aureus and Streptococcus nutans; with blestriarene B exhibiting the 
most potent antibacterial effects (YAMAKI et al., 1989).   Lusianthridin was isolated from 
another Eulophia species – E. boothii (KOVÁCS et al., 2008).   
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Tridactyle tridentata is the most difficult species to locate in herbal markets.  Very few traders 
are familiar with this „iphamba’.  While it is mostly used as a protective charm (HUTCHINGS 
et al., 1996), all crude root extracts were consistently active against Gram-positive bacteria 
(except B.s. for aqueous extract).  The use of related species or sale of previously unrecorded 
„medicinal‟ species is an indication of a lack of in-depth records, and lack of interest in orchids 
as a medicinal plant.  Without such information, the change in availability of these species, and 
subsequently, the conservation status would go unnoticed.  With regard to the genus Tridactyle, 
determining the presence of structurally related compounds in related and unrelated species 
would be of interest.  Since all organic and aqueous extracts (even after a sequential extraction 
process) produced significant antibacterial effects; a more extensive investigation of T. tridentata 
root extracts may reveal significant bioactive compounds.   
 
Current antibiotics tend to exhibit less activity against Gram-negative than Gram-positive 
bacteria possibly due to the complex cell wall structure of the former (WHITE and 
McDERMOTT, 2001).  McGAW et al. (2000) reported a tendency for plant extracts to be more 
active against Gram-positive than Gram-negative bacteria.  This perhaps could explain the 
current results obtained where more significant activity was observed against Gram-positive 
bacteria (Table 4.1. Chapter 4).  Vanillin, a constituent of V. planifolia Andrews (syn. V. 
fragrans Ames), exhibits antimicrobial properties against certain Gram-positive and Gram-
negative bacteria known to spoil food and is therefore used as a food preservative (KRUEGER 
and KRUEGER, 1983; BURRI et al., 1989; CERRUTTI et al., 1997; DAUGSCH and 
PASTORE, 2005). 
 
In terms of validating the ethnobotanical use of South African orchids in traditional medicine, 
the results obtained show bateriostatic, fungistatic and fungicidal activity in all extracts. 
Tridactyle tridentata aqueous root extract which produced the most effective antibacterial 
activity against S. aureus (0.049 mg/ml) and E. petersii DCM pseudobulb extracts which 
significantly inhibited all test organisms could be of particular interest, in terms of isolation and 
identification of active constituents.  The standard strain of C. albicans (ATCC 10231) proved to 
be resistant to most plant extracts tested but most susceptible to P. pubescens aqueous 
pseudobulb extract.  Generally, the DCM extracts showed better activity than the PE and EtOH 
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extracts which merits further investigation into the identification of the compounds present in 
these crude extracts.  There is no information on the use of orchid species as antifungal agents in 








Persons living in tropical and subtropical areas of sub-Saharan Africa, Asia and Latin America 
are especially susceptible to soil-transmitted helminth (STH) infection (HOTEZ et al., 2003; 
BETHONY et al., 2006).  The major infective agents that cause STH include: Ascaris 
lumbricoides, Trichuris trichiura and the hookworms.  Parasitic worm infestations of the 
intestine, most commonly by nematodes (round worms) are known to cause considerable distress 
to both animals and humans.  Statistics show a total of close to 2 billion people affected by 
parasitic worm infections (HOTEZ et al., 2003; WHO, 2004).  Over 1 billion people are 
thought to be infected with A. lumbricoides, 795 million with T. trichiura, and approximately 
740 million with hookworms (Ancylostoma duodenale and Nector americanus) (BETHONY et 
al., 2006).  Nematodes are free-living organisms, known to be ubiquitous in nature.  Those that 
do find their way into a human gastrointestinal tract only manifest as helminthiasis when the 
nematode load is too high (LEWIS and ELVIN-LEWIS, 1977). 
 
Helminthiasis is one of the most common tropical diseases, responsible for high morbidity and 
mortality especially in the poorer regions of developing countries (WHO, 2002b).  The tropical 
climate is favourable for the completion of the nematode life cycle in the soil.  (HOTEZ et al., 
2003).  Humans contract the infection by either ingesting the eggs from contaminated soils or the 
larve in the soil actively penetrate the skin.  Parasitic worm infections seldom lead to death 
(HOTEZ et al., 2006), however; a persistent infection has serious consequences.  Infections, 
which are more prevalent in school children, result in a feeling of general weakness, signs of 
malnutrition, depression, iron-deficiency anaemia (caused mainly by hookworm infection – 
chronic intestinal blood loss), and noticeable impaired physical and intellectual development 
(WHO, 2002b).  While the highest infection rates occur in the 5 – 15-year-old age group 
(WHO, 2002b); the long-term effects will unfortunately only manifest later in their lives.  In 
addition, it has been suggested that untreated helminthiasis could compromise the individual‟s 
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immune system, leaving them vulnerable to unrelated infections such as malaria, HIV and TB 
(HOTEZ et al., 2006; KEISER and UTZINGER, 2008).   
 
In his review BROOKER (2010) discusses the development of the standard measurement of 
burden of disease; disability adjusted life years (DALYs).  The effect of diseases such as 
helminthiasis are felt more in children and impact negatively on their physical and cognitive 
development.  Also, symptoms of helminthiasis are often “non-specific and chronic” 
BROOKER (2010); allowing the disease to continue undetected.  According to BETHONY et 
al. (2006), as a result of helminthiasis; an estimated 39 million DALYs are considered lost each 
year.  As a comparison this estimate is more than the value estimated for malaria infections (36 
million) and close to those DALYs lost to TB (44 million).  Environmental and human (social 
habits, diet, poverty, hygiene) factors are major contributors to the persistence of these infections 
(HOTEZ et al., 2006). 
 
The United Nations held a „General Assembly‟s Special Session on Children‟ in May 2002 from 
which a document entitled „A World fit for Children‟ was produced (WHO, 2002b).  Contained 
within were the resolutions by world leaders to “reduce the incidence of intestinal parasites” and 
to “reduce by one-third the prevalence of anaemia, including iron deficiency anaemia, by 2010”.  
Similarly, it is one of the World Health resolutions to provide continuous treatment against STH 
and schistosomiasis to approximately 75% of all school children in affected areas by the year 
2010.  One success story from a rural community in Cape Town, South Africa showed a decrease 
in infection (95%-20%) in 11 000 school children infected from 12 primary schools; following 
regular deworming treatment (WHO, 2002b).   
 
 
5.1.1. Anthelmintic drugs:  Modes of action 
 
SIMPKIN and COLES (1981) and KEISER and UTZINGER (2008) mention two major 
groups of anthelmintics:  benzimidazoles (albendazole and thiabendazole) and non-
benzimidazoles (levamisole, pyrantel and ivermectin).  PRICHARD (1994); MARTIN (1997) 
and KEISER and UTZINGER (2008) maintain that it is the excessive use of anthelmintic drugs 
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in veterinary medicine that has contributed to the current problem of drug resistance.  
Alternatives include the use of drugs with different modes of action on resistant parasites to 
effectively treat the infection.  Some important considerations (i.e. sufficient biological 
information on the infecting organism as well as the drugs available) should be made when 
selecting an anthelmintic agent for treatment (FRAYHA et al., 1997).  It is therefore necessary 
to be aware of the different modes of action of available anthelmintic drugs. 
 
FRAYHA et al. (1997) compiled a reference of all the available anthelmintic drugs for humans.  
Drugs were grouped according to the mechanism of action on helminths.   
 Drugs that affect the biochemical processes of the helminths include:  antimony organic 
compounds; niclosamide; bithionol; cyanine dyes; benzimidazoles; and nitroimidazoles. 
 Antimony drugs compete with fructose-6-phosphate for the same site on the enzyme 
involved in glycolysis (BUEDING, 1969).  By inhibiting the glycolysis pathway, 
antimony drugs cut off the supply of ATP, thereby killing the parasite.  The earlier use of 
antimony organic compounds (trivalent and pentavalent) has recently been opposed due 
to its toxic effects; with pentavalent compounds showing less toxicity than their trivalent 
counterparts (JAMES and GILLES, 1985).  Use of these drugs however, has resulted in 
the development of resistant parasites.  The mechanism of this is not fully understood 
(ONELETTE and PAPADOPOULOU, 1993).  ONELETTE and PAPADOPOULOU 
(1993) provided another target of antimony drugs:  enzymes involved in fatty acid ß-
oxidation where, the mechanism of action as of yet is unknown.   
 Niclosamide drugs are primarily used to treat human tapeworm infections and trematode 
parasites.  The drug is thought to remove the protective substance against proteolytic 
enzymes of the host found in parasites ROLLO (1970).  It may also affect the 
metabolism of ATP by inhibiting the process.  This may affect the uptake of glucose 
either directly or indirectly (JAMES and GILLES, 1985).  
 Bithionol has been replaced by praziquantel in the treatment of certain parasitic infections 
(JAMES and GILLES, 1985).  The mechanism of action is similar to that of other drugs 
in this group where ATP production is inhibited (JAMES and GILLES, 1985).   
 There are two cyanines:  dithiazanine (no longer in use due to its toxicity) and pyrvinium 
(still used against certain helminths).  They have two modes of action:  interference with 
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respiration and inhibition of oxygen uptake; and obstruction of glucose uptake in the 
nematode‟s intestine, thereby affecting its motility (FRAYHA et al., 1997). 
 The benzimidazoles include:  mebendazole, albendazole, flubendazole and thiabendazole.  
This group is more widely used in both human and veterinary medicine.  COOK (1990; 
1991) reported on the susceptibility of certain systemic and intestinal nematodes to one or 
more of these drugs.  Mebendazole prevents the uptake of glucose, which compels the 
parasite to use its reserve glycogen.  Consequently, its source of energy is depleted and 
its ability to survive and reproduce is hindered (FRAYHA et al., 1997).  LACEY (1990) 
provides an additional mode of action; mebendazole has an affinity to tubulin, a structural 
protein found in microtubules, and therefore prevents the formation of microtubules.  
However, albendazole, an effective broad spectrum anthelmintic, is fast replacing 
mebendazole (FRAYHA et al., 1997).  Its mode of action is found to affect the glucose 
uptake in larval and adult stages of the parasite, thereby consuming the glycogen reserves 
and reducing ATP production (FRAYHA et al., 1997).  Albendazole also inhibits 
microtubule formation.  Flubendazole and thiabendazole have similar activities on 
parasites (FRAYHA et al., 1997). 
 Nitroimidazoles consist of two groups:  metronidazole (low toxicity) and benznidazole 
(some side effects reported – De RAADT (1989)).  With metronidazole, subsequent 
derivatives have shown promising results with a prolonged effect, thereby reducing the 
number of doses required.  Whilst being a broad spectrum drug, it has an even better 
effect in combination with other drugs.  Benznidazole affects the polymerases and DNA 
templates involved in protein and RNA synthesis – inhibiting the process (FRAYHA et 
al., 1997). 
 Another familiar group of anthelmintics are the antimalarials which among other include:  
quinine, chloroquine and amodiaquine, mefloquine, halofantrine, primaquine and atovaquone 
(FRAYHA et al., 1997).  
 Other anthelmintic drugs are known to target the reproductive system and in so doing, affect 
the multiplication of the parasite (FRAYHA et al., 1997). 
 Alternatively, some anthelmintic drugs affect the neuromuscular physiology of the 
susceptible parasite (FRAYHA et al., 1997). 
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 The reference anthelmintic drug used in this investigation as a standard, levamisole, 
along with other drugs like pyrantel and morantel are considered to be agonists at the 
nicotinic acetylcholine receptors of nematode muscle which results in spastic paralysis 
(MARTIN, 1997).  The primary action affects the cholinergic receptors at the 
neuromuscular junctions that paralyse the nematodes, which are then easily excreted 
(JAMES and GILLES, 1985).  A secondary action targets energy production by 
inhibiting the enzyme succinodehydrogenase that catalyses the conversion of fumarate to 
succinate in the TCA cycle (JAMES and GILLES, 1985). 
 Other drugs such as piperazine cause flaccid paralysis by acting as agonists of nematode 
muscles, while avermectins cause paralysis of pharyngeal pumping by adjusting the 
glutamate-gated chloride channels (MARTIN, 1997).   
 Praziquantel causes rapid muscle contraction and paralysis by increasing the permeability 
of the tegument and the influx of calcium (MARTIN, 1997). 
 
Currently there are various preventative measures in place, such as:  provision of proper 
sanitation, vector control and chemotherapy. Chemotherapy has been the treatment of choice 
since ancient times, when plants with anthelmintic activity were used to prevent and treat 
parasitic infections (FRAYHA et al., 1997).  Presently, chemotherapy with broad spectrum 
anthelmintics (NJOKU et al., 1996) or the use of specific drugs is the standard treatment for 
those already infected.  Anthelmintics like other clinical drugs need to be effective against the 
infecting organism but safe for the patient to ingest. 
 
 
5.1.2. Anthelmintic resistance 
 
Anthelmintic resistance has been most notable in commercially important livestock in certain 
regions including South Africa (GEERTS et al., 1997) and has seriously affected the livestock 
industry.  GEERTS and GRYSEELS, (2001) highlight the growing concern of drug resistance 
in human helminthes and stress that the signs of drug resistance are in their early stages and 
could develop into a serious situation.  Drawing on their knowledge GEERTS et al. (1997) and 
GEERTS and GRYSEELS (2000) suggest that tolerance traits already found in some human 
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helminthes might become dominant under selective drug pressure.  GEERTS et al. (1997) 
caution against some of the methods proposed to treat helminth infections in humans.  A more 
specific group of individuals should be targeted for treatment, instead of mass therapy to avoid 
the threat of drug resistance (GEERTS and GRYSEELS, 2001).  They advise against using 
short term, low-dosage treatment to prevent the development of resistance to existing 
anthelmintics.  They do however; acknowledge that resistance may develop more slowly in 
helminths compared to other infective organisms.  It has been hypothesised that broad-spectrum 
anthelmintics used in mass therapy may encounter resistance in the long-term (GEERTS et al., 
1997).  The WHO recommended the use of anthelmintic treatments for schistosomiasis during 
dry, low transmission periods (WHO, 1992).  However, GEERTS and GRYSEELS (2001) 
advise a cautious assessment of each case before commencing with treatment campaigns.   
The current threat of AR has fatal consequences.  This scenario could be just as dire for 
anthelmintics.  With concerns of rising drug resistance rates and the limited modes of action, of 
drugs available, there is a need for the development of, and research into, safe and effective 
anthelmintic drugs.  An added concern is the inability of infected individuals to develop 
immunity to the infective agent once successfully treated.  Therefore, the search for anthelmintic 
drugs to be used in worldwide treatment programs will be a necessity until environmental and 
social factors that contribute to helminthiasis are corrected, thereby reducing the risk of re-
infection.  A review by TAYLOR et al. (2002) outlines some of the common in vitro tests used 
to detect resistance.  KWA et al. (1994) describe the molecular mechanisms (mutation in ß-
tubulin) involved in resistance to benzimidazoles in helminths.  Such studies could reveal the 
mechanisms used by resistant parasites which would aid in the search for new, effective and safe 
drugs. 
 
Records of natural products with anthelmintic activity being used by mankind date back to 
ancient times.  Extensive pharmacological studies have been carried out on some South African 
medicinal plants using the in vitro bioassay which makes use of the free-living nematode C. 
elegans (McGAW et al., 2000).  Such studies revealed some effective anthelmintic compounds 





5.2. MATERIALS AND METHODS 
 
5.2.1. Re-suspension of plant extracts 
 
Plant extracts were prepared as mentioned in Section 4.2.2.  Organic and aqueous extracts were 
prepared by reconstituting the PE, DCM, 80% EtOH extracts in 5% DMSO and water extracts in 
distilled water at a concentration of 25 mg/ml. 
 
5.2.2. Anthelmintic bioassay 
 
Crude plant extracts were evaluated using an eight-day in vitro rapid colourimetric assay for 
quantification of Caenorhabditis elegans viability.  Caenorhabditis elegans nematodes that were 
maintained on Nematode Growth (NG) agar at 20°C were used.  On day one an overnight culture 
of E. coli in 5 ml of MH broth was prepared, along with M9 buffer (6 g Na2HPO4; 3 g KH2PO4; 
5 g NaCl, 0.25 g MgSO4.7H2O in 1 liter distilled water).  On day two overnight E. coli culture 
was autoclaved and new plates of C. elegans nematodes were prepared by washing old cultures 
with 5 ml of M9 buffer and adding 100 µl of neomycin (0.5 mg/ml) to the old plates.  New NG 
agar plates were seeded with 50 µl of the autoclaved E. coli culture, after which 500 µl of the 
neomycin-treated nematodes were added.  New plates were incubated in the dark for 72 h at 
20°C.  On day five distilled water, a stainless steel trough (covered in foil), 2 McCartney bottles, 
tips and 2 Eppendorf tubes were autoclaved before the assay.  A nematode suspension was 
prepared by washing 72 h old cultures with 5 ml sterile M9 buffer.  The optical density of the 
suspension was determined at 530 nm using a VARIAN® CARY 50 Conc Spectrophotometer.  
M9 buffer was used to zero the spectrophotometer and make a more diluted suspension that 
produced an optical density value in the range of 0.04 – 0.06.  Crude plant extracts were prepared 
to a concentration of 25 mg/ml while the positive control, levamisole, was tested at a 
concentration of 1 mg/ml.  In a 96-well microtitre plate 100 µl of sterile distilled water was 
added to each well.  To this, 100 μl of each sample (crude plant extract or control substance) was 
added to the first row and a two-fold serial dilution was followed.  Thereafter, 50 µl of the 
diluted nematode suspension were added to each well.  Microplates were covered with parafilm 
and incubated in the dark at 20°C for 48 h.   On day seven, 50 µl of INT (2 mg/ml) were added to 
each well and plates were incubated for a further 24 h.  The indicator is reduced to a red colour 
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(tetrazolium salt) when acted upon by biologically active organisms.  This indicates a lack of 
anthelmintic activity.  The minimum lethal concentration (MLC) was determined as the last well 





Anthelmintic effects of extracts of seven indigenous orchid species are presented in Table 5.1.  
Cyrtorchis arcuata leaf and root extracts were the most effective anthelmintic extracts with 
MLCs of 0.041 mg/ml for 80% EtOH leaf and root extracts; 0.049 mg/ml for aqueous leaf 
extracts and 0.78 mg/ml for aqueous and DCM root extracts.  All A. africana and T. tridentata 
organic root extracts significantly affected C. elegans.  A similar significant effect was observed 
for all E. petersii organic pseudobulb extracts and DCM extracts.  The organic root extracts of B. 
scaberulum exhibited lethal effects on C. elegans.  Only the DCM tuber and root extracts of E. 




Table 5.1.:  Anthelmintic (MLC mg/ml) activity of crude extracts from seven South African medicinal orchid species against the 
nematode Caenorhabditis elegans 
Species Plant part analysed Extraction solvent MLC (mg/ml) (72 h) 
Ansellia africana Leaves PE 3.13 
  DCM 0.20 
  Ethanol 1.56 
  Water 6.25 
 Stems PE 1.56 
  DCM 2.34 
  Ethanol 1.56 
  Water 6.25 
 Roots PE 0.20 
  DCM 0.10 
  Ethanol 0.16 
  Water 3.13 
Bulbophyllum scaberulum Leaves Water >6.25 
 Pseudobulbs Water >6.25 
 Roots DCM 0.39 
  Ethanol 0.39 
  Water 3.13 
Cyrtorchis arcuata Leaves Ethanol 0.041 
  Water 0.049 
 Roots DCM 0.78 
  Ethanol 0.041 
  Water 0.78 Eulophia hereroensis Tubers DCM 0.20 
  Ethanol 1.56 
  Water >6.25 
 Roots DCM 0.39 
  Ethanol 1.56 Eulophia petersii Leaves PE 1.30 
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Species Plant part analysed Extraction solvent MLC (mg/ml) (72 h) 
  DCM 0.39 
  Ethanol 1.04 
  Water 3.13 
 Stems PE 1.56 
  DCM 0.39 
  Ethanol 0.78 
  Water >6.25 
 Pseudobulbs PE 0.78 
  DCM 0.39 
  Ethanol 0.78 
  Water 6.25 
 Roots PE 0.78 
  DCM 0.29 
  Ethanol 1.56 
  Water 6.25 
Polystachya pubescens Pseudobulbs Ethanol 1.56 
  Water >6.25 
 Roots Ethanol 1.56 Tridactyle tridentata Leaves Water 3.13 
 Roots PE 0.78 
  DCM 0.78 
  Ethanol 0.20 
  Water 3.13 










There are no previous reports of anthelmintic activity for South African orchid species.  The 
seven species were selected based on their use and availability in herbal markets in KwaZulu-
Natal.  Traditionally, crude plant extracts are made using cold or hot water extraction to produce 
infusions, decoctions and creams.  When determining the general pharmacological activity of 
medicinal plants, solvents of varying polarities are used to extract different groups of 
compounds.  All orchid crude extracts exhibited broad-spectrum anthelmintic activity. 
 
Except for C. arcuata, only the organic extracts of most other orchid species exhibited 
significant lethal effects on C. elegans.   RHEE et al. (1982) (cited in PÉREZ GUTIÉRREZ, 
2010) isolated a substance from the ethyl ether tuber extract of B. striata found in Gangweon-do 
in the Korean peninsula.  The substance was soluble in PE and demonstrated anthelmintic effects 
in vitro on various stages of Clonorchis sinensis (cercaria, excysted metacercaria and adult 
stages).  TAYLOR and VAN STADEN (2001) mention that solvents such as EtOH extract 
lipophilic compounds from plant material.  These non-polar principles may contribute to the 
anthelmintic activity observed.  
 
The presence of certain classes of compounds may influence biological activity in medicinal 
plants.   Phytochemical analysis revealed C. arcuata methanol leaf extracts to have the highest 
condensed tannin (syn. proanthocyanidin) content (1.36 mg leucocyanidin equivalent/g dry 
matter) compared to other extracts.  Recent veterinary parasitology studies have focused on the 
use of proanthocyanidin-rich diets for direct and indirect anthelmintic effects (IQBAL et al., 
2007).  Similarly, C. arcuata methanol root extracts recorded the highest flavonoid content (1.24 
mg catechin equivalent/g dry matter).  Anatomical studies of Encyclia calamara roots revealed 
the presence of flavonoid compounds (OLIVEIRA and SAJO, 1999); while the comprehensive 
survey by WILLIAMS (1979) illustrates the distribution of leaf flavonoids in Orchidaceae.  
KIM et al. (2009) reported on the lethal anthelmintic effects of flavonoids; where the natural 
flavonoid flavone inhibited embryogenesis in C. elegans.  Such reports provide credence to the 




Eulophia petersii methanol pseudobulb extract was found to contain the highest total phenolic 
content (24.73± 0.57 mg gallic acid equivalent GAE/g dry matter – Figure 6.3A Chapter 6) 
compared to other orchid extracts.  All DCM extracts of E. petersii significantly affected C. 
elegans.   The tubers of E. nuda, found in the Himalayas, are used to treat various ailments 
including, as a vermifuge to treat worm infestation.  The methanol extract and isolated phenolic 
compound of the tubers exhibited cytotoxic potential (SHRIRAM et al., 2010).  The 
anthelmintic effect of the extract may be due to the cytotoxic effect of phenolic compounds.   
Hydrolysable tannin (gallotannin) content varied among species; with E. hereroensis methanol 
root extract containing the highest amount (1.40 mg GAE/g dry matter).  MOHAMED et al. 
(2000) explored the lethal effects of gallo- and condensed tannins specifically against C. elegans.  
Hydrolysable tannins (gallic acids) are of lower molecular weight than condensed tannins and 
are more easily absorbed in the digestive tract of ruminants; and are therefore considered more 
toxic (HOSTE et al., 2006). Studies on the effect of pure compounds isolated from Rhus niveus 
on the plant-parasitic nematode (Meloidogyne incognita) revealed that gallic acid was one of the 
more potent nematicidal compounds present (SULTANA et al., 2010). MOHAMED et al. 
(2000) concluded that natural tannins could possibly contribute to the search for novel sources of 
anthelmintics and that the use of tannin-rich plants could help control nematode infection in 
animals. 
 
KEISER and UTZINGER (2008) put into context the current situation of anthelmintic drug 
efficacy in treatment of soil-transmitted helminthiasis.  They recommend research and 
development of new anthelmintics with different modes of action that could be used in 
combination with existing drugs. While BETHONY et al. (2006) agree with this, they suggest 
the development of vaccines to control helminthiasis.  They discuss ongoing clinical studies on 
hookworm vaccines.  However, in the long term, chemotherapeutic strategies to prevent and treat 
soil-transmitted helminthiasis would best be accompanied by various environmental, socio-
economic and educational programmes (WHO, 2004).   
 
This is the first report on anthelmintic activities of A. africana, B. scaberulum, C. arcuata, E. 
hereroensis, E. petersii, P. pubscens and T. tridentata currently sold in herbal markets in 
KwaZulu-Natal.  Caenorhabditis elegans was most susceptible to organic and aqueous extracts 
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of C. arcuata. The significant lethal effects of the crude 80% EtOH leaf and root extracts as well 
as the aqueous leaf extract of C. arcuata were comparable to that of Levamisole®.  The presence 
of proanthocyanidins and flavonoids in C. arcuata leaf and root extracts may have contributed to 





ACETYLCHOLINESTERASE INHIBITORY, ANTI-INFLAMMATORY 




Common degenerative diseases such as asthma, heart disease, inflammatory bowel disease and 
rheumatoid arthritis are often associated with inflammatory processes.  The development of 
inflammatory, cardiovascular and neurodegenerative disorders are also commonly linked with an 
over-production of oxidants such as ROS during an inflammatory and/or immunological 
response (WINROW et al., 1993).  The current chapter explores the role of inflammatory 
processes and oxidative stress in the development of Alzheimer‟s disease.  The search for 
potential anti-inflammatory and antioxidant natural compounds for treating common 
inflammatory and pain-related disorders are discussed.   
 
Alzheimer‟s, described as a progressive neurodegenerative disorder in aging persons, is 
characterized by an accumulation of extracellular deposits of β-amyloid peptides in senile 
plaques and intracellular formation of neurofibrillary tangles of hyperphosphorylated tau protein 
(HENEKA, 2006).  An examination of the brain of an Alzheimer‟s patient revealed a reduction 
in the size of regions responsible for learning and memory.  Also, senile plaques and neurofibril 
tangles were present in these regions and emotional centres (entorhinal cortex, hippocampus, 
basal forebrain and amygdala).  The number of synapses and neurons (associated with the 
neurotransmitters glutamate and acetylcholine) are reduced or damaged in affected brain regions 
(MATTSON, 2004).  These conditions in an aged brain lead to loss of memory, personality 
changes and impacts on quality of life in patients (MANDAIRON and DIDIER, 2010).  
 
Alzheimer‟s patients are usually older than 60 years of age (HENEKA, 2006).  The prevalence 
of the disorder has increased from 15 million to approximately 30 million cases globally 
(FRANCIS et al., 1999; SELKOE, 2005; HENEKA, 2006).  Populations are growing older, 
and as a result there is an increase in the risk of developing a neurodegenerative disorder 
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(SELKOE, 2001).  Future Alzheimer‟s incidence estimates are in the region of 90 million 
(MATTSON, 2004; HENEKA and O’BANION, 2007).  There is no known cure for 
Alzheimer‟s due to the complexity of its pathogenicity. 
 
 
6.1.1. Acetylcholinesterase and Alzheimer’s 
 
Based on the research conducted by PERRY et al. (1978) there appears to be a relationship 
between the cholinergic system and the progression of Alzheimer‟s disease.  This observation 
gave rise to the „cholinergic hypothesis‟ where a decrease in the neurotransmitter acetylcholine is 
associated with the Alzheimer‟s disorder (TABET, 2006).  The review by BARTUS et al. 
(1982) addressed the validity of the cholinergic hypothesis.  At the time, certain studies showed a 
significant relationship between changes in the cholinergic system, the aged brain and memory 
loss.  The changes in the cholinergic system were linked to the loss of neurons.  Artificially 
altered cholinergic systems in younger subjects produced comparable results to that of old 
subjects and those experiencing dementia.  Of particular interest was the positive effect of 
cholinergic drugs on aged subjects.  Nearly two decades later, while still trying to ascertain the 
exact cause of Alzheimer‟s, the hypothesis was re-examined by FRANCIS et al. (1999).  The 
authors addressed more recent developments in Alzheimer‟s research and concluded that while a 
breakdown in cholinergic function is not the cause of Alzheimer‟s it indirectly affects cognitive 
performance (FRANCIS et al., 1999).  BUCCAFUSCO (2004) reiterated that there is a 
relationship between aging, cholinergic dysfunction and breakdown in cognitive function.   
 
The cholinergic hypothesis led to the treatment of Alzheimer‟s using acetylcholinesterase 
(AChE) inhibitors.  The three most common AChE inhibitors are galanthamine, donepezil and 
rivastigmine (STUCHBURY and MÜNCH, 2005; TABET, 2006).  FRANCIS et al. (1999) 
reviewed the effect of these three cholinesterase inhibitors; all licensed in Europe for the 
symptomatic treatment of cognitive decline in Alzheimer‟s patients.  The authors also included a 
schematic representation of how AChE inhibitors act.  GIACOBINI (2004) discussed briefly the 
pharmacology of cholinesterase inhibitors (donepezil, galanthamine, huperzine A, metrifonate, 
physostigmine, rivastigmine and tacrine).  The only compound to exhibit irreversible inhibition 
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is the organophosphate metrifonate.  Pseudo-irreversible inhibition was observed for the 
carbamate compounds physostigmine and rivastigmine.  The widely used drug galanthamine has 
a phenanthrene structure and demonstrates a reversible inhibition of enzyme AChE.  
Galanthamine also affects nicotinic acetylcholine receptors which may provide an alternative 
non-cholinergic route to treat symptoms of Alzheimer‟s (GIACOBINI, 2004).  As there is still 
no cure for Alzheimer‟s, the focuses of recent research initiatives are preventative strategies and 
treatment of early-onset symptoms.  While the direct cause of Alzheimer‟s is unknown, 
processes involved in the development of Alzheimer‟s now also include inflammatory systems 





Inflammation is a cells‟ reaction to tissue damage as a result of infection, chemical or physical 
trauma, or even radiation.  Inflammation is often a symptom of other serious illnesses and 
associated characteristics of an inflammatory response include pain, fever and even a rapid heart 
rate.  VANE and BOTTING (1996) describe the inflammatory process as a complex 
combination of steps that include enzyme activation, mediator release, extravasation of fluid, cell 
migration, tissue breakdown and repair. 
 
The inflammatory process is described simply as the biosynthesis of AA to form various 
mediators including primary and intermediate prostaglandins (PGs) (eicosanoids) which manifest 
as the “pain symptom”.  Other biosynthetic metabolites of AA include thromboxanes (TXs) and 
leukotrienes (LTs) (RANG and DALE, 1987).  Eicosanoids are a family of compounds often 
implicated as mediators of basic physiological processes (CAMPBELL and HALUSHKA, 
2001).  They are produced throughout the body and are responsible for the control and 
maintenance of physiological processes such as inflammation, blood pressure regulation and 
initiation of blood clotting.  Based on the specific function of the tissue, only certain enzymes 
may be present in the cell, resulting in only certain PGs being produced (VANE, 1971; 
MANTRI and WITIAK, 1994).   
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Aside from the functions discussed above, eicosanoids are also responsible for the pain and fever 
(pyretic) symptoms of inflammation.  The metabolic conversion of AA to PGs is catalysed by the 
enzyme prostaglandin endoperoxide synthase, which has two constituents – cyclooxygenase and 
peroxidase.  Therefore the inhibition of the catalysing cyclooxygenase (COX) enzyme (VANE, 
1971; SALMON and HIGGS, 1994) seems an acceptable measure when treating painful and 


















Figure 6.1.:  An annotated schematic representation of the metabolic pathway/s of arachidonic 
acid (AA) synthesis (adapted from DeRUITER, 2002) 
 
The COX enzyme is made up of two isozymes COX-1 and COX-2.  In recent years there has 
been much debate over the number of isozymes present, their function, and their exact role and 
pathway during the inflammation process.  Initial reports described the COX-1 isozyme as a 
constitutive enzyme with a number of homeostatic cellular functions.  COX-2, on the other hand, 
was considered to be inducible by inflammation.  Recent reports contain conflicting views; with 
1Eicosatertraenoic acid, is a phospholipid triglyceride 
ester found within the cell membrane which is acted 
upon by phospholipase A2 (or phospholipase C 
followed by diacylglycerol lipase) to yield AA 
2For each pathway represented here, the reactions are 
catalysed by different enzymes.  The metabolism of 
AA by cyclooxygenase (COX) enzyme (also known 
as prostaglandin H2 synthase) yields prostaglandin H2 
(PGH2).  This structure may directly produce PGs or 
may be acted upon by prostacycline synthase and 
thromboxane synthase to produce PGs and TXs 
respectively. 
3AA metabolism by lipoxygenase (LOX) results in 
the synthesis of leukotrines 
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COX-2 now being considered by the majority to be a constitutive enzyme.  It was recently 
argued in a review by SAUTEBIN (2000) that COX-2 is not an inducible isozyme but rather a 
constitutive one (KÖMHOFF et al., 1997).  In their review, PATRIGNANI et al. (2005) cite 
publications that refer to COX-1 as an inducible enzyme in the developmental phases and COX-
2 as a constitutive enzyme in the brain tissue.  When treating pain-related symptoms, COX 
inhibition may be achieved via one of three mechanisms:  (a) competitive inhibition – described 
as the reversible competition for the COX active site (otherwise occupied by arachidonate); (b) 
non-competitive inhibition – described as an irreversible binding of the inhibiting bioactive 
compound to the COX active site; and (c) time-dependant inactivation – may be described as the 
result of an enzyme –inhibitor complex formation (MANTRI and WITIAK, 1994; SMITH and 
DEWITT, 1995).   
 
Drugs that inhibit the inflammatory process are either glucocorticoids or non-steroidal anti-
inflammatory drugs (NSAIDs); with the latter exhibiting the non-competitive inhibition 
mechanism (RANG and DALE, 1987).  NSAIDs are commonly used as therapeutic agents.  
They are further divided into:  salicylates (aspirin, diflunisal); acetic acids (indomethacin, 
diclofenac); propionic acids (ibuprofen, naproxen); fenamates (mefenamic acid, meclofenamate); 
pyrazoles (phenylbutazone); and oxicam (piroxicam) (RANG and DALE, 1987; MANTRI and 
WITIAK, 1994).  NSAIDs may have an anti-inflammatory effect (affecting the inflammatory 
process); an analgesic effect (decrease in pain); or an antipyretic effect (a decrease in high body 
temperature – fevers) all of which relate to the action of NSAIDs on COX enzyme (RANG and 
DALE, 1987).   
 
Almost all NSAIDs used to treat chronic inflammatory diseases are COX-1 inhibitors while 
other COX inhibitors are able to inhibit both COX-1 and COX-2 with different selectivity.  
Current anti-inflammatories cause side effects (diarrhoea, bloatedness, heartburn and ulceration 
(a result of chronic use)) of varying severity due to the effect on the homeostatic functioning of 
the COX-1 enzyme.  This has led to the assumption that NSAIDs are inhibiting both isozymes.  
The problem may lie in the 70% molecular homology of the isozymes and though they are 
products of different genes on separate chromosomes, they have a similar affinity to convert AA 
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to PGs (FÉLÉTOU et al., 2011).  The ambiguity may also involve cellular and molecular 
mechanisms. 
 
6.1.2.1. Role of inflammatory systems in Alzheimer’s disease 
 
The most obvious characteristic of Alzheimer‟s is the decline in cognitive performance.  The 
burden of disease affects quality of life for patients and care-givers.  The actual causes and 
mechanisms of progression of the disease are yet to be fully elucidated.  Identifying the complex 
set of systems involved in the development of Alzheimer‟s has been the focus of many 
neurological and geriatric studies.   Neuroinflammation has been closely linked to Alzheimer‟s 
disease progression (MOORE and O’BANION, 2002).  HENEKA and O’ BANION (2007) 
reviewed the role of inflammatory processes in the development of Alzheimer‟s.  The authors 
discussed how initial neurodegenerative processes induce neuroinflammatory responses.   
 
Work on prostaglandins by SAMUELSSON (1964) pioneered research of the CNS and 
associated diseases.  Since the detection of prostaglandins in the brain, the function, distribution 
and expression of all constituents including COX in the inflammatory process have been 
researched (KAUFMANN et al., 1997).  While a more comprehensive understanding is needed, 
the role of anti-inflammatory agents in the prevention or treatment of Alzheimer‟s is the focus of 
current research (MOORE and O’BANION, 2002).  According to RICH et al. (1995) and 
DeKOSKY (2003) certain NSAIDs when administered over a long term period exhibited 
positive results (decreased risk of Alzheimer‟s).  The varying effects of different classes of anti-
inflammatory agents in different trials suggest the use of anti-inflammatories as a preventative 
measure and not as a treatment (DEKOSKY, 2003).  The conflicting reports may be suggestive 
of neuroprotective pathways other than COX-inhibition (STUCHBURY and MÜNCH, 2005).   
NSAIDs which primarily inhibit the COX enzyme may affect alternative pathways of 
Alzheimer‟s progression and delay the onset of symptoms (HENEKA and O’BANION, 2007).  
MONTINE et al. (1999) demonstrated that while COX activity in persons susceptible to 
Alzheimer‟s was comparable to that of control persons; concentration levels of PGE2 in 
cerebrospinal fluid of susceptible patients had increased five times.  This study demonstrated the 




The metabolism of AA by COX to form pro-inflammatory mediator PGE2 is one of many 
pathways in the inflammatory response.  The implications of this pathway regarding treatment of 
inflammatory disorders are vast.  The exact role of both COX isozymes in neuroinflammation is 
still unclear (MOORE and O’BANION, 2002).  As mentioned earlier, current anti-
inflammatory drugs (NSAIDs) inhibit the constitutive COX-1 which contributes to reported side-
effects.  By selectively inhibiting the inducible COX-2, one could possibly produce an efficient 
and tolerable anti-inflammatory that could be used to treat symptoms of common inflammatory 
disorders such as pain and fever; and that could be used to prevent the onset and/or treat 
symptoms of diseases affecting the CNS. 
 
According to BOROVIKOVA et al. (2000) there is an established link between the cholinergic 
system and inflammation, with acetylcholine playing a role in cytokine release.  TABET (2006) 
reported on evidence that AChE inhibitors have an anti-inflammatory role through action against 
free radicals, amyloid toxicity and a reduction in release of cytokines from activated microglia in 
the brain and blood. 
 
 
6.1.3. Oxidative stress 
 
Free radicals and other ROS are constantly formed in the human body.  The superoxide anion (O-
2
.), hydrogen peroxide (H2O2) and hydroxyl (OH.) radicals are produced as natural metabolic by-
products.  The simplest free radical is a hydrogen atom.  Interest in free radicals began with the 
work of Moses Gomberg (1900) who demonstrated the existence of the triphenylmethyl radical 
(Ph3C.).  A free radical is any molecule (capable of independent existence) that possesses one or 
more unpaired electrons (MARKESBURY and CARNEY, 1999).  Consequently, radicals are 
less stable compounds (CHAUHAN and CHAUHAN, 2006).  Certain control mechanisms are 
in place to reduce the effect of oxidative damage naturally, thereby protecting the cells and 
tissues.  MARKESBURY and CARNEY (1999) however, explained how the uncontrolled 




Compounds such as antioxidants prevent oxidative stress (HELEN et al., 2000).  Antioxidants 
help prevent and/or reduce the risk of degenerative diseases (AGUDO et al., 2007).  They act as 
reducing agents, hydrogen donators, singlet oxygen quenchers and may perhaps have metal 
chelating properties (RICE-EVANS et al., 1996).  Synthetic antioxidants, such as 2- and 3-tert-
butyl-4-methoxyphenol (butylated hydroxyl-anisole (BHA)) and 2,6-di-tert-butyl-4-
methylphenol (butylated hydroxytoluene (BHT)) have long been used as food additives acting as 
protective agents. 
 
6.1.3.1. Oxidative stress in Alzheimer’s 
 
Oxidative stress has been associated with several degenerative disorders; which include cancer, 
arteriosclerosis, inflammatory disorders and neurodegenerative diseases.  Processes such as lipid 
peroxidation have been implicated in neurodegenerative diseases such as Alzheimer‟s 
(MARKESBURY and CARNEY, 1999).  The ageing process has also been associated with 
oxidative stress (MARKESBURY and CARNEY, 1999).   
 
CHAUHAN and CHAUHAN (2006) produced a comprehensive review on oxidative stress and 
its role in the development of Alzheimer‟s.  MARKESBURY and CARNEY (1999) mention 
that the brain is at risk of oxidative stress due to the high lipid content (membrane) and oxygen 
consumption rate.  Beta-amyloid plaques in the brain, characteristic in Alzheimer‟s patients, 
have been shown to promote oxidative damage via lipid peroxidation, protein oxidation and 
formation of free radicals (DeKOSKY, 2003).  During the process of neuroinflammation, free 
radical products of microglia and astrocytes such as O-2. and NO are produced, in addition to 
ROS generated via the COX pathway (STUCHBURY and MÜNCH, 2005). 
 
TABET (2006) suggested that AChE inhibitors indirectly increase the production of antioxidants 
in the brain by inhibiting the release of cytokines from microglia and monocytes.  The author 
also suggested that the anti-inflammatory effect of antioxidant compounds has a positive effect 
in Alzheimer‟s patients (TABET, 2006).  SELKOE (2005) suggested the use of antioxidants 




The toxicity of synthetic antioxidant compounds has lead to the development and/or isolation of 
natural antioxidants from botanical sources.  While this potential source of antioxidant 
compounds sounds promising, their use would be limited without relevant pharmacological and 
toxicological information.  STUCHBURY and MÜNCH (2005) mentioned that natural 
antioxidant compounds generally have a relatively low toxicity; which supports the research of 
these compounds. 
 
When discussing future treatment options for neuroinflammatory disorders such as Alzheimer‟s, 
SELKOE (2001) cited the use of anti-inflammatory drugs.  SELKOE (2001) further suggested a 
continued search for anti-inflammatory compounds that target alternative mechanisms in the 
inflammatory process.  Natural plant products have been used as poultices and or anti-
inflammatories for years.  Aspirin was one of the first plant drugs to become a common 
prescription anti-inflammatory drug.  BOHLIN (1995) listed flavonoids, naphthoquinones, 
alkylamides, phenolic phenyl-propane derivatives, among others, as those compounds 
responsible for COX inhibition in certain natural products.  In the current investigation, seven 




6.2. MATERIALS AND METHODS 
 
 
6.2.1. Anti-inflammatory evaluation 
 
Anti-inflammatory activity of crude orchid extracts was determined using an enzyme-based 
COX assay described by JÄGER et al. (1996) with slight modifications as per NOREEN et al. 
(1998) and ZSCHOCKE and VAN STADEN (2000).  Plant extracts that were previously dried 
and stored (Section 4.2.2) were re-suspended in either 80% EtOH or water to yield ethanolic or 







6.2.1.1. COX-1 Bioassay 
 
Cyclooxygenase (COX) 1 enzyme, isolated from ram seminal vesicles, was purchased from 
Sigma Aldrich®.  The enzyme (10 μl) was activated on ice with 50 μl of co-factor solution (3 mg 
L-epinephrine and 3 mg reduced glutathione in solution with 10 ml Tris buffer (pH 8.0)) and 100 
μl hematin solution.  The enzyme/co-factor solution (60 µl) was added to a) 20 μl of aqueous 
plant extract, b) 2.5 μl EtOH plant extract and 17.5 μl water or c) 2.5 μl indomethacin standard (5 
µM) and 17.5 μl water.  After an incubation period of five minutes at room temperature 20 μl of 
[14C] labeled AA (16 Ci/mol, 3 mM), was added to each sample.  The reaction mixture was then 
incubated in a water bath for 10 minutes set at 37°C.  The reaction was terminated by the 
addition of 10 μl 2 N hydrochloric acid (HCl).  To the background standard containing 2.5 μl 
EtOH and 17.5 μl water, 10 µl of 2 N HCl were added to inactivate the enzyme prior to the 
addition of the enzyme/co-factor solution and the AA.  This was kept on ice until the above assay 
was completed.  Thereafter, 4 μl (0.2 mg/ml) of unlabelled prostaglandin carrier solution 
(precursors:  PGE2:PGF2) were added in a 1:1 v/v ratio to all Eppendorf tubes. 
 
6.2.1.2. COX-2 Bioassay 
 
The same basic procedure as for the COX-1 assay was followed.  Cyclooxgenase-2 (human 
recombinant) enzyme was purchased from Sigma Aldrich®.  Aliquots (10 μl) of enzyme (3 U) 
were prepared and activated with 50 μl co-factor solution (6 mg L-epinephrine, 3 mg reduced 
glutathione, 100 µl of 1 μM hematin and 0.1 M Tris buffer (pH 8)) for 5 minutes on ice.  The 
enzyme/co-factor solution (60 µl) was added to a) 20 μl of aqueous plant extract, b) 2.5 μl EtOH 
plant extract and 17.5 μl water or c) 2.5 μl indomethacin standard (200 µM) and 17.5 μl water.  
After an incubation period of five minutes at room temperature 20 μl of [14C] labeled AA (16 
Ci/mol, 3 mM), was added to each sample.  The reaction mixture was then incubated in a water 
bath for 10 minutes at 37 °C.  The reaction was terminated by the addition of 10 μl 2 N HCl.  To 
the background standard containing 2.5 μl EtOH and 17.5 μl water, 10 µl of 2 N HCl were added 
to inactivate the enzyme prior to the addition of the enzyme/co-factor solution and the AA.  This 
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was kept on ice until the above assay was completed.  Thereafter, 4 μl (0.2 mg/ml) of unlabelled 
prostaglandin carrier solution (precursors:  PGE2:PGF2) were added in a 1:1 v/v ratio to all 
Eppendorf tubes. 
 
The samples from the two abovementioned assays were then subjected to silica column 
chromatography in an attempt to separate the [14C] labelled PGs synthesised in the Eppendorf 
tubes during the assay from any unmetabolised [14C] AA.  Eluent 1 (hexane:dioxane:acetic acid, 
350:50:1 v/v/v) was mixed with silica gel (0.063-0.200 mm particle size, Merck) and set in 
Pasteur pipettes 3 cm high.  Eluent 1 (1 ml) was added to each assayed sample and introduced to 
separate columns.  A further 4 ml of eluent 1 were added to each column. This was responsible 
for extracting the unmetabolised AA and was discarded.  Labelled PGs were then eluted into 
scintillation vials with 3 ml of eluent 2 (ethyl acetate: methanol, 425:75 v/v).  Scintillation fluid 
(4 ml) was added to the extracted PGs and the radioactivity of the mixture was measured using a 
scintillation counter (Beckman LS 6000LL scintillation counter).     
 
The effect of the plant extracts, that is percentage inhibition of PG synthesis, was determined by 
comparing the amounts of radioactivity (disintegrations per minute (DPM)) in a solvent blank to 
those of the samples.  Inhibition was indicated by a decline in PGE2 formation.  This was 
calculated using the following formula: 
 
 
DPMsample  -  DPMbackground  
Inhibition (%)  =    1 -           × 100 




Three controls were run for this assay:  the solvent blank; the background sample where the 
enzyme was inactivated with HCl before the addition of labeled AA; and the positive control 
which was the indomethacin sample.  The EC50 (mg/ml) of extracts considered significantly 





6.2.2. Antioxidant evaluation 
 
Antioxidant capacity of crude orchid extracts was determined using hydrogen atom transfer 
(HAT) and single electron transfer (SET) reaction-based assays (HUANG et al., 2005).  Plant 
extracts (prepared as mentioned in Section 4.2.2) were resuspended in methanol at different 
concentrations (0.065 – 50 mg/ml). 
 
6.2.2.1. 2,2’-Diphenylpicrylhydrazyl (DPPH) free radical scavenging assay 
 
The 2,2‟-diphenylpicrylhydrazyl (DPPH) free radical scavenging assay is based on the SET 
reaction.  The DPPH radical is an organic nitrogen radical commercially available and has a deep 
purple colour (PRIOR et al., 2005).  The assay is simple, rapid and sensitive; and measures the 
antioxidant potential of compounds based on their ability to donate hydrogen atoms to the stable 
DPPH radical.  The deep purple colour (absorption maximum at 517 nm) fades during reduction 
of the DPPH radical by antioxidant molecules.  The DPPH free radical quenching generates a 
2,2-diphenyl-1-hydrazine product which is colourless.  Ultraviolet spectrophotometry (UV 
absorption at 517 nm) is used to determine antioxidant activity; where high antioxidant activity is 
measured by a decline in the absorbance of the DPPH solution.  It is important to note that this 
particular assay measures free radical scavenging activity and not pro-oxidant activity.    
 
The free radical scavenging antioxidant capacity of crude orchid extracts were determined using 
the protocol outlined in KARIOTI et al. (2004) with slight modifications.  The DPPH radical 
used in this assay is a substrate that can be reduced to DPPH-H by antioxidants that have the 
ability to donate a hydrogen atom to the DPPH radical.  Methanolic plant samples were prepared 
at different concentrations (0.065 – 50 mg/ml).  Each sample (15 µl) was diluted with 735 µl of 
methanol in a glass test tube to which 750 µl of a methanolic DPPH solution (0.1 mM) 
(SHARMA and BHAT, 2009), prepared under green light conditions, was added.  The effective 
concentration of DPPH in the assay was 50 µM.  A separate set of samples, referred to as 
correction factor solutions, were prepared without the methanolic DPPH solution (DPPH 
solution was substituted with methanol).  Two antioxidants, ascorbic acid and BHT, were 
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prepared as the positive controls (5 – 80 µM).  Methanol served as the negative control.  All 
reaction vessels were incubated for 30 minutes at room temperature in the dark.  The absorbance 
of each sample was measured spectrophotometrically at 517 nm (Varian Cary 50, Australia).  
The percentage free radical scavenging activity (RSA) of crude plant extracts was calculated 
according to the formula:   
 
   AE – Ablank solution  
 RSA (%)  =    1 -   AD      × 100 
         
 
Where, AE is expressed as the absorbance value of plant extracts and standard antioxidants 
prepared without the DPPH solution subtracted from the absorbance value of corresponding 
samples prepared with DPPH solution and; AD is the absorbance value of the negative control. 
The concentration of extract required to scavenge 50% of the DPPH radical (EC50) for each 
sample was determined from a logarithmic non-linear regression curve using GraphPad Prism 
software version 4.03 (GraphPad Software, Inc., San Diego, USA).  A one-way analysis of 
variance (ANOVA) and Duncan Multiple Range Test of mean±standard error of mean (SEM) 
was used to determine differences and significant differences among means; using SPSS 
software version 10 (SPSS Inc., Chicago, USA).  P = 0.05 indicated significantly different 
samples. 
 
6.2.2.2. β-Carotene/Linoleic acid assay 
 
The β-carotene-linoleic acid (linoleate) assay is based on the HAT reaction.  Lipid peroxidation 
is the oxidative degradation of lipids.  It is a well known mechanism where unsaturated fatty 
acids (linoleic acid, linolenic acid, AA) are acted upon by ROS such as O-2., singlet oxygen and a 
HO. radical.  Reactive oxygen species remove a hydrogen atom off the methylene side-chain of 
unsaturated fatty acids to form free radicals.  Heat induced oxidation of the β-carotene-linoleic 
emulsion was used as an antioxidant assay.  In the presence of ROS and oxygen (O2) linoleic 
acid is oxidised and forms a peroxyl free radical.  Beta carotene reacts with the peroxyl radical, 
loses a hydrogen atom to the free radical and produces stable β-carotene epoxides (KENNEDY 
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and LEIBLER, 1991).  Due to the lost hydrogen atom, β-carotene molecules lose their 
characteristic orange colour.  Antioxidants stop the breakdown of β-carotene by neutralising the 
effect of free radicals.  The β-carotene-linoleic bioassay explores the antioxidant capacity of a 
compound by testing its ability to donate with the resulting peroxyl radical.   
 
The capacity of crude methanolic orchid extracts to prevent or reduce the coupled oxidation of β-
carotene and linoleic acid in an emulsified aqueous system (PAJERO et al., 2002) was 
determined using the protocol outlined by AMAROWICZ et al. (2004) with modifications.   
The entire assay was carried out under green light conditions as β-carotene is light sensitive.  β-
carotene was prepared in a dark 500 ml Schott bottle by dissolving 10 mg in 10 ml of chloroform 
to give a final concentration of 0.1 g/ml.  Excess chloroform was evapourated under vacuum, 
leaving a thin film of β-carotene, to which 200 µl of linoleic acid and 2 ml of polyoxyethylene 
sorbitan monolaurate (Tween 20) were added.  The total volume was made up to 500 ml with 
aerated distilled water with the final concentration of β-carotene in the assay being 20 µg/ml.  
The mixture was saturated with oxygen by vigorous agitation and formed an orange emulsion.  
The β-carotene emulsion (4.8 ml) was dispensed into glass test tubes, followed by 200 µl of 
either plant samples or positive control:  BHT (6.25 mg/ml).  The final effective concentration of 
samples and positive controls was 250 µg/ml in the reaction mixture.  The negative control 
consisted of 50% methanol.  Each sample was prepared and tested in triplicate.  The absorbance 
of each reaction mixture was measured (t = 0) at 470 nm using a spectrophotometer (Varian Cary 
50, Australia).    Reaction vessels were thereafter incubated for 2 h at 50 °C in the dark.  The 
absorbance of each sample was measured every 30 minutes during the incubation period at 470 
nm.    Tween 20 was used to blank the spectrophotometer. 
 
Antioxidant capacities were expressed as average antioxidant activity (%ANT) and oxidation 
rate ratio (ORR).  The rate of β-carotene bleaching was calculated according to first order 
kinetics using the formula:   
At=0 





where At=0 is the absorbance of the emulsion at 0 min; and At=t is the absorbance at time t (30, 
60, 90 minutes). The average rate of β-carotene bleaching was calculated based on rates at 30, 60 
and 90 minutes. The calculated average rates were used to determine the %ANT of the respective 
extracts, and expressed as percent inhibition of the rate of β-carotene bleaching in relation to the 
negative control using the formula:   
 
 Rcontrol - Rsample 
% ANT =                  Rcontrol  × 100      (2) 
 
 
where Rcontrol and Rsample represent the respective average β-carotene bleaching rates for the 
standard antioxidant and plant extracts, respectively. Antioxidant activity was further expressed 
as the ORR based on the formula:         
 
Rsample 




6.2.2.3. Ferric reducing antioxidant power (FRAP) assay 
 
The ferric reducing power assay (FRAP) is also based on a SET reaction.  It is a rapid and 
sensitive redox-linked colorimetric method.  Antioxidants serve as reductants of the 
Fe3+/ferricyanide complex to the ferrous (Fe2+) form; producing a distinctive blue colour.  All 
antioxidants donating electrons contribute to the total reducing or antioxidant activity.  
 
The protocol by LIM et al. (2009) was used to determine the ability of crude plant extracts to 
reduce the Fe3+/ferricyanide complex to the ferrous (Fe2+) form.  Using a microtitre plate, 30 µl 
of millipore water was added to each well; followed by 30 µl of methanolic plant extract (6.25 
mg/ml), ascorbic acid (0.8 mM) or BHT (0.5 mM) into the respective wells in row (A).  Each test 
sample was serially diluted in a 2-fold dilution.  Thereafter, 40 µl of 0.2 M phosphate buffer (pH 
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7.2) and 40 µl of potassium ferricyanide (1% w/v in potassium phosphate buffer) were added 
consecutively to each well.  Test solutions were incubated for 20 minutes at 50 °C in an 
incubator.  Following the incubation, 40 µl of trichloroacetic acid (10% w/v in millipore water), 
150 µl of distilled water, and 30 µl of ferric chloride (0.1% w/v in potassium phosphate buffer) 
were added to each well.  Samples were prepared and tested in triplicate.  Samples were 
incubated for a further 30 minutes at room temperature in the dark.  The absorbance was read at 
630 nm using a spectrophotometer (Varian Cary 50, Australia); where an increase in absorbance 
indicated a greater reducing power. 
 
 
6.2.3. Acetylcholinesterase (AChE) inhibitory microplate assay 
 
The capacity of crude orchid extracts to inhibit AChE enzyme was determined using the protocol 
described by ELLMAN et al. (1961).   Acetylcholinesterase enzyme activity was measured by 
spectrophotometric observation of the increase in a yellow colour produced from thiocholine 
when it reacts with the dithiobisnitrobenzoate ion.  Three buffers (A, B, C) were prepared with 
Millipore water for use in the assay.  Buffer A:  50 nm Tris-HCl,  pH 8; Buffer B:  0.5 g (0.1%) 
bovine serum albumin (BSA) in 500 ml Buffer A; Buffer C:  2.92 g NaCl and 2.03 g 
MgCl2.6H2O in 500 ml Buffer A.  The substrate acetylthiocholine iodide (ATCI), 5,5‟-dithiobio-
(2-nitrobenzoic acid) (DTNB) or Ellman‟s reagent, enzyme AChE and galanthamine were 
purchased from Sigma Aldrich®. 
 
Millipore water (25 µl) was dispensed into all wells of a 96-well microtitre plate; except wells 
H11 and H12.  Samples (25 µl) prepared at a concentration of 10 mg/ml and the solvent blank 
methanol were added in triplicate to the bottom row (H) and serially diluted in a 2-fold dilution 
up the plate till row B.  The effective concentration of samples in the assay was 0.0313, 0.0625, 
0.125, 0.25, 0.5 and 1.0 mg/ml.   Fifty microlitres of positive control galanthamine (20 µM) was 
introduced to wells H11 and H12 and serially diluted in a 2-fold dilution up the plate till row B.  
This was followed by 25 µl of substrate ATCI (15 mM), 125 µl of DTNB Ellman‟s reagent  
prepared at a concentration of 3 mM in Buffer C) and 50 µl of Buffer B in sequence to all wells.  
Microtitre plates were kept on ice.  The absorbance of the reaction mixture was read at 405 nm 
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every 45 s using an ELISA microplate reader (Opsys MRTM microplate reader, Dynex 
Technologies Inc.).  Each plate was read three times to obtain a stable background or baseline 
value, after which, 25 µl of AChE enzyme (0.2 U/ml in Buffer A) was added to each well.  The 
absorbance was read once again at 405 nm at 45 s intervals, five times.   
 




         Reaction rate sample  
Inhibition (%)  =    1 -   Reaction rate blank  × 100      
 
 
The ANOVA and Duncan Multiple Range Test of mean±SEM was used to determine differences 
and significant differences among means; using SPSS software version 10 (SPSS Inc., Chicago, 
USA).  P = 0.05 indicated significantly different samples.  The EC50 value for each sample was 
determined using a logarithmic non-linear regression GraphPad Prism software version 4.03 
(GraphPad Software, Inc., San Diego, USA). 
 
 
6.2.4. Phenolic compound analysis 
 
Plant phenolic compounds were extracted according to the protocol outlined in MAKKAR 
(1999).  Phenolic compounds were extracted in 50% methanol in a sonicator for 30 minutes in 
cold water.  The mixture was filtered under vacuum using Whatman No.1 filter paper. 
 
6.2.4.1. Folin-Ciocalteu assay for total phenolics 
 
Total phenolic content was determined using the protocol outlined in MAKKAR (1999), with 
slight modifications.  Methanolic plant extracts (50 µl) were transferred to glass test tubes and 
made up to 1 ml by adding 950 µl distilled water.  Thereafter, 500 µl of Folin C reagent (1 N) 
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(diluted with distilled water and stored in the dark) and 2.5 ml of 2% sodium carbonate were 
added consecutively.  A similar procedure was followed for the negative control (50% methanol) 
and positive control (standard gallic acid solution (0.1 mg/ml)).  Test mixtures were incubated 
for 40 minutes at room temperature.  The absorbance of each sample was read at 725 nm using a 
UV spectrophotometer (Varian Cary 50, Australia).  Total phenolic content was expressed as 
GAE per gram of extract.  The ANOVA and Duncan Multiple Range Test of mean±SEM were 
used to determine differences and significant differences among means; using SPSS software 
version 10 (SPSS Inc., Chicago, USA).  P = 0.05 indicated significantly different samples.  The 
EC50 value for each sample was determined using a logarithmic non-linear regression GraphPad 
Prism software version 4.03 (GraphPad Software, Inc., San Diego, USA). 
 
6.2.4.2. Butanol-HCl assay for condensed tannins 
 
Condensed tannin content was determined using the protocol outlined by PORTER et al. 
(1986).  Methanolic plant extracts (500 µl) were dispensed into glass test tubes set into a rack.  
This was followed by 3 ml of butanol-HCl (95:5 v/v) reagent and 100 µl ferric reagent (2 g of 
ferric ammonium sulphate dissolved in 2 N HCl (16.6 ml concentrated HCl made up to 100 ml 
with distilled water)).  Test solutions were mixed by vortexing (Chiltern) and heated for 60 
minutes in a water bath set at 100 °C.  For the negative control a similar procedure was followed 
using each plant extract, however these test solutions were not heated.  After a period of 60 
minutes the absorbance of each sample and negative control was read at 550 nm using a UV 
spectrophotometer.   
 
Condensed tannin content was recorded as leucocyanidin equivalents according to the formula: 
   A550nm x 78.26 x dilution factor  
% dry matter 
 
The ANOVA and Duncan Multiple Range Test of mean±SEM were used to determine 
differences and significant differences among means; using SPSS software version 10 (SPSS 
Inc., Chicago, USA).  P = 0.05 indicated significantly different samples.  The EC50 value for 
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each sample was determined using a logarithmic non-linear regression GraphPad Prism software 
version 4.03 (GraphPad Software, Inc., San Diego, USA). 
 
6.2.4.3. Rhodanine assay for gallotannins 
 
Total gallotannin content was determined according to the protocol outlined in MAKKAR 
(1999).  Methanolic plant extracts (50 µl) were dispensed into glass test tubes and made up to 1 
ml with distilled water.  Thereafter, 100 µl of 0.4 N sulphuric acid and 600 µl of 0.667% 
rhodanine solution (w/v in methanol) were added consecutively to each sample.  Samples were 
incubated for 5 minutes at room temperature, after which, 200 µl of 0.5 N potassium hydroxide 
was added.  Samples were incubated at room temperature for a further 2.5 minutes, after which 4 
ml of distilled water was added to each sample.  This was followed by a final incubation period 
of 15 minutes at room temperature.  Different concentrations of gallic acid (0.1, 0.05, 0.025, 
0.0125 mg/ml) were prepared and served as the positive controls, while a reaction mixture 
containing 50% methanol served as the negative control.  Test solutions were vortexed briefly 
and the absorbance of each test solution was read at 520 nm using a UV spectrophotometer.  
Gallotannin content was expressed as GAE per gram of extract.  The ANOVA and Duncan 
Multiple Range Test of mean±SEM were used to determine differences and significant 
differences among means; using SPSS software version 10 (SPSS Inc., Chicago, USA).  P = 0.05 
indicated significantly different samples.  The EC50 value for each sample was determined using 
a logarithmic non-linear regression GraphPad Prism software version 4.03 (GraphPad Software, 
Inc., San Diego, USA). 
 
6.2.4.4. Vanillin assay for flavonoids 
 
Total flavonoid content was determined according to the protocol outlined in MAKKAR (1999).  
Methanolic plant extracts (50 µl) were dispensed into glass test tubes and made up to 500 µl with 
450 µl glacial acetic acid.  Thereafter, 2.5 ml 8% HCl (v/v in glacial acetic acid) were added to 
each sample, followed by 2.5 ml vanillin reagent (1% vanillin in glacial acetic acid).  After an 
incubation period of 20 minutes at 30 °C the absorbance of each sample was read at 500 nm 
using a UV spectrophotometer.  A pink colouration of reaction mixtures indicated the presence 
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of flavonoids.  Different concentrations of the standard catechin (4, 2, 1, 0.5 mg/ml in glacial 
acetic acid) served as the positive control, while a reaction mixture containing 50% methanol 
was used as the negative control.  Flavonoid content was expressed as catechin equivalents per 






6.3.1. Anti-inflammatory activity 
 
Table 6.1. (Chapter 6) presents the anti-inflammatory activity of different crude extracts of 
seven orchid species.  Anti-inflammatory activity above 70% was considered significant 
(TAYLOR and VAN STADEN, 2001).  Out of a total of 53 evaluated extracts, 21 and 13 
extracts exhibited significant anti-inflammatory activity in the COX-1 and COX-2 assays 
respectively.  All aqueous extracts, except that of A. africana roots and B. scaberulum 
pseudobulbs, showed poor or no COX-1 and COX-2 inhibition.  The DCM tuber extract of E. 
hereroensis was the only extract to significantly inhibit both COX enzymes, 100.02±0.11% and 
87.97±8.38% respectively.  Organic extracts of A. africana were selectively effective against 
COX-1.  Similarly, certain organic extracts of E. petersii exhibited COX-1 selective inhibitory 
activity.  Polystachya pubescens pseudobulb EtOH and T. tridentata organic root extracts were 
selectively active against COX-1.  Tridactyle tridentata aqueous leaf extract and all B. 
scaberulum organic root extracts exhibited COX-2 selective inhibitory activity.   
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Table 6.1.:  The percentage inhibition of cyclooxygenase (COX) – 1 and 2 enzymes by crude organic 
and aqueous extracts of seven indigenous South African orchid species at 250 µg/ml 
Species Plant part Extraction solvent Percent inhibition (%) 
   COX-1 COX-2 Ansellia africana Leaves PE ND 66.03±13.64 
  DCM ND 57.48±20.80 
  Ethanol 104.11±1.62 0.00±0.00 
  Water 30.66±9.75 19.51±4.73 
 Stems PE ND 83.38±3.16 
  DCM 106.11±1.29 78.52±0.97 
  Ethanol 43.99±3.46 0.00±0.00 
  Water 7.91±6.05 0.00±0.00 
 Roots PE ND 16.08±11.03 
  DCM 99.36±1.35 17.21±1.50 
  Ethanol 100.15±0.36 0.00±0.00 
  Water 71.15±0.37 51.56±3.78 
Bulbophyllum scaberulum Leaves Water ND 32.81±2.14 
 Pseudobulbs Water ND 79.86.±10.70 
 Roots DCM 17.73±0.39 100.06±0.01 
  Ethanol 18.12±3.08 93.31±2.33 
  Water 5.02±11.53 58.09±3.25 
Cyrtorchis arcuata Leaves Ethanol 89.19±0.18 76.75±11.02 
  Water 44.80±8.04 ND 
 Roots Ethanol 94.05±5.67 72.26±3.35 
  Water 54.02±0.95 ND Eulophia hereroensis Tubers PE ND 98.39±6.04 
  DCM 100.02±0.11 87.97±8.38 
  Ethanol 0.00±0.00 5.89±3.32 
  Water 18.70±3.05 0.00±0.00 
 Roots DCM 84.78±3.19 73.54±2.27 
  Ethanol 60.82±0.89 54.19±0.00 
  Water 0.00±0.00 0.00±0.00 Eulophia petersii Leaves PE 109.88±1.48 27.30±9.78 
  DCM ND 22.16±13.85 
  Ethanol 74.71±9.98 74.27±10.14 
  Water 0.00±0.00 0.00±0.00 
 Stems PE 107.22±0.94 32.89±6.13 
  DCM 106.35±4.39 56.24±3.93 
  Ethanol 4.96±13.82 18.03±0.62 
  Water 37.60±12.30 39.85±1.97 
 Pseudobulbs PE 96.94±3.22 10.71±0.00 
  DCM 106.49±2.94 64.69±8.03 
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Species Plant part Extraction solvent Percent inhibition (%) 
   COX-1 COX-2 
  Ethanol 89.23±9.23 17.43±11.89 
  Water 34.80±3.92 0.00±0.00 
 Roots PE 100.83±0.93 77.29±3.02 
  DCM 109.65±0.00 84.17±4.83 
  Ethanol 99.72±2.43 28.57±12.33 
  Water 10.16±12.50 0.00±0.00 
Polystachya pubescens Pseudobulbs DCM ND 24.91±0.86 
  Ethanol 55.26±2.59 0.00±0.00 
  Water 0.00±0.00 15.05±8.06 
 Roots Ethanol 30.16±2.67 25.51±7.43 Tridactyle tridentata Leaves Water 4.56±1.02 33.06±6.20 
 Roots DCM 100.18±0.25 65.07±1.29 
  Ethanol 89.64±1.16 46.27±21.05 
  Water 26.24±24.52 14.63±2.81 Values are the mean (±) standard deviation (n = 3).  ND – not determined.  Anti-inflammatory 
activity below 20% was considered insignificant, 20-40% low, 40-70% moderate and above 70% 
was considered significant (TAYLOR and VAN STADEN, 2001); values in bold indicate those 
extracts where an EC50 was determined. 
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Table 6.2. (Chapter 6) presents the concentration of crude orchid extracts at which 50% 
inhibition of COX-1 and COX-2 is achieved (EC50).   Based on the anti-inflammatory activity 
presented in Table 6.1, the EC50 of 14 crude extracts were determined in the COX-1 assay; and 
six crude extracts were determined in the COX-2 assay.   Overall, the DCM root extract of A. 
africana was found to be the most potent extract (0.25±0.10 mg/ml).  This extract was the most 
potent extract in the COX-1 assay, while the 80% EtOH root extract of B. scaberulum was the 
most potent in the COX-2 assay (0.44±0.32 mg/ml). 
 
Table 6.2.:  Estimated EC50 (mg/ml) for cyclooxygenase (COX) – 1 and 2 inhibition of crude organic 
extracts of five South African orchid species.   
Species Plant part Extraction solvent EC50 (mg/ml) 
   COX-1 COX-2 Ansellia africana Leaves Ethanol 1.64±0.25cd ND 
 Stems PE ND 1.50±0.15
a 
  DCM 1.77±0.09
d ND 
 Roots DCM 0.25±0.10
a ND 
  Ethanol 0.42±0.09
ab ND 
Bulbophyllum scaberulum Roots DCM ND 1.43±0.86a 
  Ethanol ND 0.44±0.32
a 
Eulophia hereroensis Tubers PE ND 1.12±0.33a 
  DCM 0.87±0.28
abc 1.17±0.15a 
Eulophia petersii Leaves PE 1.32±0.18cd ND 
 Stems PE 2.79±0.04
e 7.91±1.11b 
  DCM 1.49±0.05
cd ND 
 Pseudobulbs PE 0.99±0.51
abcd ND 
  DCM 0.87±0.12
abc ND 
 Roots PE 1.17±0.06
bcd ND 
  DCM 1.41±0.64
cd ND 
  Ethanol 0.99±0.38
abcd ND 
Tridactyle tridentata Roots DCM 1.47±0.89cd ND 
Values are the mean (±) standard deviation (n = 3). ND – not determined. Different letters represent 
significant differences between EC50 means for each enzyme (same column), P = 0.05.  Values in 
bold indicate the most potent anti-inflammatory extracts.
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6.3.2. Antioxidant activity 
 
6.3.2.1. DPPH radical scavenging assay 
 
Table 6.3. (Chapter 6) presents the percent free radical scavenging activity of crude extracts of 
seven orchid species as measured in the DPPH radical scavenging assay.  While the principle of 
the assay does not stipulate the meaning of negative percentage radical scavenging activity (as 
calculated in Section 6.2.2.1), the use of a wide range of concentrations ensured the 
determination of an EC50 value.  There was a dose-dependent change in radical scavenging 
activities of crude extracts from which EC50 values were determined; and are presented in Table 
6.3. (Chapter 6).  In terms of EC50, the methanolic root extracts of all species, except that of E. 
petersii, had consistently more effective radical scavenging activity than that of other plant parts 
within each species.   The methanolic pseudobulb extract of E. petersii, was the most potent 
extract (1.32±0.86 mg/ml).  
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Table 6.3.:  The DPPH radical scavenging capacity of crude methanol extracts of seven indigenous South African orchid species 
Species Plant part Extract concentration (mg/ml) EC50 (mg/ml) 0.78 1.56 3.125 6.25 
Ansellia africana Leaves -61.36 -43.49 -23.01 25.68 11.63±1.37de 
 Stems -46.90 26.74 3.75 26.08 8.13±0.83bcde 
 Roots 0.65 17.70 64.54 96.97 2.54±0.35ab 
Bulbophyllum scaberulum Leaves -50.06 -38.71 -37.39 -15.11 26.25±1.14f 
 Pseudobulbs -36.86 -1.35 26.91 68.66 4.86±0.62abc 
 Roots -24.34 15.70 50.04 75.52 3.39±0.0595ab 
Cyrtorchis arcuata Leaves -40.42 -5.10 18.47 56.97 6.18±0.12abcd 
 Roots -34.63 -13.99 26.44 56.94 5.30±0.10abc 
Eulophia hereroensis Tubers -56.91 -61.04 -44.03 -30.23 44.45±4.05g 
 Roots -55.51 -51.37 -41.25 -36.50 ND 
Eulophia petersii Leaves -60.79 -27.76 18.43 52.01 5.96±0.1abcd 
 Stems -59.03 -40.70 -20.72 12.75 12.71±0.66e 
 Pseudobulbs -15.38 53.73 68.54 83.80 1.32±0.86a 
 Roots -38.53 -26.65 -11.68 13.45 10.90±0.11cde 
Polystachya pubescens Pseudobulbs -28.15 -34.06 -10.91 19.91 10.15±0.28cde 
 Roots -33.09 -34.50 23.74 66.95 4.99±0.0295abc 
Tridactyle tridentata Leaves -53.18 -49.58 -44.71 -25.78 254.85±6.15h 
 Roots -17.70 4.07 31.77 73.77 4.51±0.25abc 
Values; EC50 values are the mean (±) standard error (n = 2), values in bold indicate those extracts with most significant antioxidant 
activity.  In DPPH assay EC50 of ascorbic acid (0.55 µg/ml) and BHT (5.20 µg/ml).  Different letters represent significant differences 
between EC50 means, P = 0.05. ND – not detected. 
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6.3.2.2. β-Carotene/Linoleic acid assay 
 
Table 6.4 (Chapter 6) presents the antioxidant capacity of crude extracts of seven orchid species 
as measured in the β-carotene-linoleic acid assay.  Beta carotene bleaching occurs because of 
oxidation of linoleic acid; this coupled oxidation was observed by a decrease in absorbance over 
time.  Based on ORR, the leaf extract of T. tridentata and the root extracts of C. arcuata and E. 
hereroensis exhibited the best antioxidant effects (0.02, 0.023 and -0.15 respectively).  Similarly, 
the %ANT of these samples was greater than that of BHT (95.88±6.90%) and all other samples.  
Eight out of a total of 18 samples exhibited a greater capacity to prevent β-carotene oxidation in 
the assay when compared to BHT.
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Table 6.4.:  The effect of crude methanol extracts of seven indigenous South African orchid species on rate of β-carotene bleaching  
Species Plant part ORR % ANT 
Ansellia africana Leaves 0.42±0.31a 87.87±2.74bc 
 Stems 0.31±0.01a 90.61±5.25bc 
 Roots ND ND 
Bulbophyllum scaberulum Leaves 0.20±0.61a 106.19±55.61cd 
 Pseudobulbs 0.1±0.001a 104.85±5.23cd 
 Roots 1.22±1.37b 106.02±1.33cd 
Cyrtorchis arcuata Leaves 0.35±0.49a 29.45±4.22a 
 Roots 0.023±0.04a 120.63±10.48cd 
Eulophia hereroensis Tubers 0.63±0.44ab 63.96±22.98b 
 Roots -0.15±0.10a 122.64±8.41cd 
Eulophia petersii Leaves 0.31±0.18a 84.96±3.10bc 
 Stems 0.28±0.02a 92.18±2.10bc 
 Pseudobulbs 0.22±0.07a 98.62±0.50bcd 
 Roots 0.19±0.10a 92.42±0.001bc 
Polystachya pubescens Pseudobulbs 0.28±0.14a 92.75±2.78bc 
 Roots 0.23±0.09a 90.12±2.89bc 
Tridactyle tridentata Leaves 0.02±0.18a 133.79±25.74d 
 Roots 0.10±0.01a 96.66±1.00bcd 
Values are the mean (±) standard error (n = 2); Values in bold indicate those extracts with most significant antioxidant activity.  ORR 
= Average β-carotene bleaching rates as compared to the negative control (ORR for BHT = 0.18±0.07) and %ANT = average 
antioxidant activity represented as percent inhibition; %ANT for BHT (95.88±6.90%). Different letters in each column represent 
significant differences between means, P = 0.05.
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6.3.2.3. Ferric reducing power assay 
 
Figure 6.2 presents the antioxidant activity of crude extracts of seven orchid species as measured 
in the ferric reducing power assay.  All crude orchid extracts tested demonstrated a general dose-
dependent response; where an increase in extract concentration resulted in an increased reducing 
power activity.  The reducing power of ascorbic acid (0.08 mM) and BHT (0.05 mM), as 
measured as absorbance, was 1.12±0.12 and 0.73±0.08 respectively.  At 6.25 mg/ml, methanolic 
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Figure 6.2.:  Ferric reducing capacity of methanolic extracts from seven indigenous South 
African orchid species. 
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6.3.3. Acetylcholinesterase inhibitory activity 
 
Table 6.5. (Chapter 6) presents the AChE inhibitory capacity of different crude extracts of 
seven orchid species.  Generally it was the root extracts which exhibited greater AChE inhibitory 
activity.  The lowest EC50 value was observed in B. scaberulum DCM root extract (0.02±0.00 
mg/ml).  The most active extract of A. africana was the ethanolic root extract.  For C. arcuata 
the aqueous root extract proved to be the most potent.  The most effective extracts of E. 
hereroensis and E. petersii were the EtOH root and DCM stem extracts respectively.  The DCM 
root extract was the most potent extract for P. pubescens, while the most active extract of T. 
tridentata was the EtOH root extract.   
 
Table 6.5.:  Acetylcholinesterase inhibitory activity (EC50) of crude extracts of seven 
indigenous South African orchid species 
Species Plant part Extraction solvent 
EC50 (mg/ml) 
Ansellia africana Leaves PE 2.19±0.83jk 
  DCM 0.44±0.02
abc 
  Ethanol 0.47±0.22
abcd 
 Stems PE 1.86±0.12
ij 
  DCM 0.50±0.10
abcde 
  Ethanol 0.95±0.04
bcdefgh 
 Roots PE 0.33±0.03
ab 
  DCM 0.34±0.14
ab 
  Ethanol 0.24±0.03
ab 
Bulbophyllum scaberulum Roots DCM 0.02±0.00a 
  Ethanol 0.26±0.007
ab 
Cyrtorchis arcuata Leaves DCM 1.89±0.19jk 
  Ethanol 0.55±0.03
abcde 
  Water 0.72±0.07
abcdef 
 Roots PE 2.21±0.16
jk 
  DCM 1.77±0.41
ij 
  Ethanol 0.84±0.07
bcdefgh 
  Water 0.47±0.04
abcd 
Eulophia hereroensis Tubers PE 1.20±0.24cdefghi 
  DCM 0.23±0.16
ab 
  Ethanol 0.68±0.06
abcdef 
 Roots DCM 0.29±0.05
ab 
  Ethanol 0.23±0.07
ab 
Eulophia petersii Leaves PE 2.72±0.01k 
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Species Plant part Extraction solvent 
EC50 (mg/ml) 
  DCM 0.56±0.004
abcde 
  Ethanol 1.57±0.17
hij 
 Stems PE 0.56±0.16
abcde 
  DCM 0.39±0.04
ab 
  Ethanol 1.20±0.19
defghi 
 Pseudobulbs PE 1.32±0.07
fghi 
  DCM 0.51±0.14
abcde 
  Ethanol 1.37±0.23
fghi 
 Roots PE 2.22±0.62
jk 
  DCM 0.51±0.05
abcde 
  Ethanol 1.47±0.12
ghi 
Polystachya pubescens Pseudobulbs PE 0.48±0.21abcd 
  DCM 0.95±0.04
bcdefgh 
  Ethanol 1.24±0.23
efghi 
 Roots DCM 0.27±0.02
ab 
  Ethanol 0.78±0.05
abcdefg 
Tridactyle tridentata Roots  DCM 0.30±0.03ab 
  Ethanol 0.25±0.07
ab 
  Water 0.46±0.01
abcd 
Values are the mean (±) standard deviation (n = 3); Different letters represent significant 
differences between EC50 means, P = 0.05, EC50 values in bold indicate those extracts with most 
significant AChE inhibitory activity.  EC50 value of galanthamine (0.44±0.10 µM).
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6.3.4. Phytochemical evaluation 
 
Figure 6.3 presents the total phenolic (A), flavonoid (B), gallotannin (C) and condensed tannin 
(D) content of different methanol extracts of seven orchid species.  Flavonoids were not detected 
in A. africana, E. hereroensis and E. petersii.  Eulophia petersii pseudobulb extract contained a 
significantly higher content of total phenolics; while the leaf and stem/root extracts of C. arcuata 
contained significantly higher levels of flavonoids.  Ansellia africana and E. hereroensis root 
extracts had significantly high levels of gallotannin content.  Eulophia hereroensis root, B. 
scaberulum stem/root and C. arcuata leaf extracts contained the highest levels of condensed 
tannins compared to other extracts.   
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Figure 6.3.:  Phytochemical evaluation of seven indigenous orchid species bought at herbal 
markets in KwaZulu-Natal total phenolic content (A), flavonoid content (B), gallotannin content 
(C), and condensed tannin content (D).  For each graph, means with different letters are 
significantly different at P = 0.05. 
1A. africana, 2E. petersii, 3E. hereroensis, 4P. pubescens, 5B. scaberulum, 6T. tridentata, 7C. arcuata 
aLeaves, bStems, cPseudobulbs, dTubers, eRoots, fStem and root, CControl


























































Inflammatory responses such as pain and fever are commonly associated with severe microbial 
infections or with an assault on the immune system.  Approximately five species of South 
African orchids are used to treat inflammatory conditions.  Polystachya ottoniana to soothe pain 
experienced in teething babies and to treat diarrhoea.  Ansellia africana is administered as an 
antimicrobial while Eulophia species such as E. cucullata and E. ovalis, are used primarily to 
relieve pain.   
 
Anti-inflammatory activity above 70% was considered significant (TAYLOR and VAN 
STADEN, 2001).  Based on this range, 40 and 25% of the extracts tested exhibited significant 
anti-inflammatory activity in the COX-1 and COX-2 assays respectively.  On the assumption that 
users of traditional medicine would consume an aqueous concoction of plant material, aqueous 
extracts were expected to exhibit significant biological activity.  Instead, all aqueous extracts, 
except that of A. africana roots and B. scaberulum pseudobulbs, showed poor or no COX-1 and 
COX-2 inhibition (Table 6.1. Chapter 6).  Higher levels of activity were achieved with the 
organic extracts (PE, DCM and EtOH) (Table 6.1. Chapter 6).  Alternatively, traditional healers 
could be using hot water extracts (as opposed to our cold water extracts); a procedure that could 
possibly extract the less water-soluble compounds when using water as the extractant.   
 
Plant compounds such as flavonoids, naphthoquinones, alkylamides and phenolic phenyl-
propane derivatives represent the usual compounds found in certain natural products that are 
responsible for COX inhibition (BOHLIN, 1995).  Certain flavonoids are also known to be 
involved in the breakdown of glycosides (pigment-preservation compounds) (TOVAR-GIJÓN 
et al., 2006).  The flavonoid content of B. scaberulum and T. tridentata may explain the potent 
activity observed in the anti-inflammatory and AChE inhibitory assays.  The flavonoid content of 
other orchid species investigated, presented in Figure 6.3 B did not necessarily correspond to the 
biological activity of those species.  The medicinal value of flavonoids includes anti-
inflammatory, antifungal, antioxidant and wound healing.  The wound healing efficacy of 
Oncidium flexuosum, an epiphytic orchid used in Brazilian traditional medicine for inflammation 
and wounds, was attributed to the presence of flavonoids and tannins (De GASPI et al., 2011).  
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When comparing significant anti-inflammatory activity to phytochemical content it was observed 
that A. africana, and E. hereroensis methanol root extracts had significantly higher levels of 
gallotannin content (Figure 6.3 C).  Eulophia hereroensis root and B. scaberulum stem/root 
extracts contained one of the higher levels of condensed tannins compared to other extracts 
(Figure 6.3 D).  All three species shared similar levels of total phenolic content (Figure 6.3 A).   
 
The results of the current investigation indicate the presence of active compounds in certain polar 
and non-polar extracts.  Natural plant constituents such as polyphenols, saponins, certain 
pigments and even fatty acids are often extracted when using non-polar solvents (LOWER, 
1985).  The EtOH extract of G. elata, traditionally used to treat inflammatory disorders such as 
rheumatism, demonstrated potent anti-angiogenic effects in the CAM assay; while the n-butanol 
fraction showed dose-dependent activity at IC50 0.47 μg/egg.  In vivo vascular permeability, an 
early sign of inflammatory response, was significantly inhibited; while strong analgesic and anti-
inflammatory activity was observed.  AHN et al. (2007) postulated that such activity was a result 
of inhibited NO production and COX-2 expression.  Compounds such as 4-hydroxybenzyl 
alcohol and 4-hydroxybenzaldehyde, isolates of G. elata, are thought to be responsible for the 
anti-inflammatory effects (AHN et al., 2007). 
 
Primary metabolites such as carbohydrates are commonly extracted with water (ZHA et al., 
2007).  Cyrtopodium cardiochilum hot water pseudobulb extract produced the CC 
polysaccharide.  It was found to significantly increase the phagocytic index when compared to 
the standard (Zymosan) and exhibited a similar significant anti-inflammatory effect when 
compared to Indomethacin (10 mg/kg body weight).  An increase in vascular permeability is one 
of the early signs of an inflammatory response.  The CCP glucomannan suppressed vascular 
permeability by approximately 20% of the control (BARRETO and PARENTE, 2006). 
 
When testing methanolic crude extracts in two different SET reaction-based assays, the E. 
petersii pseudobulb extract, was the most potent radical scavenging extract; and one of two 
extracts (A. africana root) that were most efficient in reducing power capacities (Table 6.3. 
Chapter 6 and Figure 6.2).  Alternatively, when using the β-carotene-linoleic acid assay, a HAT 
reaction-based assay, the ORR revealed the leaf extract of T. tridentata and the root extracts of 
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C. arcuata and E. hereroensis to have the best antioxidant effects (Table 6.4. Chapter 6).  
Similarly, the overall %ANT of these three samples to prevent the coupled oxidation of β-
carotene and linoleic acid were greater than that of BHT and all other samples.  The total 
phenolic content of E. hereroensis pseudobulb extracts may contribute to the antioxidant 
activity; while the flavonoid content in the leaf and root extracts of T. tridentata and C. arcuata, 
respectively, may play a role in the antioxidant activity observed in the HAT reaction-based 
assay.  An alternative mechanism may have been affected due to the presence of the flavonoids.   
 
Antioxidant activity of orchid extracts and their isolates using various antioxidant assays has 
been previously established.  Dendroflorin, moscatilin and nobilone, a 2,7-dihydroxy-4-
methoxy-9-fluorenone, were isolated from D. nobile 60% EtOH stem extracts (ZHANG et al., 
2007).  The antioxidant activity was determined using DPPH free radical scavenging and ORAC 
assays.  Dendroflorin and moscatilin exhibited significant scavenging activities when compared 
to Vitamin C (IC50 16.2±0.2 and 14.5±0.3) in the DPPH assay.  There was markedly higher 
peroxyl radical scavenging activity for dendroflorin, nobilone and moscatilin than for Vitamin C 
in the ORAC assay (0.596±0.003, 0.432±0.005 and 0.625±0.013 µM Trolox equivalent/µM).  Of 
the 70 herbal medicines tested for their active-oxygen scavenging activity D. plicatile methanol 
stem extract was one of those that demonstrated potent activity (72% inhibition) against the 
superoxide anion radical (·O2-)  (OHSUGI et al., 1999).  The rhizome of G. conopsea found in 
China and Nepal region, traditionally referred to as Wangla, has been used in Tibetan medicine 
for coughs, asthma and as a tonic in Chinese medicine.  Antioxidant and anti-hepatitis B effects 
have been established (PCT INT. APPL. WO 2004, 2004; CAI et al., 2006).   
 
Dichloromethane extract of the aquatic orchid H. repens yielded habenariol (bis-p-
hydroxybenzyl-2-isobutylmalate).  A structurally similar 2- [1-methylpropyl]malate ester was 
isolated from the rhizomes of the non-aquatic orchid, G. faberi (LI et al., 1993; WILSON et al., 
1999).  Habenariol has been characterized as an antifeedant (WILSON et al., 1999).  Like most 
phenolic compounds, habenariol has also demonstrated antioxidant properties in the human LDL 
lipid peroxidation model.  When compared to the more effective α-tocopherol, habenariol (25 
μM) produced a maximum oxidation rate of 0.0048 with a lag-phase time of 180 minutes and a 
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concentration dependent inhibition of copper-induced lipid hydroperoxide production (IC50 35 
μM) (JOHNSON et al., 1999). 
 
Two orchid species currently traded in South African herbal markets yet not mentioned in any 
South African ethnobotanical literature as being used for medicinal purposes were found to 
exhibit interesting anti-inflammatory effects.  The ethanolic root extract of B. scaberulum 
exhibited the most potent inhibitory effect on COX-2 (Table 6.2. Chapter 6).  While the DCM 
tuber extract of E. hereroensis, was the only extract to significantly inhibit both COX enzymes 
(Table 6.2. Chapter 6).  Interestingly, B. scaberulum DCM root extract was also the most 
effective crude orchid extract to inhibit AChE 18 times greater activity than galanthamine (Table 
6.4. Chapter 6). As an example of how science can enhance the effectiveness of a natural 
compound:  4-hydroxybenzaldehyde, an active compound isolated from G. elata has exhibited 
potent antioxidant activity and GABA transaminase inhibitory effects but weak AChE inhibitory 
activity.  Researchers, looking for compounds with more extensive biological activities, 
produced a new class of active and selective AChE inhibitors by introducing amino acid moieties 
into the backbone of 4-hydroxybenzaldehyde.  The resultant compounds exhibited more potent 
AChE inhibitory activity.  Two compounds 4b (IC50 0.19 μM) and 4i (IC50 0.28 μM) performed 
better than galanthamine (IC50 0.55 μM); and 4i was selective for AChE (WEN et al., 2007).  
Orchid extracts that performed well in both anti-inflammatory and AChE inhibitory assays may 
be potential natural plant product targets for inflammatory disorders.   Extracts include:  A. 
africana EtOH root, B. scaberulum DCM root, E. petersii DCM stem and T. tridentata DCM 
root extracts.  The distinct COX-2 selective inhibition by B. scaberulum root extracts and T. 
tridentata aqueous leaf extracts are indications of potential drug targets with alternative 
mechanisms of action without the side-effects commonly associated with COX-1 inhibition. 
 
The Bulbophyllum and Eulophia genera are not only traded in South African herbal markets for 
medicinal uses, they also feature in a list of 21 genera listed in Ayurvedic literature as being used 
for medicines (SINGH et al., 2007).  The medicinal usefulness of the Bulbophyllum and 
Eulophia genera is supported by the pharmacological and phytochemical assessment of the genus 
Vanda which also features on this list of common medicinal plant sources in Indian traditional 
medicine (SINGH et al., 2007). SIMMLER et al. (2010) evaluated the skin photoprotective 
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effect of Vanda coerulea stilbenoids based on the widespread use of orchid extracts in the 
cosmetic industry.  Ultraviolet - induced damage often results in oxidative stress and associated 
inflammatory processes.  Ultraviolet B (UVB) radiation is known to increase PGE2 production 
(due to the upregulation of COX-2 expression) and ROS; resulting in skin inflammation.  
SIMMLER et al. (2010) mention natural photoprotective polyphenol compounds such as 
proanthocyanidins and resveratrol with proven antioxidant and related anti-inflammatory 
activities. Stem methanolic solutions of isolated stilbenoids from V. coerulea performed better 
than “hydro-alcoholic” solutions in the in vitro DPPH/.O radical scavenging and ParameterTM 
PGE-2 enzyme immunological assays.  Imbricatin, a stilbenoid isolated previously from 
Bulbophyllum and other orchid genera, was one of three isolated stilbenoids recommended for 
use as skin photoprotectants based on antioxidant, anti-inflammatory and immunomodulatory 
effects (SIMMLER et al., 2010).  The neuroprotective, antioxidant and anti-inflammatory 
potential for South African orchid extracts especially for Bulbophyllum scaberulum root extracts 
are therefore great.   
 
The potent anti-inflammatory and antioxidant effect of E. hereroensis and E. petersii supports 
the use of species from this genus for inflammatory-related symptoms (Table 3.1 Chapter 3) in 
South African traditional medicine.  The overall %ANT of P. pubescens pseudobulb and root 
extracts was greater than 90%, which might validate the use of species from this genus as 
substitutes to P. ottoniana, to treat certain inflammatory disorders.  The current investigation 
quantitatively determined the presence of flavonoids in the pseudobulbs and roots of P. 
pubescens.  During the survey of leaf flavonoid content in Orchidaceae, WILLIAMS (1979) 
isolated xanthones, mangiferin and isomangiferin from five species of Polystachya and 
Maxillaria.  The author also observed that there was no pattern of flavonoid distribution within 
the family Orchidaceae, and geographical location played a significant role in the presence of 
flavonoid compounds (WILLIAMS, 1979).  All four species, that did register some flavonoid 
content, shared similar distribution ranges; and are all epiphytic species. 
 
The use of Prosthechea michuacana, a Mexican medicinal orchid used for diabetes, renal disease 
and inflammation was validated in the study by PÉREZ GUTIÉRREZ and SOLIS (2009).  
Similarly, the medicinal uses of C. arcuata (treatment of diabetes and skin infections) and T. 
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tridentata (treatment of psychological disorders such as madness) may be validated based on 
their significant anti-inflammatory and antioxidant effects (Table 6.1, 6.2, 6.4 Chapter 6) 
(BULPITT, 2005).  The anti-inflammatory and antioxidant capacity demonstrated in this 
investigation may suggest cellular and neuroprotective effects.  These two species also share a 
similar distribution pattern, which may result in the accumulation of similar bioactive 
compounds and account for the comparable antioxidant effects.  The use of the same vernacular 
name for C. arcuata, various Eulophia species and Tridactyle species, may be explained by their 
comparable positive anti-inflammatory and antioxidant effects in this investigation.   
 
The COX assay was not designed to detect compounds with pro-inflammatory effects (therefore 
extracts that produced negative inhibitory values were designated as 0% activity).  Similarly, an 
EC50 value was only determined for extracts (10 mg/ml) which exhibited inhibitory effects 
greater than 95 and 80% in the COX-1 and 2 assays respectively.  However, an EC50 value was 
not determined for extracts that lacked a concentration-dependant inhibitory response.  When 
evaluating antioxidant potential of natural products, there is the possibility of discovering 
prooxidant effects.  Common natural antioxidants and food additives have the capacity to exert 
prooxidant effects by promoting free radical damage.  The antioxidant α-tocopherol 
demonstrated concentration-dependent prooxidant effects in vitro (CILLARD et al., 1980).  A 
similar concentration-dependent trend was observed for ascorbic acid, where prooxidant and 
antioxidant effects were observed at low and high concentrations respectively (ERDMAN and 
KLEIN, 1982).   
 
Different classes of well established anti-inflammatories have been shown to exhibit varied even 
limited effects in patients with neuroinflammatory disorders such as Alzheimer‟s.  With 
prolonged use, other NSAIDs have demonstrated a positive response (DeKOSKY, 2003).  Such 
varied responses to anti-inflammatory drugs, is indicative of alternative neuroprotective 
pathways other than COX-inhibition (STUCHBURY and MÜNCH, 2005). This observation, 
and the potential of COX-inhibitors in treatment of Alzheimer‟s, is further supported by the 
report by MONTINE et al. (1999) where COX activity in persons susceptible to Alzheimer‟s 
was comparable to that of control persons; while concentration levels of PGE2 in cerebrospinal 
fluid of susceptible patients had increased five times.  The current study demonstrated the anti-
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inflammatory, antioxidant and AChE inhibitory activities of various orchid crude extracts.  Such 
biological activity further demonstrates the potential of identifying novel treatment options for 
Alzheimer‟s.  Non-steroidal anti-inflammatory drugs often relieve inflammation and associated 
pain by inhibiting specific enzymes (RANG and DALE, 1987).  The effectiveness of anti-
inflammatory and antioxidant drugs in treating inflammatory and degenerative disorders has 
been widely documented (HOWES and HOUGHTON, 2003; HOUGHTON et al., 2007).   
 
Generally the results obtained in this study validate the use of certain orchid species in South 
Africa traditional medicine for pain-related ailments.  Other pharmacological conditions linked 
to inflammation were also investigated to establish other potential activities of the medicinal 
plant extracts.  A more comprehensive assessment of the chemistry of South African orchids 
would allow one to more confidently assert a relationship between chemical profiles, interaction 
between different classes of compounds, biological activity and influence of geographical 
location.  The results obtained in this study provide scientific information that could aid in the 
isolation of potential pharmacologically active compounds with fewer side-effects from some of 





MUTAGENICITY AND TOXICITY EVALUATION 
 
“All substances are poisons; there is none which is not a poison.  The right dose differentiates a 
poison from a remedy.” Paracelsus 
7.1. INTRODUCTION 
 
The toxicity of a drug is directly related to the dose of the drug being administered.  Toxicological 
evaluations form an integral part of the drug discovery process, where an effective, yet safe dose is 
determined. With the advent of pure chemicals as medication, toxic substances were also found to 
act as a result of metabolic activation within the body.  While this is a mechanism adopted by the 
body to excrete the compound, it produces certain reactive chemical groups that bind to and change 
the structure of DNA thus causing a mutation.  It is important to draw the distinction between a 
mutagen and a carcinogen.  A mutagen causes a change in the sequence or structure of DNA, while 
a carcinogen promotes the development of cancerous cells (KIMBALL, 2008b).  The Ames test, a 
short-term bacterial reverse mutation assay, determines the mutagenic potential of a substance that 
may not be a carcinogen.  The test is used extensively in the food and pharmaceutical industry to 





With a higher incidence of cancer reports in recent years there is a need to search for new and 
improved chemopreventative drugs (KUNDU et al., 2005). A carcinogen is a cancer causing agent 
that acts by changing the information that the cell receives and often prevents the differentiation into 
a functional cell (KIMBALL, 2008b).  Unfortunately, such agents are present in our everyday lives 
and environment.  The sun‟s UV rays are one source, while substances in our food or even the 
oxygen we breathe can induce malignant cell formation (KIMBALL, 2008b).  From a historical 
perspective, cancer has only recently been linked to the exposure to carcinogenic agents.  It was 
during the 18th century that Sir Percival Potts made the connection.  In vitro mutagenic activity as 
well as toxic and carcinogenic activity has been shown in plants used for medicinal purposes 




Selecting plants based on their use in traditional medicine is a good starting point as the majority of 
currently used clinical drugs are derived from plants known to be used in traditional medicine 
(FARNSWORTH, 1984).  However, studies such as those conducted by FOURIE et al. (1992) 
showed that 9% of plants investigated exhibited toxic effects.  In addition, VERSCHAEVE and 
VAN STADEN (2008), highlight the lack of toxicological studies on traditional medicinal plants as 
compared to pharmaceutical compounds.  It is generally accepted that the ancient use of these plants 
renders them safe to use.  African traditional medicine has not been captured in pharmacopoeia and 
there is fear of misinterpretation of indigenous knowledge by the younger generations; where the 
misadministration of traditional medicines could lead to poisoning and/or severe side effects.  There 
is no pharmacological record of South African medicinal orchids being used as anticancer treatment 
or having toxic side effects.  This lack of information in the literature needs to be addressed, as it 
creates the perception that plant extracts in these age-old remedies have no harmful effects. 
 
Most pharmacological and toxicological investigations are carried out to determine, respectively, 
the efficacy and safety of medicinal plants.  The relationship between the dose of a compound and 
its effect on a living organism forms the basis of toxicological studies.  VARANDA et al. (2002) 
reported on mutagenic furocoumarins in the root bark of Brosimum gaudichaudii, while 
RIETJENS et al. (2005) described certain flavonoids that exhibited mutagenic properties.  There 
have been previous investigations into the mutagenic potential of a number of South African 
medicinal plants with only a few species exhibiting significant mutagenic properties 
(ELGORASHI et al. 2003).  However, mutagenic plants have also benefited the medical system.  
Compounds such as taxol and vinblastine are known mutagens that are used as anticancer drugs 
(GLASS-MARMOR and BEITNER, 1999; 2003; SRIVASTAVA et al., 2007).  This beneficial 
aspect of mutagenic research and the need to assess other medicinal plants for mutagenic properties 
is highlighted by such investigations. 
 
 
7.1.2. Mutagenicity evaluation techniques 
 
The Ames Salmonella/ microsome mutagenicity (ASMM) assay is a useful assay that detects 
various chemical substances that cause genetic damage and ultimately gene mutations.  It is a short-
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term bacterial reverse mutation assay that makes use of some mutant histidine-dependent 
Salmonella typhimurium strains.  The use of S. typhimurium as a test organism is not ideal as it does 
not represent the human body system; however it is a rapid in vitro model that can be adapted to 
incorporate eukaryotic cells.  When the Salmonella mutagenicity test was revised in 1983 (MARON 
and AMES, 1983) the tester strains TA98 and TA100 were retained.   
 
A bacterial model is useful as gene mutations are measured by a noticeable/visible change in growth 
requirements (MORTELMANS and ZEIGER, 2000).  These bacterial strains contain different 
mutations in genes in the histidine operon which serve as targets for mutagens that cause DNA 
damage.  Salmonella typhimurium may be manipulated to being a histidine mutant by either 
exposing it to radiation or chemicals.  This mutation renders the bacteria unable to produce the 
amino acid, histidine (MORTELMANS and ZEIGER, 2000).  This essential amino acid is 
necessary for the bacteria to grow and form new colonies.  In the presence of a mutagen, new 
mutations occur near or at the site of the original mutation that restore the function of the gene and 
thus the synthesis of histidine.  The bacteria are therefore able to grow and form colonies in the 
absence of histidine in the media, referred to as revertant colonies.  The Ames test is therefore also 
known as the reversion assay (MORTELMANS and ZEIGER, 2000).  A reverse mutation works 
such that the function of a mutated gene is returned.  The deletion mutation (hisD3052) carried by 
the TA98 strain (also shared by TA1538 strain) affects a CG repetitive sequence which is 
deteriorated back to the wild-type by frameshift events (ISONO and YOURNO, 1974).  The 
TA100 strain carries a deletion mutation at hisG46 gene where a leucine codon is replaced with a 
proline combination.  A base-pair substitution, by a mutagen, at the one GC pair, reverts the strain 
to the wild-type strain.  When using the TA102 strain, one is able to detect mutagens that act via 
transitions/transversions (MORTELMANS and ZEIGER, 2000).  At the hisG428 mutation site 
there are AT instead of GC base-pairs.  An ochre mutation, described as an alteration of a codon to a 
stop codon, causes premature termination of a polypeptide chain.  Since the mutation is at the hisG 
gene, in the presence of a mutagen, all likely base-pair changes are possible; resulting in transitions 
and transversions (MORTELMANS and ZEIGER, 2000).   
 
The Ames test is quantitatively scored.  The mutagenic effect of a substance will cause histidine-
requiring strains of S. typhimurium (His-) to regain the ability to grow in the absence of histidine, 
thus forming colonies (MORTELMANS and ZEIGER, 2000).  These colonies are different from 
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the spontaneous colonies that form a background.  Therefore the presence of colonies is an 
indication of a reverse mutation of the His+ gene to its active form.  When compared to the 
spontaneous mutations found in the negative controls, the substance can be regarded as either 
mutagenic or non-mutagenic. 
 
In other words, only Salmonella strains that are histidine independent will be able to form colonies.  
In the assay some bacterial mutants (histidine dependent) are able to revert spontaneously to 
histidine independence, and form colonies (MORTELMANS and ZEIGER, 2000).  This value is 
relatively constant; therefore, when a mutagen is introduced, the resultant number of revertant 
colonies is clearly visible.  However, some substances could be promutagens; that is they require 
some biochemical stimulation to be converted to mutagenic products (MORTELMANS and 
ZEIGER, 2000).  This phenomenon is common in humans, and without a suitable modification the 
Ames test will not identify such substances.  Often, a mixture of liver enzymes (S9) is incorporated 
to mimic the enzymatic conversion of a promutagen to a mutagen, taking into consideration the 
effect of body metabolism on substances and allowing for the detection of such substances using the 
Ames test.  The S9 microsomal mixture contains a cytochrome-based P450 oxidation system.    
 
The Ames assay was initially performed as a spot test and progressed to the more sensitive and 
quantitative plate incorporation assay (MORTELMANS and ZEIGER, 2000).  An alternative 
assay that determines the toxicity more quantitatively is the „treat and plate‟ suspension assay.  The 
plate incorporation assay has an advantage over this procedure in that there are fewer steps involved 
and the presence of trace amounts of histidine with the plant extract allows for the bacteria to 
become sensitized to mutagenesis by undergoing some cell division (MORTELMANS and 
ZEIGER, 2000).  There have been some modifications to the plate incorporation assay to allow for 





The toxicity of crude plant extracts were determined by investigating the background „lawn‟ of the 
minimum glucose plates.  The overnight Salmonella culture contains mainly histidine-dependent 
bacteria and relatively few histidine-independent bacteria.  With a trace amount of histidine present 
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in the top agar all the bacteria go through a few cell divisions until the histidine is exhausted.  
Colonies that are clearly visible are the revertant colonies while microcolonies of histidine-
dependent bacteria form the hazy background lawn.  Toxicity is therefore characterised as the 
thinning of the background lawn (usually a decrease in number of revertant colonies is also 
observed); absence of background lawn; or the production of pinpoint non-revertant colonies 
(MORTELMANS and ZEIGER, 2000).  With regard to the toxicity of a compound, the dose of 
the compound may determine just how toxic it is.  Initially, three concentrations are tested in the 
Ames assay to assess the toxic effect of the crude plant extracts.  Usually the response is expected to 
follow a dose-dependent curve.  A wider range of concentrations can be tested for those extracts that 
show mutagenic and toxic effects. 
 
Possible errors that could result in either false positives or false negatives have to be guarded 
against.  For example, the top agar which contains 0.05 mM histidine requires special attention 
during preparation.  Too little histidine may not support the growth of a uniform background lawn, 
resulting in a plant sample being incorrectly considered to be toxic. This error is easily identified by 
observing the negative control which should produce a uniform background lawn.  Alternatively, 
with the addition of too much histidine, heavy growth could make visibility difficult 
(MORTELMANS and ZEIGER, 2000).   
 
The Ames test is normally used as a preliminary test to determine the potential mutagenic activity of 
new chemicals and drugs.  The ability of a chemical substance to induce a mutation is an essential, 
almost standard, consideration when conducting a safety analysis.  Also, the continuous formulation 




7.2. MATERIALS AND METHODS 
 
 
7.2.1. Re-suspension of plant extracts 
 
A dilution series of the crude plant extracts (prepared as described in Section 4.2.2) was prepared by 
re-suspending extracts in 10% DMSO.  Adequate sample was prepared to run three replicates of 




7.2.2. Ames Salmonella/microsome mutagenicity assay (Ames test) 
 
An in vitro mutagenicity assay was carried out to determine the mutagenic activity of crude plant 
extracts of seven orchid species using three S. typhimurium bacterial strains (MARON and AMES, 
1983).  Bacterial strains were maintained at -70°C (stock bacteria).  Using sterile bench technique, 
overnight cultures of TA98, TA100 and TA102 were prepared by inoculating 10 ml of Oxoid 
nutrient broth No. 2 with 100 µl of each stock bacterium.  The cultures were incubated on an orbital 
shaker over a 16 h period at 37°C.  A dilution series of the crude plant extracts was prepared by re-
suspending extracts in 10% DMSO.  A positive control, 4-nitroquinoline-1-oxide (4NQO), was 
prepared from a stock solution of 2 mg/ml to a concentration of 2 µg/ml by mixing 10 µl of 4NQO 
(stock) with 990 µl DMSO.  From this, 100 µl of 4NQO (20 µg/ml) was added to 900 µl distilled 
water to produce a 2 µg/ml solution.   
 
Minimum glucose plates were prepared in advance using 90 mm Petri dishes.  To make a litre of 
agar:  15 g of Difco agar and a magnetic stir bar was added to 930 ml of distilled water and 
autoclaved for 20 mins at 121°C.  Thereafter, 20 ml of sterile Vogel-Bonner medium (50X VB) (10 
g of MgSO4.7H2O; 100 g citric acid monohydrate; 500 g K2HPO4; 175 g NaHNH4(PO4.4H2O) were 
added consecutively to 670 ml warm distilled water and adjusted to one litre) and 50 ml of 40% 
glucose was added to the liquid media.  The media were stirred thoroughly and 30 ml was dispensed 
into each Petri dish, which was allowed to set.  On day two, two water baths were filled with 
sufficient water and set at 37°C and 50°C. Culture tubes were transferred onto racks (nine tubes per 
crude extract, three for the positive control and five tubes for the negative controls).  The assay was 
conducted under sterile conditions where an ample supply of 70% EtOH is available and a constant 
flame was present.  One hundred microlitres of each concentration of sample and control substance 
were dispensed into the respective culture tubes, followed by 500 µl of sterile 0.2 M sodium 
phosphate buffer (60 ml of 0.2 M NaH2PO4.H2O (13.8 g/500 ml) added to 40 ml 0.2 M Na2HPO4 
(14.2 g/ 500 ml) adjusted to pH 7.4 with 0.2 M NaH2PO4.H2O).  One hundred millilitre aliquots of 
sterile top agar (6 g Difco agar, 5 g NaCl in one litre distilled water, were dispensed into glass 
Schott bottles and stored at 4°C) were defrosted in a microwave oven and placed in the 50°C water 
bath to cool.  While waiting, 100 µl of overnight bacterial culture (2 x 108 cell/ml) were added to 
each tube.  Minimum agar plates were labelled.  Thereafter, 10 ml of 0.5 mM histidine/biotin 
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solution (12 mg D-biotin and 10.5 mg L-histidine / 100 ml sterile distilled water) were added to the 
liquid top agar.  From this enriched top agar, with a trace of histidine, 2 ml were added to 18 culture 
tubes at a time (to prevent the agar from solidifying).  Culture tubes were immediately placed in the 
37°C water bath, while the contents of each tube were vortexed and poured onto the respective 
minimum glucose plates.  The same procedure was carried out for the remaining culture tubes.  
Minimum glucose plates were allowed to set, inverted and thereafter incubated in a 37 °C oven for 
48 h.  A similar procedure was used when determining mutagenic potential with S9 metabolic 
activation.  An S9 mixture (5% (v/v) S9 fraction sourced from Sprague-Dawley male rats (Sigma-
Aldrich, Co., St Louis) in mixed enzymic cofactors with NADP) kept on ice was used in place of 
the phosphate buffer (500 µl).  A separate positive control 2-aminoanthracene (2AA) was used.  At 
the end of the incubation period, the number of revertant colonies was counted using an electronic 
counter.  Toxicity was measured by examining the background of the glucose plates.  Samples were 
compared to the control plate, which is very dense.  Therefore a less dense glucose plate could 
indicate a toxic sample.  A crude extract was considered to be mutagenic if the number or revertant 
colonies were twice the number found in the negative controls and showed a dose-dependent curve.  
The mutagenic index (MI) was also determined; where a MI ≥ 2 and a dose-dependent response was 





Table 7.1. (Chapter 7) shows the average number of induced revertant colonies, the standard 
deviation and the MI at different concentrations (5, 0.5, 0.05 mg/ml) of crude orchid extracts using 
three S. typhimurium strains (TA98, TA100 and TA102).  A crude extract was considered to be 
mutagenic if the number or revertant colonies were twice the number found in the negative controls 
and showed a dose-dependent response.  Mutagenic extracts were observed for the TA98 strain 
only.  All concentrations of A. africana DCM leaf and stem extracts tested, the DCM root extract 
(0.5, 0.05 mg/ml) and EtOH leaf, stem and root extracts at 5 mg/ml exhibited mutagenic effects.  
The EtOH root extracts (5, 0.5 mg/ml) of B. scaberulum exhibited mutagenic indices comparable to 
that of 4NQO (17.00 and 13.00, respectively).  Eulophia petersii PE pseudobulb extract 
demonstrated mutagenic potential at the highest concentration tested (5 mg/ml).  The ethanolic root 
extracts of T. tridentata showed mutagenic effects at 5 and 0.5 mg/ml. 
153 
 
Table 7.1.:  Mutagenicity of crude orchid extracts as determined in the Salmonella/microsome assay 
(without metabolic activation) expressed as average revertants per plate and mutagenicity index. 




Salmonella typhimurium strains 
TA98 TA100 TA102 













Ansellia africana Leaves DCM 5000 47.34±12.3 3.95 174.00±19.80 1.66 656.00±67.88 1.57 
   
500 36.67±7.1  3.06 158.00±8.49 1.50 354.00±76.37 0.85 
   
50 32.67 ± 1.9 2.72 162.00±14.15 1.54 476.00±28.28 1.14 
  
Ethanol 5000 25.34±10.4 2.11 112.00±0.00 1.07 430.00±36.77 1.03 
   
500 20.17±4.9  1.68 84.00±1.10 0.80 414.00±25.46 0.99 
   
50 12.67±1.2 1.06 106.00±36.77 1.01 512.00±11.31 1.22 
 Stem DCM 5000 41.00±6.6  3.42 68.00±5.66 0.65 572.00±30.55 1.37 
  
  
500 26.00±1.4  2.17 120.00±28.28 1.14 322.00±14.14 0.77 
      50 34.00±6.1  2.83 140.00±28.28 1.33 396.00±56.57 0.95 
  
Ethanol 5000 27.00±9.9  2.25 154.00±25.46 1.47 560.00±27.72 1.34 
   
500 22.84±6.8  1.90 122.00±48.08 1.16 ND ND 
   
50 18.17±1.2  1.51 114.00±2.83 1.09 560.00±14.00 1.34 
 Root DCM 5000 36.50±12.02 3.04 146.00±19.80 1.39 428.00±11.31 1.02 
      500 31.50±9.19 2.63 118.00±14.14 1.12 420.00±152.7 1.00 
      50 22.50±3.54 1.88 106.00±31.11 1.01 338.00±127.3 0.81 
  
Ethanol 5000 31.50±9.19 2.63 154.00±19.80 1.47 360.00±16.97 0.86 
   
500 ND ND 146.00±2.82 1.39 ND ND 
   
50 ND ND 110.00±19.80 1.05 ND ND 
Bulbophyllum 
scaberulum 
Root DCM 5000 20.50±6.36 1.71 143.00±9.90 1.36 175.50±6.36 0.42 
   
500 18.50±9.19 1.54 101.00±4.24 0.96 253.50±0.71 0.61 
   
50 18.00±9.90 1.50 127.00±7.07 1.21 280.50±17.68 0.67 
  
Ethanol 5000 204.00±31.1 17.00 118.00±4.95 1.12 189.00±26.87 0.45 
   
500 156.00±28.28 13.00 ND ND 184.00±8.49 0.44 
   
50 11.50±4.95 0.96 ND ND 199.00±4.24 0.48 
Cyrtorchis 
arcuata 
Leaf PE 5000 18.00±4.24 1.50 168.00±5.66 1.60 226.00±42.43 0.54 
   
500 15.50±7.78 1.29 154.00±8.49 1.47 274.00±70.71 0.66 
   
50 13.50±0.71 1.13 116.00±5.66 1.10 350.00±59.40 0.84 
  
DCM 5000 16.00±5.66 1.33 146.00±14.14 1.39 342.00±53.74 0.82 
   
500 11.50±4.95 0.96 130.00±2.82 1.24 318.00±121.6 0.76 
   
50 11.00±5.66 0.92 128.00±33.94 1.22 358.00±36.77 0.86 
  
Ethanol 5000 9.00±5.66 0.75 154.00±19.80 1.47 352.00±28.28 0.84 
   
500 7.50±0.71 0.63 160.00±62.23 1.52 288.00±22.63 0.69 
   
50 12.50±2.12 1.04 166.00±25.46 1.58 338.00±19.80 0.81 
 
Roots DCM 5000 7.50±6.36 0.63 122.00±8.46 1.16 390.00±98.99 0.93 
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Salmonella typhimurium strains 
TA98 TA100 TA102 













   
500 8.50±0.71 0.71 72.00±11.31 0.69 410.00±65.05 0.98 
   
50 13.00±1.41 1.08 148.00±0.00 1.41 330.00±70.71 0.79 
  
Ethanol 5000 9.00±2.83 0.75 128.00±16.97 1.22 186.00±36.77 0.44 
   
500 11.50±2.12 0.96 124.00±22.63 1.18 248.00±33.94 0.59 
   
50 13.50±4.95 1.13 120.00±11.31 1.14 358.00±25.46 0.86 
Eulophia 
hereroensis 
Tuber Ethanol 5000 15.00±4.24 1.25 132.00±4.24 1.26 226.00±22.63 0.54 
   
500 14.50±2.12 1.21 89.00±0.00 0.85 217.50±45.96 0.52 
   
50 15.50±4.95 1.29 124.00±9.90 1.18 301.00±24.04 0.72 
 Roots DCM 5000 11.50±0.71 0.96 116.00±22.63 1.10  ND ND 
      500 15.00±2.82 1.25 98.00±8.49 0.93 387.00±21.21 0.93 
      50 18.00±0.00 1.50 140.00±0.00 1.33 384.00±50.91 0.92 
    Ethanol 5000 17.50±2.12 1.46 147.00±31.11 1.40 347.50±28.99 0.83 
      500 11.00±1.41 0.92 124.50±0.71 1.19 322.00±15.56 0.77 
      50 14.00±5.66 1.17 119.00±12.73 1.13 329.50±43.13 0.79 
Eulophia petersii Leaf DCM 5000 22.00±0.00 1.83 ND ND 540.00±5.66 1.29 
   
500 26.00±0.00 2.17 ND ND 342.00±104.7 0.82 
   
50 ND ND ND ND 422.00±127.3 1.01 
  
Ethanol 5000 14.00±4.24 1.17 118.00±19.80 1.12 242.00±25.46 0.58 
   
500 9.00±1.41 0.75 168.00±5.66 1.60 326.00±8.49 0.78 
   
50 11.00±5.66 0.92 120.00±11.31 1.14 324.00±0.00 0.78 
 Stem DCM 5000 14.50±0.71 1.21 170.00±25.46 1.62 234.00±42.43 0.56 
      500 21.50±2.12 1.79 164.00±11.31 1.56 460.00±164.1 1.10 
      50 15.00±5.66 1.25 140.00±0.00 1.33 368.00±33.94 0.88 
  
Ethanol 5000 18.50±9.19 1.54 106.00±14.14 1.01 624.00±11.31 1.49 
   
500 19.50±3.54 1.63 160.00±0.00 1.52 716.00±175.4 1.71 
   
50 15.00±4.24 1.25 116.00±22.63 1.10 492.00±22.63 1.18 
 
Pseudobulb PE 5000 26.00±4.24 2.17 ND ND 434.00±53.74 1.04 
   
500 19.50±0.71 1.63 ND ND 308.00±62.23 0.74 
   
50 16.00±2.82 1.33 ND ND 418.00±132.9 1.00 
   DCM 5000 13.00±2.82 1.08 116.00±0.00 1.10 206.00±14.14 0.49 
      500 16.50±3.54 1.38 88.00±0.00 0.84 390.00±76.37 0.93 
      50 9.00±2.82 0.75 124.00±5.66 1.18 404.00±164.1 0.97 
    Ethanol 5000 21.50±0.71 1.79 156.00±5.66 1.49 370.00±116.0 0.89 
      500 17.50±4.95 1.46 168.00±10.61 1.60 340.00±22.63 0.81 
      50 15.00±1.41 1.25 144.00±39.60 1.37 274.00±8.49 0.66 
  Root DCM 5000 15.50±0.71 1.29 116.00±50.91 1.10 483.00±26.87 1.16 
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Salmonella typhimurium strains 
TA98 TA100 TA102 













   500 11.50±6.36 0.96 146.00±8.49 1.39 194.00±42.43 0.46 
      50 16.00±1.41 1.33 134.00±42.43 1.28 322.00±76.37 0.77 
  
Ethanol 5000 14.50±0.71 1.21 94.00±14.14 0.90 340.00±28.28 0.81 
   
500 16.50±2.12 1.38 152.00±62.23 1.45 322.00±48.08 0.77 
   
50 16.00±1.41 1.33 148.00±45.26 1.41 236.00±45.25 0.56 
Polystachya 
pubescens 
Pseudobulb PE 5000 11.50±3.54 0.96 135.00±12.73 1.29 214.50±4.95 0.51 
   
500 6.00±2.82 0.50 120.00±0.00 1.14 243.50±16.26 0.58 
   
50 16.50±6.36 1.38 114.00±28.28 1.09 228.00±28.28 0.55 
  
DCM 5000 12.00±1.41 1.00 126.00±42.42 1.20 127.50±33.23 0.31 
   
500 12.00±4.24 1.00 112.00±0.00 1.07 226.50±7.78 0.54 
   
50 9.50±2.12 0.79 108.00±22.63 1.03 204.50±16.26 0.49 
  
Ethanol 5000 17.00±1.41 1.42 132.00±50.91 1.26 184.00±22.63 0.44 
   
500 16.00±1.41 1.33 204.00±50.91 1.94 247.00±24.04 0.59 
   
50 18.50±3.54 1.54 108.00±16.97 1.03 278.00±8.49 0.67 
 
Root PE 5000 14.50±9.19 1.21 123.00±7.07 1.17 193.50±2.12 0.46 
   
500 15.50±0.71 1.29 ND ND 240.00±28.28 0.57 
   
50 12.00±5.66 1.00 120.00±14.14 1.14 266.50±36.06 0.64 
  
DCM 5000 13.00±5.66 1.08 ND ND 204.00±16.97 0.49 
   
500 14.00±1.41 1.17 ND ND 193.50±44.55 0.46 
   
50 11.50±2.12 0.96 ND ND 160.00±52.33 0.38 
  
Ethanol 5000 11.00±4.24 0.92 88.00±11.31 0.84 242.50±2.12 0.58 
   
500 13.00±1.41 1.08 112.00±5.66 1.07 228.00±57.98 0.55 
   
50 13.50±0.71 1.13 90.00±2.83 0.86 260.00±22.63 0.62 
Tridactyle 
tridentata 
Roots PE 5000 12.50±0.71 1.04 143.00±9.90 1.36 139.50±16.26 0.33 
   
500 15.50±2.12 1.29 123.00±13.44 1.17 244.00±4.24 0.58 
   50 15.00±0.00 1.25 136.00±4.95 1.30 187.00±21.21 0.45 
  
DCM 5000 16.00±0.00 1.33 134.00±7.78 1.28 56.50±4.95 0.14 
   
500 16.00±1.41 1.33 131.00±3.54 1.25 164.50±10.61 0.39 
   50 16.50±2.12 1.38 131.00±8.49 1.25 260.00±45.26 0.62 
  
Ethanol 5000 ND ND 132.00±10.61 1.26 154.00±5.66 0.37 
   
500 94.50±9.19 7.88 129.00±3.54 1.23 255.00±33.94 0.61 
   
50 41.50±3.54 3.46 ND ND 204.00±33.94 0.49 
Positive control 
   
196.00±2.83 16.33 1868.0±231.9 17.79 1679.0±175.4 4.02 
Negative control 
   
12.00±0.71 1.00 105.00±13.43 1.00 418.00±11.31 1.00 
Values are the mean (±) standard deviation (n = 3); values in bold indicate those extracts with most 
significant mutagenic index.  ND – not determined. 
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Table 7.2. (Chapter 7) shows the average number of induced revertant colonies, the standard 
deviation and the MI at different concentrations (5, 0.5, 0.05 mg/ml) of crude orchid extracts using 
S. typhimurium strain TA98 with metabolic activation.  A crude extract was considered to be 
mutagenic if the number of revertant colonies were twice the number found in the negative controls 
and showed a dose-dependent response.  None of the extracts tested demonstrated mutagenic 
effects. 
 
Table 7.2.:  Mutagenicity of crude orchid extracts as determined in the Salmonella/microsome 
assay (with metabolic activation) expressed as average revertants per plate and mutagenicity index. 
Values are the mean (±) standard deviation (n = 3); values in bold indicate those extracts with most 
significant mutagenic index. 




Salmonella typhimurium strain (TA98) 
    
Revertants per plate Mutagenicity index 
  Ansellia africana Stem DCM 5000 16.50±4.95 0.67 
      500 12.50±2.12 0.51 
      50 11.50±2.12 0.47 
  Root DCM 5000 11.50±3.54 0.47 
      500 13.00±2.82 0.53 
      50 9.00±2.82 0.37 
  Eulophia hereroensis Roots DCM 5000 19.00±0.00 0.78 
      500 21.00±2.82 0.86 
      50 25.50±2.12 1.04 
    Ethanol 5000 11.50±2.12 0.47 
      500 16.00±2.82 0.65 
      50 16.50±2.12 0.67 
  Eulophia petersii Stem DCM 5000 11.00±0.00 0.45 
      500 14.00±0.00 0.57 
      50 15.50±0.71 0.63 
    Ethanol 5000 16.00±8.49 0.65 
      500 10.50±0.71 0.43 
      50 13.00±1.41 0.53 
  Root DCM 5000 11.50±2.12 0.47 
      500 18.00±4.24 0.73 
      50 11.50±2.12 0.47 
Tridactyle tridentata Roots PE 5000 15.00±1.41 0.61 
      50 18.00±0.00 0.73 
      DCM 50 8.50±6.36 0.35 
Positive control 
   
141±9.19 5.76 
Negative control 






Mutagenicity assessment programs have increased dramatically especially due to cancer concerns.  
There are two major concerns regarding mutagens, these are:  their ability to either induce cancer or 
to affect the germ line and future generations.  The Ames test is commonly used to determine the 
potential mutagenic property of a substance.  It is assumed that a mutagenic substance may be 
carcinogenic.  However, not all cancer causing substances show positive results in the Ames test.  A 
positive result indicates the ability of a substance to produce a change in DNA structure; that is, 
gene point mutations or the gain or loss of whole chromosomes.  However, further analysis is 
required to determine the carcinogenic potential of the substance.  In industry the Salmonella 
mutagenicity (Ames) test, which detects gene mutations, (VERSCHAEVE et al., 2004) is used 
extensively as a preliminary indicator to identify possible carcinogens and/or the mutagenic 
potential of crude plant extracts and clinical drugs.  ELGORASHI et al. (2003) reported on the 
possible mutagenic effects of 51 South African medicinal plant species.  REID et al. (2006) 
evaluated 42 other South African species.  There has been extensive research into the mutagenic and 
anti-mutagenic potential of medicinal plants used in the South African traditional medical system 
(ELGORASHI et al., 2002).   
 
This investigation is the first report of mutagenic properties of seven medicinal orchids of South 
Africa.  Plants were selected on the basis of their ethnobotanical use and availability.  A plant 
extract was considered mutagenic when a MI of ≥2 for any concentration of that extract was 
observed; together with a dose-dependent response (VARGAS et al., 1993).  An increase in number 
of His+ revertant colonies over the negative control indicated genotoxic effects.  Of the seven orchid 
species considered in this investigation, C. arcuata root extract contained the highest flavonoid 
content (1.24 mg catechin equivalent/g dry matter).  Organic leaf and root extracts of C. arcuata 
produced no genotoxic effects (Table 7.1. Chapter 7).  Food derived flavonols such as quercetin, 
kaempferol and myricetin have been reported to affect the cell cycle and growth of cancer cells, 
thereby reducing the risk of cancer (VERMA et al., 1988; YOSHIDA et al., 1990).  The non-
genotoxic effects of C. arcuata coupled with the high flavonoid content necessitates further 
investigation.  ZHANG et al. (2005) also established that dimerised phenanthrenes are required to 
inhibit cancer cell growth.  Research on compounds such as moscatilin; with known anti-
inflammatory, cytotoxic, anti-platelet aggregation and anti-proliferative properties; and erianin, 
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provide insight into the mechanisms involved in cancer progression.  Similary, orchid extracts that 
demonstrate significant biological activities should be researched further for other biological 
activities.   
 
The ASMM assay revealed that mutagenic extracts were observed for the TA98 strain only.  
Without metabolic activation, certain organic extracts of A. africana leaf, stem and root extract at 
various concentrations tested (0.5 and 0.05 mg/ml) exhibited genotoxic effects; while the EtOH root 
extracts (5 and 0.5 mg/ml) of B. scaberulum exhibited mutagenic indices comparable to that of 
4NQO.  A more comprehensive chemical and toxicological profile is required for B. scaberulum.  
Bioactive E. petersii PE pseudobulb extract demonstrated mutagenic potential at the highest 
concentration tested (5 mg/ml).  The ethanolic root extracts of T. tridentata showed mutagenic 
effects at 5 and 0.5 mg/ml. With metabolic activation using TA98, no mutagenic effects were 
observed for all crude orchid extracts tested. 
 
The primary aim of mutagenicity testing of bioactive natural plant extracts is to determine their 
safety.  The herbicidal potential of gymnopusin, a phenanthrene derivative from M. densa, was 
weak as it displayed cytotoxic effects in vitro against four mammalian cell lines H4TG (IC50 
13.0±0.9 µM), MDCK (IC50 11.0±0.5 µM), NIH3T3 (IC50 12.0±1.0 µM) and KA31T (IC50 21.0±0.5 
µM) (VALENCIA- ISLAS et al., 2002).  Interestingly, other researchers have previously 
determined various approaches to synthetically produce gymnopusin (WANG and SNIECKUS, 
1991).  Collectively, such information can benefit further research efforts dealing with bioherbicides 
and their safety. 
 
A fairly large number of phenanthrenes have been reported from the Orchidaceae family; 
particularly the Dendrobium, Bulbophyllum, Eria, Maxillaria, Bletilla, Coelogyna, Cymbidium, 
Ephemerantha and Epidendrum genera. Denbinobin, a phenanthraquinone isolated from D. nobile, 
E. lonchophylla and E. fimbriata, exhibited cytotoxic effects (TALAPATRA et al., 1982; 
TEZUKA et al., 1991; TEZUKA et al., 1993; LEE et al., 1995).  Orchid extracts are key 
ingredients in the five major traditional medicines used in Chinese traditional medicine (Chapter 3 
Section 3.5.1.).  Those used in the treatment of cancers include:  Bai-Ji (Bletilla striata) used to 
treat haemorrhagic disorders and cancers and Shan-Ci-Gu (Cremastra appendiculata) used to treat 
tonsillitis, hypertension and cancers (XUE et al., 2006; BULPITT et al., 2007).   Phenanthrenes 
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were mainly isolated from whole plants, cortex, tubers or stems and a large number where isolated 
from B. striata and B. vaginatum (KOVÁCS et al., 2008).  Lusianthridin, isolated from B. striata 
had no activity on a leukaemic P388 cell line in vitro but displayed antitumor activity at 20 µg/kg 
(TAKAGI et al., 1983).  In the current study, B. scaberulum ethanolic root extracts exhibited 
mutagenic properties comparable to 4NQO (Table 7.1. Chapter 7).  Further chemical and 
pharmacological investigation of other organs of this species could reveal phenanthrenes and 
antitumor properties of B. scaberulum.  Taxol and vinblastine, well known mutagens, are used as 
anticancer drugs.  Orchid extracts that exhibit mutagenic effects (A. africana organic leaf, stem and 
root, B. scaberulum EtOH root, E. petersii PE pseudobulb and T. tridentata EtOH root extracts) 
should be examined further to determine their full potential.  Such compounds may effectively treat 
cancers; in addition to providing insight into the mechanisms involved in its progression.   
 
There are a number of antitumor, antimutagenic and anti-angiogenesis reports for the Dendrobium 
genus (LEE et al., 1995; WANG et al., 1997; MIYAZAWA et al., 1999; GONG et al., 2004; 
ZHANG et al., 2005; GONG et al., 2006; CHEN et al., 2008a; KOVÁCS et al., 2008; TSAI et 
al., 2010).  Similarly, antitumour activities have been detected in the Bulbophyllum genus (YAO et 
al., 2005a), with B. odoratissimum, in particular, containing cytotoxic phenolics (CHEN et al., 
2008b).  Glycosides were reported in D. chrysanthum [denchryside-A] and Bletilla striata.  
KOVÁCS et al. (2008) referred to the anticancer potential of these compounds due to their 
cytotoxic properties.  Sesquiterpene glycosides dendroside-A and dendronobilosides A and B were 
also detected in D. nobile stem extracts.  Calanquinone-A isolated from C. arisanensis also 
exhibited cytotoxic activity (LEE et al., 2008).  Ephemeranthol-A and fimbriol-A, isolated from E. 
rigidum exhibited potent phytotoxicity against A. hypochondriacus (IC50 0.12 µM and 5.90 µM, 
respectively) (HERNÁNDEZ-ROMERO et al., 2005).  Compounds with phytotoxic properties 
may be further investigated for their herbicidal potential. 
 
Toxicity was determined by examining the density of the background lawn of spontaneous colonies, 
compared to that of the negative control.  The resultant population of microcolonies of His+ 
bacteria, form the hazy background lawn (MORTELMANS and ZEIGER, 2000).  A thinning or 
absent lawn indicates toxicity.  The results of this technique revealed minimal toxic effects for all 
crude extracts when compared to the 10% DMSO control.  In order to determine a definite 
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relationship between the lack of mutagenic potential and toxicity, other toxicity tests need to be 
conducted.   
 
The toxicology and mutagenicity of medicinal plants needs equal consideration in medicinal plant 
research. Most of the orchid species used for cultural practices is administered as emetics. It would 
be important to know what the effects of these orchid-derived medicines are on the human body and 
more especially their safety.  The detection of mutagenic substances has become a necessary 
measure in most industries‟ safety evaluations (MORTELMANS and ZEIGER, 2000).  There has 
been a recent upsurge of mutagenicity and toxicological studies mainly due to the possibility of 
mutagenic substances being cancer causing agents (MORTELMANS and ZEIGER, 2000).  Other 
toxicological tests such as the Micronucleus Test (MNT), Comet assay, Umu-C and VITOTOX® 
tests and antimutagenic assays could be used; where significant results warrant further investigation 
to determine the potential of plant compounds.   Qualitative and quantitative HPLC analysis could 




GENERAL DISCUSSION AND CONCLUSIONS 
 
It is well known that orchids are used for medicinal purposes around the world.  The medicinal 
value of orchids was realised by early civilizations and they were subsequently used as therapeutic 
agents to treat common ailments.  BULPITT (2005) described the widespread medicinal use of 
orchids.  In early European history, Theophrastus (372-286 BC) derived the word orchid from the 
Greek word orchis (as the tubers of many European terrestrial orchids resembled testicles).  The 
Americans made extensive use of the vanilla orchid as a flavourant and perfume, a tradition passed 
on from the ancient Aztecs to modern civilizations.  The Australian aborigines and early settlers 
mainly used Cymbidium and Dendrobium species to treat dysentery, as an oral contraceptive, to 
relieve pain, and to cure ringworm infection.  Some species were consumed as a food source.  In the 
Ayurvedic pharmacopoeia of India, over 40 orchid species from 21 genera were identified as 
important medicinal sources:  Acampe, Bulbophyllum, Calanthe, Coelogyne, Cymbidium, 
Cypripedium, Dactylorhiza, Dendrobium, Epipactis, Eria, Eulophia, Filckingeria, Habenaria, 
Liparis, Luisia, Malaxis, Pecteilis, Pholidota, Rhynchostylis, Satyrium and Vanda (SINGH et al., 
2007).  In Chinese traditional medicine BULPITT et al. (2007) highlighted the five major 
traditional medicines of which orchids are key ingredients – Shi-Hu (five Dendrobium species) used 
to treat deficiency disorders in the kidney, lung and stomach, Tian-Ma (Gastrodia elata) used to 
relieve dizziness, convulsions, hypertension and to treat stroke patients, Bai-Ji (Bletilla striata) used 
to treat haemorrhagic disorders as well as cancers; Jin-Xian-Lian (two Anoectochilus species) used 
mainly to treat nephritis, cystitis and pneumonia and Shan-Ci-Gu (Cremastra appendiculata) used 
to treat tonsillitis, hypertension and cancers.  On the African continent, Malawians use 
approximately nine species to treat stomach ailments and two more for fertility problems.  
Cyrtorchis arcuata is used to treat diabetes and skin infections; epilepsy is prevented by using 
Eulophia cucullata and psychological disorders such as madness is treated with Tridactyle tricuspis 
(BULPITT, 2005).  While there is an awareness of medicinally used orchids around the world, the 
extensive use of certain southern African orchids for medicinal and magical purposes is not well 
documented.   
 
Based on an extensive literature search, compared to the South African perspective, it is evident that 
medicinal orchid research has surged ahead in other countries.  Pharmacological studies of orchids 
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have revealed anti-angiogenic, anti-cancer, anti-inflammatory, antioxidant, antimicrobial, anti-red 
blood cell sickling, anti-tumour, antiviral, cytotoxic, immunomodulatory, phytotoxic, spasmolytic 
and neuroprotective activities.  Phytochemical research of orchid species has elucidated a number of 
bioactive compounds generally grouped as polyphenols, lignans, alkaloids, monoterpenes, 
triterpenes, stilbenoids, bibenzyls and phenanthrenes (GARO et al., 2007).  Compounds of 
particular interest include: gigantol, which demonstrated significant anti-inflammatory and 
vasorelaxant properties, 4-hydroxybenzyl alcohol and 4-hydroxybenzaldehyde which exhibited 
considerable anti-angiogenic, analygesic, anti-inflammatory, antioxidant and memory consolidation 
properties, gastrodin which positively affected memory retention and learning abilities, exhibited 
antioxidant, anticonvulsant effects and neuroprotective properties in Alzheimer‟s research.  The 
aromatic vanillin, originally isolated from Vanilla species, has demonstrated the greatest medicinal 
potential despite its more common use in the culinary industry as a flavourant.  Vanillin exhibited 
antioxidant, prooxidant, apoptosis inhibitory effects, neuroprotective, antimicrobial, anti-
carcinogenic, anti-mutagenic and anti-clastogenic properties.  Furthermore, ZHANG et al. (2004) 
provided details on the vanillin prodrug MX-1520, which was synthesized to treat red blood cell 
sickling with vanillin, in vivo.  These significant developments in medicinal orchid research 
worldwide resulted from an ethnobotanical approach used to select the various orchid species which 
yielded valuable bioactive compounds.   
 
The current investigation revealed for the first time, the pharmacological potential of seven 
indigenous orchid species of South Africa:  Ansellia africana Lindl., Bulbophyllum scaberulum 
(Rolfe) Bolus, Cyrtorchis arcuata (Lindl.) Schltr., Eulophia hereroensis Schltr., Eulophia petersii 
(Rchb.f.) Rchb.f., Polystachya pubescens (Lindl.) Rchb.f. and Tridactyle tridentata (Harv.) Schltr.  
The phytochemical evaluation of these species provided insight into the classes of chemical 
compounds present and their possible role in the observed biological activities.   
 
According to KOVÁCS et al. (2008) phenanthrenes and their dihydro-phenanthrene derivatives 
constitute the major phytoalexins in orchids.  A phytochemical report by BLITZKE et al. (2000) 
revealed five phenanthrenes and several phytosterols from the roots of Eulophia petersii collected in 
Yemen.  Lusianthridin, one of the phenanthrenes, demonstrated antimicrobial properties, cytotoxic 
activity in vitro and in vivo, anti-tumour effects and increased muscle contractions (KOVÁCS et 
al., 2008).   With a number of South African orchid species demonstrating antimicrobial properties 
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(Section 4.4.) future research should focus on determining the presence and biological activity of 
phenanthrenes in orchid species.  The organic root extracts of Eulophia hereroensis and organic and 
pseudobulb extracts of E. petersii, respectively, exhibited significant antimicrobial effects (Table 
4.1. Chapter 4).  A more focused project such as a complete phytochemical and pharmacological 
assessment of the South African Eulophia species might reveal results that could be compared to 
that of other Eulophia species.      
 
The presence of certain classes of compounds may influence biological activities in medicinal 
plants.   Phytochemical analysis revealed C. arcuata methanol root extracts to have the highest 
flavonoid content.  Anatomical studies of Encyclia calamara roots revealed the presence of 
flavonoid compounds (OLIVEIRA and SAJO, 1999), while the comprehensive survey by 
WILLIAMS (1979) illustrates the distribution of leaf flavonoids in Orchidaceae.  KIM et al. 
(2009) reported on the lethal anthelmintic effects of flavonoids, where the natural flavonoid flavone 
inhibited embryogenesis in Caenorhabditis elegans.  Such reports provide credence to the 
significant anthelmintic effects observed in all C. arcuata extracts tested.   
 
Cyrtorchis arcuata methanol leaf extracts contained the highest condensed tannin content, while E. 
hereroensis methanol root extract contained the highest amount of hydrolysable tannin.  Recent 
veterinary parasitology studies have focused on the use of proanthocyanidin-rich diets for direct and 
indirect anthelmintic effects (IQBAL et al., 2007).  MOHAMED et al. (2000) explored the lethal 
effects of gallo- and condensed tannins specifically against C. elegans.    Hydrolysable tannins 
(gallic acids) are of lower molecular weight than condensed tannins and are more easily absorbed in 
the digestive tract of ruminants.  They are therefore considered more toxic (HOSTE et al., 2006). 
Studies on the effect of pure compounds isolated from Rhus niveus on the plant-parasitic nematode 
(Meloidogyne incognita) revealed that gallic acid was one of the more potent nematicidal 
compounds present (SULTANA et al., 2010). MOHAMED et al. (2000) concluded that natural 
tannins could possibly contribute to the search for novel sources of anthelmintics and that the use of 
tannin-rich plants could help control nematode infection in animals. 
 
Eulophia petersii methanol pseudobulb extract was found to contain the highest total phenolic 
content.  All DCM extracts of E. petersii significantly affected C. elegans.   The tubers of Eulophia 
nuda, found in the Himalayas, are used to treat various ailments including, as a vermifuge to treat 
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worm infestation.  The methanol extract and isolated phenolic compounds of the tubers exhibited 
cytotoxic potential (SHRIRAM et al., 2010).  The anthelmintic effect of the extract may be due to 
the cytotoxic effect of phenolic compounds.   Further analysis of Cyrtorchis and Eulophia species 
may reveal phenolic, flavonoid and tannin-based anthelmintic compounds that could be used in a 
more practical application in both veterinary and human nematode infections.    
 
The medicinal value of flavonoids include:  anti-inflammatory, antifungal, antioxidant and wound 
healing properties.  The wound healing efficacy of Oncidium flexuosum, an epiphytic orchid used in 
Brazilian traditional medicine for inflammation and wounds, was attributed to the presence of 
flavonoids and tannins (De GASPI et al., 2011).    The flavonoid content of B. scaberulum and T. 
tridentata may explain the potent activity observed in the anti-inflammatory and AChE inhibitory 
assays.  The ethanolic root extract of B. scaberulum exhibited the most potent inhibitory effect on 
COX-2 and AChE; while the DCM tuber extract of E. hereroensis, was the only extract to 
significantly inhibit both COX enzymes.  The flavonoid content in the leaf and root extracts of T. 
tridentata and C. arcuata, respectively, may play a role in the antioxidant activity observed in the 
HAT reaction-based assay.  The presence of the flavonoids in certain orchid species may require 
further testing for antioxidant properties using alternative antioxidant mechanisms to that used in 
this investigation. 
 
When testing for skin photoprotective effects, isolated stilbenoids from Vanda coerulea performed 
better than “hydro-alcoholic” solutions in the in vitro DPPH/.O radical scavenging and ParameterTM 
PGE-2 enzyme immunological assays.  Imbricatin, a stilbenoid isolated previously from 
Bulbophyllum and other orchid genera, was one of three isolated stilbenoids recommended for use 
as skin photoprotectants based on antioxidant, anti-inflammatory and immunomodulatory effects 
(SIMMLER et al., 2010).  The antioxidant and anti-inflammatory potential for South African 
orchid extracts is therefore great.  Science can also enhance the effectiveness of a natural 
compound.  Researchers produced a new class of active and selective AChE inhibitors by 
introducing amino acid moieties into the backbone of 4-hydroxybenzaldehyde.  The resultant 
compounds exhibited more potent AChE inhibitory activity which performed better than 
galanthamine and demonstrated selectivity for AChE (WEN et al., 2007).  Orchid extracts that 
performed well in both anti-inflammatory and AChE inhibitory assays may be potential natural 
plant product targets for inflammatory disorders.   Extracts include:  A. africana EtOH root, B. 
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scaberulum DCM root, C. arcuata EtOH root, E. petersii DCM stem and T. tridentata DCM root 
extracts.   
 
The current investigation quantitatively determined the presence of flavonoids in the pseudobulbs 
and roots of P. pubescens.  In the survey of leaf flavonoid content in Orchidaceae, WILLIAMS 
(1979) revealed xanthones, mangiferin and isomangiferin isolated from five species of Polystachya 
and Maxillaria.  The author also observed that there was no pattern of flavonoid distribution within 
the family Orchidaceae, and geographical location played a significant role in the presence of 
flavonoid compounds (WILLIAMS, 1979).  All four species, that did yield some flavonoid content, 
shared similar distribution ranges; and are all epiphytic species.  The anti-inflammatory and 
antioxidant activity demonstrated in the current investigation was suggestive of cellular and 
neuroprotective effects of orchid extracts.  Cyrtorchis arcuata and T. tridentata also share a similar 
distribution pattern, which may result in the accumulation of similar bioactive compounds and 
account for the comparable antioxidant effects.  The use of the same vernacular name for C. 
arcuata, various Eulophia species and Tridactyle species, may be explained by their comparable 
positive anti-inflammatory and antioxidant effects detected during this investigation.  A more 
comprehensive assessment of the chemistry of South African orchids would allow more confident 
assertions on relationships between chemical profiles, interaction between different classes of 
compounds, biological activity and influence of geographical location.  
 
Determining the biological safety of natural plant products is as important as determining biological 
efficacy.  Mutagenicity assessment programs have increased dramatically especially due to cancer 
concerns.  There are two major concerns regarding mutagens, these are:  their ability to either 
induce cancer or to affect the germ line in future generations.  Compounds that affect mechanisms 
involved in the cell cycle and growth of cancer cells have long been targets in cancer research.  
Food derived flavonols such as quercetin, kaempferol and myricetin have been reported to reduce 
cancer risk by such mechanisms (VERMA et al., 1988; YOSHIDA et al., 1990).  The non-
genotoxic effects of C. arcuata coupled with the high flavonoid content necessitates further 
investigation in anti-cancer research. Primary compounds found in orchid extracts have also shown 
promise in anti-angiogenesis research; by reducing vascular permeability, one of the early signs of 
an inflammatory response and thus, one of the focus areas of cancer research.  In the current 
investigation B. scaberulum roots exhibited mutagenic indices comparable to that of 4NQO.  The 
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phytochemical profile of B. scaberulum stem/root extracts revealed phenolics, tannins and 
flavonoids.   Antitumour activities have been detected in the Bulbophyllum genus (YAO et al., 
2005a), with B. odoratissimum, in particular, containing cytotoxic phenolics (CHEN et al., 2008b).  
Phenanthrenes were mainly isolated from whole plants, cortex, tubers or stems and a large number 
where isolated from Bulbophyllum vaginatum (KOVÁCS et al., 2008).  A more comprehensive 
chemical, toxicological, antimutagenic and pharmacological investigation of other organs of this 
species could reveal phenanthrenes, antitumor, anti-angiogenic, cytotoxic and phytotoxic properties 
of South African Bulbophyllum species.  Compounds with phytotoxic properties may also be further 
investigated for their herbicidal potential. 
 
The determination of the chemistry of orchid species may be beneficial to other avenues of orchid 
research.  Taxonomic relationships within the Orchidaceae family are often described in relation to 
their chemical profiles with specific reference to certain classes of compounds such as alkaloids 
(LAWLER and SLAYTOR, 1969) or flavonoids (WILLIAMS, 1979).  More recently, the 
chemicals and molecular mechanisms involved in the diverse pollination systems have been of 
interest, where chemical mimicry or deceit is used to encourage visits from pollinators (NILSSON, 
1992; BRODMANN et al., 2008; SCHLÜTER and SCHIESTL, 2008; TSAI et al., 2008).  
Biotechnology, commonly used as an alternative method of orchid propagation (SMITH and 
READ, 2008b), can be applied to produce and recover significant metabolites from orchids 
(WALTON et al., 2000). 
 
Recent medicinal plant research efforts address two main topics:  the conservation of the more 
commonly used plants and their cultivation; and the pharmacological evaluation of the plants to 
verify their medicinal value and efficacy.  Given the vast plant biodiversity and rich cultural 
heritage of South Africa and the renewed interest in medicinal plant research and conservation 
concerns, medicinal plants and holders of indigenous knowledge are valuable resources in our 
society.  African traditional medicine is deeply rooted in ancient tradition and it is mainly the elders 
of a rural community that hold significant knowledge of herbal medicine (LALONDE, 1993).  
According to VAN WYK et al. (1997) such traditions are adaptable and open to change through 
modern developments.  SIMON and LAMIA (1991) reported the dispensation of effective 
conventional medication such as penicillin by traditional healers.  They have also shown keen 
interest in primary health care training programmes (RICHTER, 2003).  Such partnerships should 
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be encouraged in future medicinal plant research.  Furthermore, by formally documenting 
indigenous knowledge, conducting scientific investigations on medicinal and related plants to 
validate their use and providing adequate and suitable governmental support, African traditional 
medicine may become globally recognized as an established medical system 
 
Plants are an important source of compounds that are ultimately used for drug development.  High-
value secondary metabolites have also been applied in cosmetic, food and agricultural industries.  
For previously identified high-value compounds, research has been channeled towards maintaining 
reliable sources.  Current research is geared towards a continuous search for novel compounds, 
identification of biosynthetic pathways and determining the safety and commercial potential.  
Historically, plants were the only source of medication and they continue to demonstrate their 
therapeutic usefulness by being a part of, or possibly the only primary health care system in certain 
regions (RIBEIRO et al., 2010). In regions such as India, The Far East and South America, 
traditional medicinal practices are well integrated and plants used in these systems are widely 
studied in their respective countries and have made significant contributions to modern medicine 
(CRAGG and NEWMAN, 2001).  A large percentage of modern medicines were derived from 
bioactive compounds isolated from plants already in use in traditional medicine.   
 
The use of African traditional medicine is still not fully recognised in South Africa and abroad, and 
the medicinal plant research field is still establishing itself in South Africa, therefore orchids have 
not featured as yet.  A number of biologically active compounds have been isolated from certain 
Orchidaceae species around the world on the basis of their traditional medicinal uses. Often their 
indigenous uses are validated, novel compounds are identified and potential uses in industries are 
discussed. The ethnobotanical uses of orchids in South Africa (Table 3.1. Chapter 3) have not been 
exploited pharmacologically (CHINSAMY et al., 2011).  Scientific validation is essential as the 
uses are indigenous and unique to South African orchids.  Also, given that the geographical location 
of plant species is one of the determining factors in the type and quantity of secondary metabolites 
produced; and that 75% of orchids in the southern African region are endemic (STEWART et al., 
1982) it could be assumed that their unique geographical location would have some influence on the 
chemical composition of medicinally used species.  There is therefore, great potential for revealing 
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